Document:

EX-10.20

 Exhibit 10.20 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 
 BPS804 ASSET PURCHASE AGREEMENT 

by and between 

NOVARTIS PHARMA AG 
 and

 MEREO BIOPHARMA 3 LIMITED 

Dated as of July 28, 2015 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
		
	 Article I TRANSFER OF PROPERTIES AND ASSETS OF SELLERS
	  	 	1	 
			
	 Section 1.1
	 	Sale and Transfer of Properties and Assets	  	 	1	 
	 Section 1.2
	 	Excluded Assets	  	 	2	 
	 Section 1.3
	 	Assumed Obligations	  	 	3	 
	 Section 1.4
	 	Excluded Obligations	  	 	3	 
	 Section 1.5
	 	Purchase Price	  	 	3	 
	 Section 1.6
	 	Withholding of Taxes	  	 	7	 
	 Section 1.7
	 	Novartis Closing Deliveries	  	 	8	 
	 Section 1.8
	 	Buyer Closing Deliveries	  	 	8	 
	 Section 1.9
	 	Closing	  	 	9	 
	 Section 1.10
	 	Tangible Purchased Assets; Assigned Books and Records	  	 	11	 
		
	Article II REPRESENTATIONS AND WARRANTIES OF NOVARTIS	  	 	11	 
			
	 Section 2.1
	 	Corporate Organization, Standing and Power	  	 	11	 
	 Section 2.2
	 	Consents, Authorization and Enforceability	  	 	12	 
	 Section 2.3
	 	Title to Assets; Sufficiency of Assets	  	 	12	 
	 Section 2.4
	 	Non-Contravention	  	 	12	 
	 Section 2.5
	 	Contracts and Commitments	  	 	13	 
	 Section 2.6
	 	Intellectual Property	  	 	13	 
	 Section 2.7
	 	Litigation	  	 	14	 
	 Section 2.8
	 	Compliance with Law	  	 	15	 
	 Section 2.9
	 	Taxes	  	 	15	 
	 Section 2.10
	 	Inventory	  	 	15	 
		
	Article III LICENSE GRANT AND ENFORCEMENT	  	 	16	 
			
	 Section 3.1
	 	License to Purchased IP Know-How	  	 	16	 
	 Section 3.2
	 	License to Intellectual Property	  	 	16	 
	 Section 3.3
	 	Maintenance of Purchased IP	  	 	16	 
		
	Article IV REPRESENTATIONS AND WARRANTIES OF BUYER	  	 	17	 
			
	 Section 4.1
	 	Organization, Standing and Authority	  	 	17	 
	 Section 4.2
	 	Consents and Authorization	  	 	17	 
	 Section 4.3
	 	Non-Contravention	  	 	17	 
	 Section 4.4
	 	Litigation and Claims	  	 	18	 
	 Section 4.5
	 	Financing	  	 	18	 

  
 i 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

							
	Article V COVENANTS	  	 	18	 
			
	 Section 5.1
	 	Access to Information	  	 	18	 
	 Section 5.2
	 	Obligations of Confidentiality and Non-Use	  	 	19	 
	 Section 5.3
	 	Technical Assistance	  	 	20	 
	 Section 5.4
	 	Product Development and Commercialization; Reports	  	 	20	 
	 Section 5.5
	 	Further Assurances; Consents	  	 	22	 
	 Section 5.6
	 	Indemnity	  	 	23	 
	 Section 5.7
	 	Supply	  	 	25	 
	 Section 5.8
	 	Noncompetition	  	 	25	 
	 Section 5.9
	 	Product Inquiries	  	 	26	 
		
	Article VI MISCELLANEOUS	  	 	26	 
			
	 Section 6.1
	 	Definitions	  	 	26	 
	 Section 6.2
	 	Survival of Representations and Warranties and Covenants	  	 	32	 
	 Section 6.3
	 	Notices	  	 	32	 
	 Section 6.4
	 	Governing Law; Jurisdiction	  	 	33	 
	 Section 6.5
	 	Waiver of Jury Trial	  	 	34	 
	 Section 6.6
	 	Payments; Expenses	  	 	34	 
	 Section 6.7
	 	Counterparts	  	 	34	 
	 Section 6.8
	 	Entire Agreement	  	 	34	 
	 Section 6.9
	 	Amendment and Modification	  	 	34	 
	 Section 6.10
	 	Binding Effect; Benefits	  	 	34	 
	 Section 6.11
	 	Assignability	  	 	35	 
	 Section 6.12
	 	Interpretation Provisions	  	 	35	 
	 Section 6.13
	 	Severability	  	 	35	 
	 Section 6.14
	 	Specific Performance	  	 	36	 
	 Section 6.15
	 	Disclaimer	  	 	36	 
	 Section 6.16
	 	Obligations of Party’s Affiliates	  	 	36	 

 Schedules: 
 Schedule
1.1(a) – Purchased IP 
 Schedule 1.1(b) – Assumed Contracts 

Schedule 1.1(c) – Regulatory Filings and Approvals 
 Schedule
1.1(e) – Purchased Inventory 
 Schedule 1.7(f) – Novartis Disclosure Schedule 

Schedule 1.7(g) – Consents 
 Exhibits: 

Exhibit A – Morphosys Sublicense 
 Exhibit B –
Subscription Agreement 
 Exhibit C – Bill of Sale 

Exhibit D – [Intentionally Omitted] 

  
 ii 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 Exhibit E – Patent Assignment 

Exhibit F – Loan Note 
 Exhibit G – Compound 

Exhibit H – Form of Novartis Invoice 

  
 iii 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 EXECUTION COPY 

BPS804 ASSET PURCHASE AGREEMENT 

This BPS804 ASSET PURCHASE AGREEMENT (this “Agreement”) is entered into as of July 28, 2015, by and between
Novartis Pharma AG, a Swiss company (“Novartis”), and Mereo BioPharma 3 Limited, a private limited company incorporated in England and Wales (“Buyer”) and a wholly owned subsidiary of Mereo BioPharma Group Limited,
a company incorporated in England and Wales (“Mereo”). Hereinafter, “Parties” shall mean Novartis and Buyer together, and “Party” shall mean either Novartis or Buyer, as the context requires.

 RECITALS 

WHEREAS, Novartis desires to sell, and Buyer desires to acquire, certain assets/rights of Novartis and its Affiliates related to the Compound
or Products (hereinafter defined) on the terms set forth in this Agreement. 
 WHEREAS, concurrently with the foregoing sale and
acquisition, Novartis and Buyer desire to enter into a sublicense agreement in the form attached hereto as Exhibit A (the “Morphosys Sublicense”) with respect to certain rights of Novartis licensed by it from Morphosys AG
(“Morphosys”) pursuant to the Second Amended and Restated Collaboration and License Agreement dated November 6, 2012 by and between Morphosys and Novartis. 

WHEREAS, in connection with this Agreement, concurrently with the execution and delivery of this Agreement, Novartis and Mereo are
entering into a subscription agreement in the form attached hereto as Exhibit B (the “Subscription Agreement”) pursuant to which Novartis will subscribe for equity in Mereo.  

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, Buyer, Mereo, and, on
behalf of itself and, as applicable, its Affiliates, Novartis hereby agree as follows: 
 ARTICLE I 

TRANSFER OF PROPERTIES AND ASSETS OF SELLERS 

Section 1.1 Sale and Transfer of Properties and Assets. 

Upon the terms and subject to the conditions of this Agreement, Buyer shall purchase and acquire, and Novartis shall, and, as
applicable, shall cause its Affiliates to, sell, transfer, convey, assign and deliver to Buyer, free and clear of all mortgages, pledges, charges, hypothecations, liens, claims, and encumbrances of any kind, nature or description (collectively,
“Liens”) (except as expressly permitted in this Agreement and except Permitted Liens), at the closing (the “Closing”), all right, title and interest of Novartis and its Affiliates (collectively,
“Sellers” and each a “Seller”) in and to the following assets and rights (collectively, the “Purchased Assets”): 

(a) all Purchased IP, including the Patent rights listed on Schedule1.1(a); 

  
 1 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 (b) all rights of any of the Sellers under Contracts to the extent related to the Compound,
including the Contracts listed on Schedule 1.1(b), as such Contracts may have been amended prior to the date hereof (the “Assumed Contracts”); 

(c) all Regulatory Filings and Approvals to the extent related to the Compound, including the Regulatory Filings and Approvals set forth on
Schedule 1.1(c); 
 (d) all intangibles and goodwill of Sellers arising from the Purchased IP; 

(e) all Inventory of the Compound or Products, including the Inventory listed on Schedule 1.1(e), that is not consumed in the ordinary
course of the Business prior to the Closing Date (the “Purchased Inventory”); 
 (f) [Intentionally omitted]; 

(g) all books, records, files, manuals, and other documentation (including clinical study reports, investigator brochures, and laboratory
books), or portion thereof, in the Control of any Seller to the extent relating to the Compound or Products, including (i) all data in all databases for all clinical and pre-clinical studies for all drug trials undertaken in connection with the
Compound, (ii) all Purchased IP files, file histories and other technical documents and correspondence, and (iii) all business information, tangible or intangible, to the extent relating to the Compound or Products (the “Assigned
Books and Records”); and 
 (h) all claims (including claims for past infringement or misappropriation of the Purchased IP), causes
of action, judgments and demands of whatever kind or description, or portion thereof (regardless of whether or not such claims and causes of action have been asserted by Seller), to the extent relating to any of the Purchased Assets. 

Within [***] days after the Closing, Novartis shall deliver to Buyer, a schedule setting forth in reasonable detail the location of all tangible Purchased
Assets, whether held by any of the Sellers or by Third Parties on behalf of any Sellers. 
 Section 1.2 Excluded Assets. 

All assets, properties, rights and interests of Sellers not included in the Purchased Assets and any Assumed Contracts that may not be
assigned to Buyer without the written consent of a Third Party which has not been obtained prior to the Closing are expressly excluded from the purchase and sale contemplated hereby until such time, if any, as such consent is obtained, and as such
are not included in the Purchased Assets and shall remain the assets, property rights and interests of Sellers until such time, if any, as such consent is obtained (collectively, the “Excluded Assets”), subject to Sellers’
obligation pursuant to Section 5.5(c) to use commercially reasonable efforts to obtain such consent promptly after the Closing and to cooperate, in all commercially reasonable respects, to make the benefits of such Assumed Contract available to
Buyer. 

  
 2 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 Section 1.3 Assumed Obligations. 

Upon the terms and subject to the conditions of this Agreement, at the Closing, Buyer shall assume and, from and after the Closing,
shall pay, perform, satisfy and discharge (or cause to be paid, performed, satisfied and discharged on behalf of Buyer) when due, all obligations of Sellers to be performed under the Assumed Contracts on or after the Closing pursuant to such Assumed
Contracts (the “Assumed Obligations”). In addition, (a) Buyer shall indemnify, defend and hold harmless Novartis and its Affiliates from, against and in respect of any and all Losses arising out of or relating to the
Development, Manufacture or Commercialization of the Compound, Product or Purchased Assets following the Closing on the terms and subject to the conditions of Section 5.6(b), and (b) Novartis shall indemnify, defend and hold harmless Buyer
and its Affiliates from, against and in respect of any and all Losses arising out of or relating to the Development, Manufacture or Commercialization of the Compound, Product or Purchased Assets prior to the Closing on the terms and subject to the
conditions of Section 5.6(a).  
 Section 1.4 Excluded Obligations. 

Notwithstanding anything to the contrary in this Agreement, the Assumed Obligations do not include any obligations whatsoever not
expressly assumed by Buyer under Section 1.3 (collectively, the “Excluded Obligations”). 

Section 1.5 Purchase Price. 

Upon the terms and subject to the conditions of this Agreement, in consideration for (i) the sale, conveyance, assignment, transfer
and delivery of the Purchased Assets and (ii) Novartis’s entering into the Morphosys Sublicense, Buyer agrees to assume the Assumed Obligations at the Closing, to deliver the Loan Note, to make the Sales Related Payments and the Change of
Control Transaction Payments (collectively, the “Purchase Price”) as follows: 
 (a) Sales Related Payments.

 (i) During the Sales Related Payments Term, Buyer shall pay to Novartis (in U.S. dollars via wire transfer of immediately
available funds to such account(s) as may be designated from time to time by Novartis in writing) [***] at the graduated rates specified in the following table with respect to the aggregate annual worldwide Net Sales of all Products during the
applicable [***] (the “Sales Related Payments”): 
  

					
	 Aggregate Annual Worldwide Net Sales (USD)

of All Products in a Calendar Year
	  	Sales Related
Payments Rate	 
	 Portion of aggregate Net Sales by Buyer and its Affiliates up to and including [***]
	  	 	[	***] 
	 Portion of aggregate Net Sales by Buyer and its Affiliates greater than [***] up to and including
[***]
	  	 	[	***] 

  
 3 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

					
	 Aggregate Annual Worldwide Net Sales (USD)

of All Products in a Calendar Year
	  	Sales Related
Payments Rate	 
	 Portion of aggregate Net Sales by Buyer and its Affiliates greater than [***] up to and including
[***]
	  	 	[	***] 
	 Portion of aggregate Net Sales by Buyer and its Affiliates greater than [***] up to and including
[***]
	  	 	[	***] 
	 Portion of aggregate Net Sales by Buyer and its Affiliates greater than [***]
	  	 	[	***] 

 For illustration purposes only, if the aggregate annual worldwide Net Sales by Buyer and its Affiliates for a particular year
are [***], Novartis would be entitled to receive Sales Related Payments calculated as follows: [***] x [***] (or [***]) plus [***] x [***] (or [***]) = [***]. Notwithstanding the other provisions of this Section 1.5(a)(i), for any period during
the Sales Related Payments Term in which there has occurred Loss of Market Exclusivity with respect to any Product in any country, the Net Sales of Buyer and its Affiliates for such country to be included in [***] worldwide Net Sales for the purpose
of the calculation of the Sales Related Payments due under this Section 1.5(a)(i) shall be reduced by [***] of such Net Sales. For purposes of illustrating the immediately preceding sentence only, if the aggregate [***] Net Sales of Buyer and
its Affiliates for [***] in a country in which Loss of Market Exclusivity has occurred are [***], Novartis would be entitled to receive Sales Related Payments calculated as follows: [***] x US$[***] (or US$[***]) [***] (or [***]) = US$[***]. 

(ii) In the event that Buyer reasonably determines that rights to intellectual property Controlled by a Third Party (“Third Party IP
Rights”) are reasonably necessary to research, Develop, Manufacture, or Commercialize any Product, Buyer shall notify Novartis (“Third Party IP Rights Notice”) prior to entering into an agreement with respect to a license
to such Third Party IP Rights. If Novartis disagrees that such Third Party IP Rights are reasonably necessary to research, Develop, Manufacture, or Commercialize any Product, then senior management from the Parties will discuss the matter and
attempt to resolve the disagreement. In the event senior management is unable to resolve the disagreement within [***] days following the date of the Third Party IP Rights Notice, then such disagreement shall be resolved by referring the
disagreement for determination by [***], jointly selected by the Parties (the “[***]”). If the Parties are unable to jointly select the [***], then such [***] shall be selected, at the request of either Party, by the [***] or such [***].
The fees and expenses of the [***] shall be [***]. In the event Novartis consents to the acquisition of such Third Party IP Rights by Buyer, or the [***] that such Third Party IP Rights are reasonably necessary to research, Develop, Manufacture, or
Commercialize any Product, Buyer shall have the right to deduct from the Sales Related Payments due to Novartis pursuant to Section 1.5(a)(i) [***] of the amounts paid (including upfront payments, milestone payments, royalties or other license
fees) by Buyer for such Third Party IP Rights; provided, however, that in no event shall the Net Sales Payments due to Novartis from Buyer be reduced by more than [***] in [***] (such maximum reduction, the “Reduction Cap”). Any
amount that Buyer is entitled to deduct, but is unable to deduct in any calendar year due to the operation of the Reduction Cap shall be carried 

  
 4 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 
forward and Buyer may deduct such amount from subsequent Net Sales Payments due to Novartis, subject, in each [***], to the Reduction Cap, until the full amount that Buyer was entitled to deduct
is deducted. 
 (iii) As used herein, “Net Sales” with respect to a Product means the gross amount invoiced by Buyer or any of
its Affiliates to third party customers for the Product, less: 
 (A) normal and customary trade and quantity discounts and
non-affiliated brokers’ or agents’ commissions actually allowed and taken and not already reflected in the amount invoiced; 

(B) amounts repaid or credited by reason of defects, rejections, returns, recalls, allowances, or government-imposed
retroactive price reductions; 
 (C) third party cash rebates and chargebacks related to sales of Products, to the extent
allowed; 
 (D) government-imposed retroactive price reductions that are actually allowed or granted; 

(E) tariffs, duties, excise, sales, value-added, and other consumption taxes and customs duties to the extent included in the
invoice price and paid by or on behalf of Buyer; 
 (F) cash discounts for timely payment; 

(G) delayed ship order credits; 

(H) discounts pursuant to indigent patient programs and patient discount programs of any nature; 

(I) a fixed charge of [***] to cover warehousing and distribution expenses; 

(J) any otherwise specifically identifiable costs or charges included in the gross invoiced sales price of such Product
falling within categories equivalent to those listed above, to the extent the deduction of such costs or charges are consistent with the Accounting Standards; and 

  
 5 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 (K) uncollectible amounts on previously sold Products, but not such amounts
that, but for the failure to collect such amounts within [***] from the date of the respective invoice, would have been collectible; provided that: 

(1) in the case of any sale or other disposal of a Product between or among Buyer and its Affiliates or licensees, for resale,
Net Sales shall be calculated as above only on the value charged or invoiced on the first arm’s length sale to a third party; 

(2) in the case of any sale, which is not invoiced or is delivered before invoice, Net Sales shall be calculated at the time
of shipment; 
 (3) in the case of any sale or other disposal, such as barter or counter-trade, of any Product, or part
thereof, otherwise than in an arm’s length transaction exclusively for money, Net Sales shall be calculated as above on the value of the consideration received or, if higher, on the fair market price of the Product in the relevant country of
sale or disposal; and 
 (4) in the event that a Product is sold as part of a Combination Product, Net Sales of the Product,
for the purpose of determining Net Sales Payments, shall be determined by multiplying Net Sales of the Combination Product by the fraction A/(A+B), where A is the weighted (by sales volume) average sales price of the Product when sold separately in
finished form and B is the weighted average sale price of the other product(s) sold separately in finished form. In the event that such average sales price cannot be determined for both the Product and the other product(s) in combination, Net Sales
for purposes of determining payments hereunder shall be mutually agreed by the Parties based on the relative value contributed by each component, [***]. 

(iv) Within [***] days after the end of each [***] following the First Commercial Sale, Buyer shall provide Novartis a report summarizing
total Net Sales, on a country by country basis, during the relevant [***] and the calculation of amounts owed. After receipt of such report, Novartis shall submit an invoice to Buyer substantially in the form of Exhibit H with respect to the Sales
Related Payments payableto Novartis with respect to such total Net Sales. Sales Related Payments shall be made by Buyer to the bank account designated by Novartis in writing within [***] days after the date of receipt of of the relevant original
invoice issued by Novartis. Further, for so long as Buyer is required pursuant to Section 5.4(c)(i), Buyer will provide quarterly reports to Novartis within [***] days following the end of [***] (A) indicating the countries in which
a First Commercial Sale has occurred, and (B) summarizing, on a country by country basis, total Net Sales during the [***], it being understood that such [***] reports are for information only and shall not be binding on Buyer with respect to
the calculation of Sales Related Payments. For purposes of computing Net Sales sold in a currency other than U.S. dollars, the US Dollar equivalent shall be calculated using Buyer’s then-current standard exchange rate methodology as applied in
its external reporting for the conversion of foreign currency sales into US Dollars. If at any time legal restrictions in any country of the Territory prevent the prompt remittance of any payments with respect to sales therein, Buyer shall have the
right and option to make such payments by depositing the payment amount in local currency to Novartis’s account in a bank or depository designated by Novartis in the relevant country. 

  
 6 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 (b) Change of Control Transaction Payment. 

(i) In addition to the Sales Related Payments, in the event of a Change of Control Transaction, Buyer shall pay or cause to be paid to
Novartis (in U.S. dollars via wire transfer of immediately available funds to such account(s) as may be designated from time to time by Novartis in writing) an amount (the “Change of Control Transaction Payment”) simultaneously with
the completion of such Change of Control Transaction (or if any amounts payable in respect of such Change of Control Transaction are not payable at completion, immediately following payment of such amounts) equal to [***] of the Transaction
Proceeds. 
 (ii) As used herein: 

(A) “Change of Control Transaction” means a transaction in which Buyer conveys, transfers, [***] on
[***], assigns or [***] or [***] of [***] to any Third Party, [***] the Compound and related assets. For the avoidance of doubt, any transaction involving equity interests of Mereo, a merger or consolidation of Mereo, or a sale of any assets of
Mereo shall not constitute a Change of Control Transaction.  
 (B) “Transaction Proceeds”
means [***] amounts, including [***] and/or [***] or [***] of [***] or [***] in connection with a Change of Control Transaction (“Gross Proceeds”), less (1) an amount equal to the costs and expenses incurred by Buyer or its
equity holders for legal, financial and accounting advisory services directly related to such Change of Control Transaction in an amount not exceeding [***] of [***], and (2) payments for research and development support, patent expense
reimbursement, supply purchases and other arms’ length matters. Any [***] that are [***] or [***] shall [***] until such [***] by [***] or [***], as the case may be. For purposes of illustrating clause (1) of the immediately preceding
sentence, if the proceeds of a Change of Control Transaction were [***], and the aggregate financial advisory, legal and accounting fees directly related to such Change of Control Transaction were $[***], then $[***] would be deducted from the Gross
Proceeds, and Novartis would be entitled to receive a Change in Control Transaction Payment calculated as US$[***] = US$[***]. 

Section 1.6 Withholding of Taxes. 

Buyer shall be entitled to deduct and withhold from any amounts payable or otherwise deliverable pursuant to this Agreement to Novartis such
amounts as may be required to be deducted or withheld therefrom under any provision of federal, state, local or foreign Tax law or under any Applicable Laws. To the extent such amounts are so deducted and withheld, such

  
 7 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 
amounts shall be treated for all purposes under this Agreement as having been paid to Novartis. Each Party shall cooperate and otherwise take commercially reasonable efforts to obtain appropriate
exemptions for or refunds of any such applicable Taxes and to minimize any such Taxes. 
 Section 1.7 Novartis Closing
Deliveries. 
 Novartis shall deliver to Buyer at the Closing: 

(a) a bill of sale, dated the Closing Date, in the form attached hereto as Exhibit C (the “Bill of Sale”), duly
executed by Novartis; 
 (b) [Intentionally omitted]; 

(c) a patent assignment agreement, dated the Closing Date, in the form attached as Exhibit E (the “Patent
Assignment”), duly executed by Novartis; 
 (d) the Subscription Agreement, duly executed by Novartis; 

(e) the Morphosys Sublicense, dated the Closing Date, duly executed by Novartis; 

(f) the Novartis Disclosure Schedule set forth on Schedule 1.7(f); 

(g) the consents or approvals set forth on Schedule 1.7(g); and 

(h) such other customary instruments of transfer, assumptions, filings or documents, in form and substance reasonably satisfactory to Buyer,
as may be required to give effect to this Agreement. 
 Notwithstanding anything herein to the contrary, subject to Sellers’ compliance with
Section 5.5(c), the failure by Sellers to obtain the consent of any Third Party to the assignment of any contract prior to Closing shall not be a breach of Seller’s obligations under this Section 1.7. 

Section 1.8 Buyer Closing Deliveries. 

Buyer shall deliver to Novartis at the Closing: 

(a) the Bill of Sale, duly executed by Buyer; 

(b) [Intentionally omitted]; 

(c) the Subscription Agreement, duly executed by Mereo; 

(d) the Morphosys Sublicense, duly executed by Buyer; and 

  
 8 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 (e) a loan note, dated the Closing Date, in the form attached hereto as Exhibit F (the
“Loan Note”), duly executed by Buyer. 
 Section 1.9 Closing. 

(a) The Closing will take place at Novartis Campus, Basel, Switzerland at 10:00 a.m. (local time) on the first business day following
the fulfillment or waiver of the conditions precedent set forth in Sections 1.9(b) and (c) or at such other time and place as the parties hereto may mutually agree. The date on which the Closing occurs is referred to as the “Closing
Date.” Subject to the fulfillment or waiver of such conditions precedent, Sellers shall make the Closing deliveries specified in Section 1.7 and Buyer shall make the Closing deliveries specified in Section 1.8, all of which shall
be deemed to have occurred simultaneously and none of which shall be deemed completed unless and until all of them shall have been completed (or waived in writing by the Party entitled to performance). 

(b) The obligations of Buyer to consummate the transactions contemplated by this Agreement are subject to the following conditions, except to
the extent waived by Buyer in writing at the Closing: 
 (i) All representations and warranties of Novartis contained in this Agreement
shall be accurate in all material respects as of the Closing with the same effect as if made on and as of such date. 
 (ii) Novartis shall
have delivered to Buyer the documents set forth in Section 1.7. 
 (iii) There shall not have been instituted or threatened any
legal proceeding (A) relating to, or seeking to prohibit or otherwise challenge this Agreement, the BCT197 Asset Purchase Agreement or the BGS649 Asset Purchase Agreement (collectively, the “Purchase Agreements”), the
consummation of the transactions contemplated by any of the Purchase Agreements, or seeking to obtain substantial damages with respect to any of the Purchase Agreements, or (B) which would reasonably be expected to have a Material Adverse
Effect. 
 (iv) There shall not have been any action taken, or any law, rule, regulation, order, judgment, or decree proposed,
promulgated, enacted, entered, enforced, or deemed applicable to the transactions contemplated by any of the Purchase Agreements, by any federal, state, local, or other governmental authority or by any court or other tribunal, including the entry of
a preliminary or permanent injunction, which would reasonably be expected to: (A) makes any of the transactions contemplated by any of the Purchase Agreements illegal or (B) imposes material limitations on the ability of any buyer under
any of the Purchase Agreements to operate the Business (as defined in the respective Purchase Agreements) or to exercise full rights of ownership of the Purchased Assets (as defined in the respective Purchase Agreements). 

  
 9 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 (v) The conditions precedent to the obligations of each buyer under the Purchase Agreements to
consummate the transactions contemplated by the respective Purchase Agreement shall have been satisfied or waived by such buyer in writing at the Closing. 

(vi) There shall not have occurred any Material Adverse Effect (as defined in the respective Purchase Agreements). 

(vii) Novartis shall have delivered to Buyer, at or prior to the Closing, such other documents as Buyer shall have reasonably requested to
carry out the provisions of and the transactions contemplated by this Agreement in form and substance reasonably satisfactory to Buyer. 

(viii) Mereo shall have received funds from subscribers for equity in Mereo, including Novartis pursuant to the Subscription Agreement, in an
aggregate amount not less than GBP £ 20,000,000 less the Investor Counsel Fees (as defined in the Subscription Agreement). 
 (c) The
obligations of Novartis to consummate the transactions contemplated by this Agreement are subject to the following conditions, except to the extent waived by Novartis in writing at the Closing: 

(i) All representations and warranties of Buyer contained in this Agreement shall be accurate in all material respects as of the Closing with
the same effect as if made on and as of such date. 
 (ii) Buyer shall have delivered to Novartis the documents set forth in
Section 1.8. 
 (iii) There shall not have been instituted or threatened any legal proceeding relating to, or seeking to prohibit or
otherwise challenge any of the Purchase Agreements, the consummation of the transactions contemplated by any of the Purchase Agreements, or seeking to obtain substantial damages with respect to any of the Purchase Agreements. 

(iv) There shall not have been any action taken, or any law, rule, regulation, order, judgment, or decree proposed, promulgated, enacted,
entered, enforced, or deemed applicable to the transactions contemplated by any of the Purchase Agreements, by any federal, state, local, or other governmental authority or by any court or other tribunal, including the entry of a preliminary or
permanent injunction, which would reasonably be expected to make any of the transactions contemplated by any of the Purchase Agreements illegal. 

(v) The conditions precedent to the obligations of Novartis to consummate the transactions contemplated by each of the Purchase Agreements
shall have been satisfied or waived by Novartis in writing at the Closing. 

  
 10 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 (vi) Buyer shall have delivered to Novartis, at or prior to the Closing, such other documents as
Novartis shall have reasonably requested to carry out the provisions of and the transactions contemplated by this Agreement in form and substance reasonably satisfactory to Novartis. 

(vii) Mereo shall have received funds from subscribers for equity in Mereo, including Novartis pursuant to the Subscription Agreement, in an
aggregate amount not less than GBP £ 20,000,000 less the Investor Counsel Fees (as defined in the Subscription Agreement). 

Section 1.10 Tangible Purchased Assets; Assigned Books and Records. 

(a) Sellers shall, without charge to Buyer, hold all tangible Purchased Assets (other than tangible Purchased Assets that are held on behalf of
any Seller by any Third Party) on behalf of Buyer until such time or times that Buyer or its designees takes possession thereof; provided, however, that Buyer or its designees shall take possession of all tangible Purchased Assets no later than the
date that is [***] after the Closing. With respect to tangible Purchased Assets held by any Third Parties on behalf of any Sellers, Sellers shall assist Buyer in arranging to have such Third Parties continue to hold such tangible Purchased Assets on
behalf of Buyer at Buyer’s expense. Sellers shall maintain casualty insurance for the replacement value of tangible Purchased Assets in its possession and Buyer shall reimburse Sellers for the cost thereof. If requested by Buyer, Sellers shall
cooperate with Buyer in arranging for Third Parties who are in possession of tangible Purchased Assets to maintain casualty insurance for the replacement value of such Purchased Assets at Buyer’s expense. 

(b) Subject to Section 5.1, Sellers may retain copies of any Assigned Books and Records to the extent necessary for tax,
accounting, regulatory, compliance or litigation purposes, or to perform and discharge the Excluded Liabilities and their obligations under this Agreement, or if such Assigned Books and Records contain information with respect to any Excluded Asset
or Excluded Obligation. 
 ARTICLE II 

REPRESENTATIONS AND WARRANTIES OF NOVARTIS 

Novartis hereby represents and warrants to Buyer and Mereo as follows, with each such representation and warranty subject only to such
exceptions, if any, as are set forth on that section of the Novartis Disclosure Schedule that is numbered and captioned to correspond to, and is referenced in, such representation or warranty: 

Section 2.1 Corporate Organization, Standing and Power. 

Novartis is a company duly organized, validly existing and in good standing under the laws of Switzerland. Novartis has all necessary corporate
power and authority to execute and deliver this Agreement and the other Transaction Documents to which it is a party and to perform its obligations hereunder and thereunder. Each Seller has all requisite corporate power and authority to carry on its
business as now being conducted as relates to the Purchased Assets. 

  
 11 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 Section 2.2 Consents, Authorization and Enforceability. 

(a) No consent, waiver, approval, order or authorization of, or registration, declaration or filing with, or notice to any Governmental
Authority or other Third Party is required by, or with respect to, Novartis or the Purchased Assets in connection with the execution and delivery of this Agreement or the other Transaction Documents to which it is a party, the performance by
Novartis of its obligations under this Agreement or the other Transaction Documents, or the consummation of the transactions contemplated hereby or thereby, except (i) as set forth on Section 2.2(a) of the Novartis Disclosure
Schedule and (ii) such other consents, waivers, approvals, authorizations, registrations, declarations, filings or notices, the absence of which, would not, individually or in the aggregate, have or reasonably be expected to have a Material
Adverse Effect. 
 (b) All requisite corporate action necessary to authorize the execution, delivery and performance by Novartis of this
Agreement and the other Transaction Documents to which it is a party and the consummation of the transactions contemplated hereby and thereby has been taken. This Agreement constitutes a valid and binding obligation of Novartis, enforceable against
Novartis in accordance with its terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium, arrangement or other similar Applicable Law or equitable principles relating to or limiting creditors’ rights generally. 

Section 2.3 Title to Assets; Sufficiency of Assets. 

Sellers have good, valid and marketable title to all of the Purchased Assets. Sellers hold all of the Purchased Assets free and clear of all
Liens except for: (a) those Liens set forth on Section 2.3 of the Novartis Disclosure Schedule, (b) mechanics’, materialmen’s, carriers’, workmen’s, warehousemen’s, repairmen’s, landlords’ or
other like Liens and security obligations incurred in the ordinary course of business for immaterial amounts, (c) statutory liens for Taxes, assessments or other statutory or governmental charges not yet due and payable, and (d) Liens that
do not, individually or in the aggregate materially impair the use of the relevant Purchased Asset (collectively, “Permitted Liens”). To Novartis’ Knowledge, the Purchased Assets are sufficient for Buyer to continue the
Development of the Compound on substantially the same basis as the Development of the Product conducted by Sellers prior to the Closing. 

Section 2.4 Non-Contravention. 

The execution and delivery by Novartis of this Agreement and the other Transaction Documents to which it is a party, the performance by
Novartis of its obligations hereunder and thereunder, and the consummation of the transactions contemplated hereby and thereby, do not and will not (a) violate any provision of the certificate of incorporation or similar governance

  
 12 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 
documents that may be applicable to Novartis, (b) result in a breach (or any event which, with notice or lapse of time or both, would constitute a breach) of any term or provision of, or
constitute a default under, any Contract to which Novartis is a party or by which it is bound, (c) result in the creation of any Lien on the Purchased Assets (other than a Permitted Lien) or (d) violate in any respect any Applicable Law or
any judgment, decree, order, regulation or rule of any Governmental Authority by which Novartis is bound or subject. 
 Section 2.5
Contracts and Commitments. 
 Novartis has made available to Buyer true and complete copies of the Assumed Contracts and, to the
Knowledge of Novartis, each such Contract is valid and binding on the Seller that is a party thereto in accordance with its terms and is in full force and effect. There is not under any Assumed Contract: (a) any existing material default by
such Seller or, to Novartis’s Knowledge, by any other party thereto; or (b) any event which, after notice or lapse of time or both, would constitute a material default by such Seller or, to Novartis’s Knowledge, by any other party, or
result in a right to accelerate or terminate or result in a loss of any rights of Seller. Except as set forth on Schedule 1.1(b), there are no Contracts to which Novartis or any of its Affiliates is a party pursuant to which Novartis
in-licenses intellectual property rights exclusively related to the Compound or any Product. 
 Section 2.6 Intellectual
Property. 
 (a) Schedule 1.1(a) sets forth a complete and accurate list of all Patent rights owned or in-licensed by Sellers
relating exclusively to the Compound or any Product that the manufacture, use, sale, offer for sale or importation of the Compound or any Product would infringe, specifying as applicable: (i) the title thereof, if any; (ii) the
registration or application number thereof, if any; and (iii) the jurisdiction in which such item exists or is registered. 
 (b) All
Purchased IP is exclusively owned by Sellers, and is free and clear of any (i) liens, charges, security interests, and encumbrances or licenses and (ii) claims or covenants that would give rise to any Third Party claims for payment against
Buyer. Neither Novartis nor any of its Affiliates has entered into any agreement or otherwise licensed, granted, assigned, transferred, conveyed or disposed of any right, title or interest in or to any of its assets, including any intellectual
property rights or the Compound or any Product, that would conflict with or impair the scope of any rights within the Purchased IP or licenses granted hereunder. None of Novartis or any of its Affiliates is a party to any license, sublicense or
other agreement pursuant to which Novartis or such Affiliate has received a license or other rights relating to any Compound or Product. There are no agreements to which any Seller is a party pursuant to which any Seller has granted any Third Party
any rights in and to any Purchased IP. 
 (c) There are no claims pending or, to Novartis’s knowledge, threatened in writing against any
Seller or before any Governmental Authority, challenging the validity of any Patents within the Purchased IP. 

  
 13 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 (d) The Patents listed on Schedule 1.1(a) have been duly applied for and registered in accordance
with applicable Law, and the Sellers have paid all filing fees, issue fees, annuities and other fees and charges applicable to the Purchased IP, including those required for the issuance, registration, maintenance, filing and prosecution of the
Purchased IP. No Purchased IP is the subject of any pending or, to Novartis’s knowledge, threatened interference, opposition, cancellation, protest, litigation or other challenge or Action. The Sellers and their patent counsel have satisfied
statutory requirements with respect to the filing, prosecution, and maintenance of all registered Purchased IP. 
 (e) Sellers have secured
from all employees, consultants, contractors and other Persons who have contributed to the creation or invention of any of the Purchased IP a written agreement setting forth obligations of confidentiality and assigning to Novartis or its Affiliates
all rights to such creations, inventions, and Purchased IP, and such Affiliates have assigned all such rights to Novartis or its Affiliates. None of Sellers has received any written communication challenging any Seller’s ownership of or right
to use the Purchased IP. 
 (f) To Novartis’s Knowledge, no Person has infringed, misappropriated, or otherwise violated, and no Person
is currently infringing, misappropriating, or otherwise violating, any claim of an issued (granted) and unexpired Patent within the Purchased IP, or has misappropriated any Know-how within the Purchased IP. 

(g) No Action has been instituted by any Third Party or, to Novartis’s Knowledge, is pending against any Seller or has been threatened by
any Third Party in writing that (i) challenges the right of any Seller with respect to its use or ownership of the Purchased IP, or (ii) alleges that any of the issued claims included in the Patents within the Purchase IP are invalid or
unenforceable, or that Development or Manufacture of the Purchased IP, Compound or any Product infringed or misappropriated, or would infringe or misappropriate, the intellectual property rights of such Third Party. 

(h) Novartis has furnished or made available to Buyer all material information that is in the possession of Novartis or any of its Affiliates
concerning the Purchased IP, the Compound or any Product relevant to the safety or efficacy thereof, and all material Regulatory Filings and other material correspondence with Regulatory Authorities relating to the Compound or any Product, and to
Novartis’s Knowledge, such information is accurate, complete and true in all material respects. 
 (i) The Compound is the only
compound, biologic or product whose mechanism of action targets sclerostin that has been Developed or is being Developed by Novartis or its Affiliates for the therapeutic treatment of osteogenesis imperfecta. 

Section 2.7 Litigation. 

(a) There is no action, cause of action, suit, claim, charge, demand, directive, inquiry, subpoena, proceeding, arbitration, mediation or other
investigation (collectively, “Actions”) pending or, to Novartis’s Knowledge, threatened against any Seller or any 

  
 14 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 
predecessor in interest to any Seller (i) relating to or affecting the Purchased Assets or the Assumed Obligations, (ii) relating to or seeking to prevent Novartis’s performance of
this Agreement and the transactions contemplated hereby, (iii) that would reasonably be expected to adversely affect the Development, Manufacture or Commercialization of the Compound or any Product. 

(b) None of the Purchased Assets is subject to any order, writ, judgment, award, injunction or decree of any Governmental Authority. 

Section 2.8 Compliance with Law. 

(a) Sellers have conducted, and are now conducting, their businesses as applied to or in connection with the Purchased Assets in compliance in
all material respects with Applicable Laws. Neither Novartis nor any of its Affiliates has received any notice alleging any violation under any Applicable Law. 

(b) No Seller has employed or used any person that has been debarred, excluded or disqualified under Section 306(a) or 306(b) of the U.S.
Federal Food, Drug and Cosmetic Act in the Development of any Product. 
 (c) Sellers have conducted all clinical and pre-clinical studies
for all drug trials undertaken in connection with the Compound or any Product in accordance with applicable Health Care Laws and no Seller has received any notice from a Governmental Authority alleging any violation under any applicable Health Care
Law or requiring the termination, suspension or material modification of such clinical or pre-clinical studies. 
 Section 2.9
Taxes. 
 There are no Liens for Taxes on any of the Purchased Assets (other than Permitted Liens) and there are no Taxes of Sellers
related to the Purchased Assets which could become liabilities of Buyer. None of the Purchased Assets constitutes a “United States real property interest” for federal income tax purposes. 

Section 2.10 Inventory. 

To Novartis’ Knowledge, the Inventory listed on Schedule 1.1(e) comprises all Inventory as of June 25, 2015, and such Inventory has
been stored and maintained in compliance with applicable FDA good manufacturing practices and in conformity with relevant specifications for such Inventory. 

  
 15 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 ARTICLE III 

LICENSE GRANT AND ENFORCEMENT 

Section 3.1 License to Purchased IP Know-How. 

Buyer hereby grants to Novartis, subject to the terms and conditions of this Agreement, an irrevocable, transferable, royalty-free, fully paid,
non-cancellable, non-exclusive world-wide right and license, with the right to sublicense, under the Purchased IP Know-How to research, develop, make, have made, manufacture, market, use, sell, offer for sale or import any product or service other
than (a) the Compound or any Product, or (b) any other compound, biologic or product Developed, Manufactured or Commercialized for the therapeutic treatment of osteogenesis imperfecta. Novartis will give Buyer notice of any exercise by
Novartis of its rights to transfer or sublicense pursuant to this Section 3.1, such notice to be given no later than the time such rights are exercised. 

Section 3.2 License to Intellectual Property. 

Sellers hereby grant to Buyer, subject to the terms and conditions of this Agreement, and solely for use in connection with the Development,
Manufacture, or Commercialization of the Compound or any Product, an irrevocable, transferable, royalty-free, fully paid, non-cancellable, world-wide right and license, with the right to sublicense, under any Intellectual Property Rights Controlled
by Novartis or any of its Affiliates (other than the Purchased IP) that would be [***] to use in connection with the Development, Manufacture, or Commercialization of the Compound or any Product. Such license is exclusive, even as to Novartis, with
respect to the Compound and any Product. Buyer will give Novartis notice of any exercise by Buyer of its rights to transfer or sublicense pursuant to this Section 3.2, such notice to be given no later than the time such rights are exercised.

 Section 3.3 Maintenance of Purchased IP. 

Buyer shall have the right and obligation to maintain and diligently prosecute the Purchased IP at Buyer’s expense, except with respect to
any Purchased IP Buyer plans to abandon and notifies Novartis of such plans. Novartis shall have a right to assume responsibility for any Purchased IP that Buyer plans to abandon or otherwise cause or allow to be forfeited. Buyer shall give Novartis
reasonable written notice and in any event no less than [***] days prior to abandonment or other forfeiture of any patent or patent application within the Purchased IP so as to permit Novartis to exercise its rights under this
Section 3.3, at its own expense. In the event Novartis exercises such right, Novartis hereby grants to Buyer an irrevocable, transferable, royalty-free, fully paid, non-cancellable, non-exclusive world-wide right and license, with the
right to sublicense, under such Purchased IP to use in connection with the Development, Manufacture, and Commercialization of the Compound or any Product. 

  
 16 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 ARTICLE IV 

REPRESENTATIONS AND WARRANTIES OF BUYER 

Buyer hereby represents and warrants to Novartis as follows: 

Section 4.1 Organization, Standing and Authority. 

Buyer is a private limited company duly organized, validly existing and in good standing under the laws of England and Wales. Buyer has all
necessary corporate power and authority to execute and deliver this Agreement and the other Transaction Documents to which it is a party and to perform its obligations hereunder and thereunder. 

Section 4.2 Consents and Authorization. 

(a) No consent, waiver, approval, order or authorization of, or registration, declaration or filing with, or notice to any Governmental
Authority or other Third Party is required by, or with respect to, Buyer in connection with the execution and delivery of this Agreement or the other Transaction Documents to which it is a party or the consummation of the transactions contemplated
hereby or thereby, except for any notice filings or registrations of transfer with any Governmental Authority that may be required in connection with the assignment and transfer of the Purchased Assets, and such other consents, waivers, approvals,
authorizations, registrations, declarations, filings or notices, the absence of which, would not, individually or in the aggregate, have or reasonably be expected to have a materially adverse effect on the ability of Buyer to consummate the
transactions contemplated hereby (a “Buyer Material Adverse Effect”). 
 (b) All requisite corporate action necessary to
authorize the execution, delivery and performance by Buyer of this Agreement and the other Transaction Documents to which it is a party and the consummation of the transactions contemplated hereby and thereby has been taken. This Agreement
constitutes a valid and binding obligation of Buyer, enforceable against Buyer in accordance with its terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium, arrangement or other similar Applicable Law or equitable
principles relating to or limiting creditors’ rights generally. 
 Section 4.3 Non-Contravention. 

The execution and delivery by Buyer of this Agreement and the other Transaction Documents to which it is a party, the performance by Buyer of
its obligations hereunder and thereunder, and the consummation of the transactions contemplated hereby and thereby, do not and will not (a) violate any provision of the certificate of incorporation or similar governance documents that may be
applicable to Buyer, (b) result in the breach (or an event which, with notice or lapse of time or both, would constitute a breach) of any term or provision of, or constitute a default under any Contract to which Buyer is a party or by which it
is bound or (c) violate in any respect any Applicable Law or any judgment, decree, order, regulation or rule of any Governmental Authority to which Buyer is bound or subject, except, with respect to the immediately preceding clauses (b)
and (c), for any violations, breaches or defaults that would not, individually or in the aggregate, have a Buyer Material Adverse Effect. 

  
 17 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 Section 4.4 Litigation and Claims. 

There is no Action pending, or to the Knowledge of Buyer, threatened, against Buyer before or by any Governmental Authority which seeks to
prevent Buyer’s performance of this Agreement and the transactions contemplated hereby or that would, individually or in the aggregate, have a Buyer Material Adverse Effect. 

Section 4.5 Financing. 

Buyer has a reasonable basis to believe that it will obtain financing sufficient to fund the Development and Commercialization of a Product.

 ARTICLE V 

COVENANTS 

Section 5.1 Access to Information. 

(a) For so long as a Party maintains books, records, files and other information that is subject to this Section 5.1, during normal
business hours following reasonable prior notice, such Party will permit the other Party and its accountants, counsel, and other representatives, subject to the obligations set forth in Section 5.2 of this Agreement, to have reasonable
access to and examine and make copies of all Assigned Books and Records and all other books and records of a Party which are reasonably requested by the other Party and are necessary or useful in connection with: (i) any Tax inquiry, audit,
investigation or dispute with a Third Party; (ii) any Action by any Governmental Authority or any dispute with any Third Party reasonably requiring access to any such books and records; or (iii) with respect to Buyer, the Development,
Manufacture or Commercialization of the Product, in each case relating to or arising out of transactions or events occurring prior to the Closing and that relate to the Purchased Assets. The Party requesting access to any such Assigned Books and
Records or Sellers’ retained books and records or other information shall bear all of the out of pocket costs and expenses (including attorneys’ fees, but excluding reimbursement for salaries and employee benefits) reasonably incurred in
connection with providing access to and copies of such Assigned Books and Records, Sellers’ retained books and records or other information. 

(b) Buyer and Sellers will direct their respective employees (without substantial disruption of employment) to render any assistance that
Buyer or any Seller may [***] in examining or utilizing the Assigned Books and Records. 
 (c) Neither Buyer nor any Seller will destroy any
books, records, files or other information or data that are subject to this Section 5.1 until the expiration of the applicable regulatory record retention period under Applicable Laws (giving effect to any and all extensions or waivers)
without giving at least [***] days’ prior written notice to the other Party (the “Retaining Party”). Upon receipt of such notice, the Retaining Party may (i) cause to be delivered to it the books and records intended to be
destroyed, at its expense or (ii) notify the 

  
 18 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 
Party intending to destroy the books and records that it will pay the cost of storing and maintaining such books and records (including any necessary costs of moving such books and records to a
location under control of the Retaining Party and the costs of reviewing and removing from such books and records any information that the Retaining Party is not entitled to receive). 

(d) Buyer and Sellers will keep all information referred to in this Section 5.1 confidential in accordance with
Section 5.2 of this Agreement. 
 Section 5.2 Obligations of Confidentiality and Non-Use. 

(a) Each Party agrees that the Party receiving or otherwise possessing Confidential Information (the “receiving Party”) from
the other Party (the “disclosing Party”), pursuant to this Agreement shall, and shall cause its employees, directors, officers, contractors, consultants, service providers and other representatives to, keep confidential and not
publish or otherwise disclose, and take all reasonable steps to prevent disclosure of, such Confidential Information and not use such Confidential Information except for the limited purposes set forth in this Agreement. No provision of this
Agreement shall be construed to preclude disclosure of Confidential Information (i) to actual or potential sources of financing; provided that such sources are bound to the terms of this Section 5.2 to the same extent as if they
were parties hereto; (ii) in connection with disclosure obligations that arise in connection with an initial public offering; or (iii) to the extent required to be disclosed by applicable statute, rule or regulation of any court or
regulatory authority with competent jurisdiction; provided that the disclosing Party shall be notified as soon as reasonably possible and the receiving Party shall, if requested by the disclosing Party, use reasonable good faith efforts to assist in
seeking a protective order (or equivalent) with respect to such disclosure or otherwise take reasonable steps to avoid making such disclosure. For the avoidance of doubt, from and after the Closing that portion of the Confidential Information
included in the Purchased Assets shall be deemed to constitute Confidential Information of Buyer. 
 (b) Neither Party shall, directly or
indirectly, issue any press release or other public statement relating to the terms of this Agreement or the transactions contemplated hereby without the prior approval of the other Party (which shall not be unreasonably delayed, conditioned or
withheld), except (i) to the extent required by any Applicable Laws, (ii) as reasonably necessary to obtain any requisite consents and approvals contemplated by this Agreement, or (iii) to the extent necessary for a Party to comply
with its obligations hereunder. Notwithstanding anything to the contrary in the foregoing, each Party shall be permitted to make such releases or public announcements or communications to the extent consistent with previous disclosures made in
accordance with this Section 5.2(b). 
 (c) Novartis, hereby releases, on behalf of Novartis and its Affiliates, Buyer and its
officers, directors, employees and consultants from all obligations they may have with respect to that portion of the Confidential Information included in the Purchased Assets under any confidentiality agreement with or policy of any Seller covering
such Confidential Information. 

  
 19 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 Section 5.3 Technical Assistance. 

(a) For a period of eighteen (18) months from and after the Closing Date, Sellers shall fully cooperate with and provide assistance to
Buyer, through documentation, consultation, training and face-to-face meetings, to enable Buyer or its designee, in an efficient and timely manner, to proceed with Development and manufacturing of the Compound and Products and to make and obtain all
appropriate Regulatory Filings and Approvals. For any such assistance after the [***] after the Closing Date, Buyer shall compensate Sellers at [***]. 

(b) Sellers shall, [***], make appropriate personnel available to assist Buyer at any time and from time to time as reasonably requested by
Buyer, and shall provide the appropriate personnel of Buyer with access to the personnel and manufacturing and other operations of Sellers for such periods of time (not to exceed [***] following the Closing Date) and in such manner as is reasonable
in order to familiarize the personnel of Buyer or its designee with know-how relating to the Development and Manufacture of the Compound and Products and the application of the same within such four-month period. 

Section 5.4 Product Development and Commercialization; Reports. 

(a) Development. 
 (i)
Buyer shall itself, or through its Affiliates or licensees, use Commercially Reasonable Efforts to Develop at least one Product. 
 (ii)
Buyer will (A) determine the regulatory plans and strategies for the Compound or Products, (B) (either itself or through its Affiliates or licensees) make all Regulatory Filings with respect to the Products and (C) will be responsible
for making, obtaining and maintaining Regulatory Filings and Approvals in its name or that of its Affiliates or licensees, in each case, to the extent, and in a manner, consistent with [***]. 

(iii) Buyer shall (A) comply in all material respects with applicable Laws, and (B) not employ or use any person that has been
debarred under Section 306(a) or 306(b) of the U.S. Federal Food, Drug and Cosmetic Act. 
 (b) Commercialization. Sellers shall
have no responsibility for any aspects of Development or Commercialization of the Products, including planning and implementation, distribution, booking of sales, pricing or reimbursement. 

  
 20 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 (c) Reporting and Planning. 

(i) Buyer will submit to Novartis [***] with respect to Development and Commercialization activities with respect to the Compound, until the
earlier of (A) regulatory approval of a Product, or (B) cessation of Development prior to regulatory approval of a Product, consistent with Commercially Reasonable Efforts. 

(ii) Following the Closing, Buyer shall develop and provide to Novartis a detailed plan for the Development of the Compound, including with
respect to all Development work to be performed, clinical trials, milestones and any other key issues related to Development. 
 (iii)
Prior to regulatory approval of a Product, the Parties and Mereo will hold [***] (during the [***] following the Closing Date) and thereafter [***] meetings, or meetings at such longer intervals as the Parties and Mereo may agree (in any case, in
person or by teleconference) to review and discuss the Development work performed, clinical trials, milestones, any key issues and the overall status of Development. Buyer will consider in good faith comments or proposals made by Novartis during
such meetings; provided, however, that Buyer shall have sole control over all Development activities and sole decision-making authority with respect to the Development and Commercialization of Products. 

(d) Records and Audit Rights. 

(i) Each Party shall keep complete, true and accurate books and records in accordance with internationally recognized accounting standards in
relation to this Agreement, including, with respect to Buyer, in relation to Net Sales and Sales Related Payments. Each Party will keep such books and records for at least [***] following the [***] to which they pertain. 

(ii) Novartis may, upon written notice to Buyer, appoint an internationally-recognized independent accounting firm (the
“Auditor”) to inspect the relevant reports, statements, records or books of accounts (as applicable) of Buyer or its Affiliates in connection with the calculation of any Sales Related Payments. Before beginning its audit, the
Auditor shall execute an undertaking acceptable to Buyer and Novartis pursuant to which the Auditor agrees to keep confidential all information reviewed during such audit. The Auditor shall have the right to disclose to Novartis its conclusions
regarding any payments owed under this Agreement. 
 (iii) Buyer and its Affiliates shall make their records available for inspection by
such Auditor during regular business hours at such place or places where such records are customarily kept, upon receipt of reasonable advance notice from Novartis. The records shall be reviewed solely to verify the calculation of any Sales Related
Payments. Such inspection right shall not be exercised more than [***] (other than any year in which a Change of Control Transaction occurs, in which year such right may be exercised [***]) and not more frequently than [***] with respect to records
covering any [***]. Novartis agrees to hold in strict confidence all information received and all information learned in the course of any audit or inspection, except to the extent necessary to enforce its rights under this Agreement or if
disclosure is required by Applicable Law, regulation or judicial order. 

  
 21 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 (iv) The Auditor shall provide its audit report (the “Audit Report”) and
basis for any determination to Buyer at the same time the Audit Report is provided to Novartis. Buyer shall have the right to request a further determination by the Auditor as to matters which Buyer disputes by providing Novartis and the Auditor
with a reasonably detailed statement of the grounds upon which it disputes any findings in the Audit Report within [***] days following receipt of the Audit Report. The failure by Buyer to dispute the Audit Report within such [***] day period shall
constitute Buyer’s acceptance of all of the items reflected in the Audit Report. If a request for further determination is timely delivered by Buyer, the Auditor shall undertake to complete such further determination within [***] days after the
dispute notice is provided, which determination shall be limited to the disputed matters. Any matter that remains unresolved shall be resolved in accordance with the dispute resolution procedures contained in Article V. 

(v) In the event that the Audit Report (as finally agreed upon by the Parties) reveals an undisputed underpayment or overpayment in respect
of Sales Related Payments or other payments hereunder, the underpaid or overpaid amount shall be settled promptly. 
 (vi) Novartis shall
be solely responsible for all costs and expenses relating to any and all such audits as described in this Section 5.4(d). 

Section 5.5 Further Assurances; Consents. 

(a) Prior to Closing, each Party shall use commercially reasonable efforts to take such action as is reasonably necessary or appropriate in
order to complete the transactions contemplated hereby on the terms and subject to the conditions set forth herein. 
 (b) After the
Closing, at the request of Buyer from time to time Sellers shall (i) use commercially reasonable efforts to obtain and deliver such Third Party consents and (ii) execute and deliver to Buyer such certificates, consents and other
instruments of sale, conveyance, assignment and transfer, and take such other action, in each case, as may reasonably be requested by Buyer to more effectively sell, convey, assign and transfer to Buyer, to the extent required under this Agreement,
the Purchased Assets and such other assets of Sellers, if any, as are solely related to the Compound or any Product. 
 (c) To the extent
any Assumed Contract does not permit assignment or transfer by a Seller to Buyer pursuant to the Transaction Documents without the consent of a Third Party, and such consent is not obtained prior to Closing, Buyer shall waive the obligation to
obtain such consent prior to Closing. In such case, such Seller shall (i) use commercially reasonable efforts to obtain such consent promptly after the Closing, and (ii) until the earliest of: (A) the date all such consents are
obtained, (B) the date all such Assumed Contracts expire or are terminated or (C) the date which is [***] days from the Closing, such Seller and Buyer shall cooperate, in all commercially reasonable respects, to make the benefits of such
Assumed Contract available to Buyer, to the extent consistent with the terms of such Assumed Contract 

  
 22 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 
([***] by [***] of such [***]), and shall comply with all of its obligations under such Assumed Contract and, to the extent any Third Party is in breach of such Assumed Contract, enforce the
terms and conditions of such Assumed Contract if requested by Buyer at Buyer’s expense. 
 Section 5.6 Indemnity. 

(a) Novartis shall indemnify, defend and hold harmless the Buyer and its Affiliates (the “Buyer Indemnified Parties”)
from, against, and in respect of, all losses, costs, charges, claims (including Third Party claims), damages or expenses of whatever kind (including attorneys’ fees and expenses and the costs of enforcing any right to indemnification hereunder)
against or incurred by them (“Losses”) to the extent arising out of or relating to: 
 (i) any breach of any
representation or warranty of Novartis set forth in this Agreement; 
 (ii) any breach of any covenant, agreement or undertaking made by
Novartis in this Agreement; 
 (iii) any Excluded Asset or Excluded Obligation; or 

(iv) the Development, Manufacture or Commercialization of the Compound, Product or Purchased Assets prior to the Closing. 

(b) Buyer shall indemnify, defend and hold harmless Novartis and its Affiliates (the “Novartis Indemnified Parties”)
from, against and in respect of any and all Losses arising out of or relating to: 
 (i) any breach of any representation or
warranty of the Buyer set forth in this Agreement; 
 (ii) any breach of any covenant, agreement or undertaking made by the Buyer in this
Agreement; 
 (iii) any Assumed Obligation; or 

(iv) the Development, Manufacture or Commercialization of the Compound, Product or Purchased Assets following the Closing. 

(c) Notice of Claims. If any of the Persons to be indemnified under this Section 5.6 (the “Indemnified
Party”) has determined that any matters (other than a Third Party Claim) has given or could give rise to a right of indemnification under this Agreement, the Indemnified Party shall so notify the Party from whom indemnification is sought
(the “Indemnifying Party”) promptly, describing in reasonable detail, the basis for such claim. If any Indemnified Party receives written notice of the assertion of any Action (in equity or at law) instituted by a Third Party (a
“Third Party Claim”) with respect to which the Indemnified Party  

  
 23 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 
intends to claim any Loss under this Section 5.6, the Indemnified Party shall promptly notify the Indemnifying Party of such Action (the “Third Party Claim
Notice”), describing in reasonable detail, the basis for such claim. A failure by the Indemnified Party to give notice of any Action in a timely manner pursuant to this Section 5.6(c) shall not limit the obligation of the
Indemnifying Party under this Section 5.6, except (i) to the extent such Indemnifying Party is actually prejudiced thereby or (b) as provided in Section 6.2. 

(d) Third Party Claims. 

(i) The Indemnifying Party under this Section 5.6 shall have the right, but not the obligation, exercisable by written notice to
the Indemnified Party within [***] days of receipt of the Third Party Claim Notice, to assume the conduct and control, at the expense of the Indemnifying Party and through counsel of its choosing that is reasonably acceptable to the Indemnified
Party, of any Third Party Claim; provided, that the Indemnified Party shall have the right to participate in, but not control, the defense of any such Third Party Claim through counsel chosen by the Indemnified Party, whose fees and expenses shall
be borne by the Indemnified Party; and provided further that if and to the extent the Indemnifying Party cannot defend such Third Party Claim on behalf of the Indemnifying Party as a result of a conflict of interest between the Indemnifying Party
and the Indemnified Party that cannot be waived, then the Indemnifying Party [***]. If the Indemnifying Party fails to provide written notice within [***] days of receipt of a Third Party Notice that it has elected to assume the defense of such
Third Party Claim, then the Indemnified Party shall be entitled to assume the defense of such Third Party Claim at the expense of the Indemnifying Party; provided that the Indemnified Party may not compromise or settle any Third Party Claim except
as provided in Section 5.6(d)(ii). For the avoidance of doubt, if the Indemnifying Party elects not to control or conduct the defense of a Third Party Claim, the Indemnifying Party nevertheless shall have the right to participate in the
defense of any Third Party Claim and, at its own expense, to employ counsel of its own choosing for such purpose. 
 (ii) The Indemnifying
Party may compromise or settle a Third Party Claim; provided, that the Indemnifying Party shall give the Indemnified Party advance written notice of any proposed compromise or settlement and shall not, without the prior written consent of the
Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed), consent to or enter into any compromise or settlement that commits the Indemnified Party to take, or to forbear to take, any action or does not provide for
a full and complete written release by the applicable third party of the Indemnified Party. No Indemnified Party may compromise or settle any Third Party Claim for which it is seeking indemnification hereunder without the consent of the Indemnifying
Party (which consent shall not be unreasonably withheld, conditioned or delayed). No Indemnifying Party may consent to the entry of any judgment that does not relate solely to monetary damages arising from any such Third Party Claim without the
prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed). 

  
 24 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 (iii) The Parties shall cooperate in the defense of any Third Party Claim, with such cooperation
to include (i) the retention and the provision to the Indemnifying Party of records and information that are reasonably relevant to such Third Party Claim and (ii) reasonable access to employees on a mutually convenient basis for providing
additional information and explanation of any material provided hereunder. 
 Section 5.7 Supply. 

(a) The Parties shall endeavor in good faith to execute within [***] days after the Closing a supply agreement, in form and substance
reasonably satisfactory to the Parties and with pricing and commercial terms reflecting the terms customarily pertaining to Seller’s arms’ length agreements for the supply of similar products, for the clinical products that Novartis elects
to supply, and that Buyer elects to purchase from Novartis. 
 (b) For the clinical products that Novartis elects not to supply, or that
Buyer elects not to purchase from Seller, Buyer shall source such products from Third Parties, and Sellers shall, at their sole cost and expense, provide Buyer and such Third Parties with reasonable assistance in connection therewith for a period of
[***] from and after the Closing Date. After such [***] period, Sellers shall provide assistance to Buyer at an agreed cost. Sellers will not supply to Buyer commercial product, commercial active pharmaceutical ingredient or commercial finished
product. 
 Section 5.8 Noncompetition. During the period ending on the third anniversary of the Closing, neither Novartis nor
any of its Affiliates shall conduct, participate in, or directly fund, itself or with any Affiliate or Third Party, Clinical Trial activities involving any indication whose mechanism of action targets sclerostin including osteogenesis
imperfecta. Notwithstanding the foregoing, (a) Novartis and its Affiliates may [***] or [***] in, or [***], a [***] may [***] any [***] or [***] for the [***] of [***] of [***], provided (i) the [***] of such [***] is not [***] in the
[***] of [***] or [***] for the [***] of [***] of [***], and (ii) [***] and [***] any [***] or [***] for the [***] of [***] of [***] that are [***] at the [***] of such [***] to the extent reasonably necessary to [***] the [***] or [***] of
[***] in such [***]; (b) this Section 5.8 shall only apply to the extent Novartis has the ability to control the use of funds relating to, or to otherwise direct and control, such Clinical Trial activities; and (c) this
Section 5.8 shall not apply to any Third Party relationships, collaborations or contracts of Novartis that exist as of the Closing Date (including [***] any [***] to (i) [***] or [***] or (ii) [***] or [***]). 

  
 25 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 Section 5.9 Product Inquiries. 

From and after the Closing, Sellers shall direct all Product-related inquiries to Buyer. 

ARTICLE VI 

MISCELLANEOUS. 

Section 6.1 Definitions. 

As used in this Agreement, the following terms shall have the following meanings: 

“Accounting Standards” means, with respect to Buyer, International Financial Reporting Standards
(“IFRS”), consistently applied. Each Party shall promptly notify the other in the event that it changes the Accounting Standards pursuant to which its records are maintained, it being understood that each Party may only use
internationally recognized accounting principles (e.g. IFRS, United States generally accepted accounting principles, etc.). 

“Affiliate” means with respect to any Person, any other Person directly or indirectly controlling, controlled by, or
under common control with such other Person. 
 “Applicable Law” means all federal, provincial, state, local
and foreign law (including United States), (statutory, common or otherwise), constitution, treaty, convention, ordinance, code, rule, regulation, order, injunction, judgment, decree, ruling or other similar requirement. 

“BCT197 Asset Purchase Agreement” means that certain BCT197 Asset Purchase Agreement dated as of July 28, 2015
between Novartis and Mereo BioPharma 1 Limited. 
 “BGS649 Asset Purchase Agreement” means that certain
BGS649 Asset Purchase Agreement dated as of July 28, 2015 between Novartis and Mereo BioPharma 2 Limited. 

“Business” means the business of Developing and Manufacturing the Compound and includes any other actions taken in
furtherance of the Business. 
 “Clinical Trial” means any Phase 1 Clinical Trial, Phase 2 Clinical Trial,
Pivotal Clinical Trial, Phase 4 clinical trial and/or variations or subsets of such trials (for example, Pivotal Clinical Trial/Phase 4 clinical trial or Phase 1B); “Phase 1 Clinical Trial” means a controlled human clinical trial
that would satisfy the requirements of 21 C.F.R. 312.21(a) or foreign equivalents thereof; “Phase 2 Clinical Trial” means a controlled human clinical trial that would satisfy the requirements of 21 C.F.R. 312.21(b) or foreign
equivalents thereof; “Pivotal Clinical Trial” means (i) a human clinical trial of a Product that is intended to be a pivotal trial for obtaining Regulatory Approval (e.g., in the United States such clinical trial is conducted
after the end of phase 2 meeting with the FDA) and to otherwise establish safety and efficacy in patients with the disease or condition being studied and to provide an adequate basis for physician labeling, for purposes of filing a MAA for Product,
and that would satisfy the requirements under 21 C.F.R. 312.21(c) or foreign equivalents thereof, or (ii) any other clinical  

  
 26 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 
trial that is intended to establish that a pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions, and adverse reactions that are associated
with such pharmaceutical product in the dosage range to be prescribed, which clinical trial is a registration trial intended to be sufficient for filing an application for a Regulatory Approval for such product in the United States or another
country or some or all of an extra-national territory, solely as evidenced by the acceptance for filing for a Regulatory Approval for such product after completion of such clinical trial. 

“Closing Date” means the date on which the Closing occurs. 

“Commercialize” means to market, promote, distribute, import, export, offer to sell or sell Products or conduct other
Commercialization, and “Commercialization” means commercialization activities relating to Products, including activities relating to marketing, promoting, distributing, importing, exporting, offering for sale or selling Products.

 “Commercially Reasonable Efforts” means the expenditure of those efforts and resources normally used by a
comparable and similarly situated company as Buyer in the pharmaceutical industry in pursuing Development or Commercialization of similar pharmaceutical products with similar market and economic potential, within the scope of the rights granted
hereunder, and at a similar stage in Development or product life, taking into account efficacy, safety, approved labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietary position of the Products, the
likelihood of regulatory approval given the regulatory structure involved, the profitability, and other relevant factors commonly considered in similar circumstances.  

“Combination Product” means a Product that includes at least one additional active ingredient other than Compound.
Drug delivery vehicles, adjuvants, and excipients will not be deemed to be “active ingredients”, except in the case where such delivery vehicle, adjuvant, or excipient is recognized as an active ingredient in accordance with 21 C.F.R.
§ 210.3(b)(7) (as amended), or any foreign counterpart.  
 “Compound” means the active pharmaceutical
ingredient identified in Exhibit G. 1 
 “Confidential
Information” means all information and data, regardless of form, including a formula, pattern, compilation, program, method, technique, process, inventory, chemical, physical material, chemical structure or activity, design, prototype,
drawings, samples, source code, business plan, business opportunity, customer or personnel list, or financial statement proprietary to a Party or its Affiliate, except any portion thereof which: 

(a) is known to the receiving Party prior to receipt from the disclosing Party, as established by contemporaneously created written records;

  

	1 	Note to draft: include esters, salts, derivatives, etc, to the extent relevant to the particular Compound. 

  
 27 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 (b) is disclosed to the receiving Party by a Third Party, as evidenced by the receiving
Party’s contemporaneously created written records, who is under no obligation of confidentiality to the disclosing Party with respect to such information and who otherwise has a right to make such disclosure; 

(c) is or becomes published, as evidenced by a written version thereof, or generally known in the trade through no fault of the receiving
Party; or 
 (d) is independently developed by the receiving Party, without resort to the disclosing Party’s Confidential Information,
by persons having no access thereto, as evidenced by the receiving Party’s contemporaneously created written records. 
 All information and data
included within the Purchased Assets that immediately prior to Closing constitutes Confidential Information of Sellers (without regard to clause (a) or (b) above) shall, from and after Closing, be deemed to constitute Confidential
Information of Buyer, except that Novartis and its Affiliates shall continue to have the right to use such information and data for the purposes set out in Section 5.1 or to otherwise use and disclose such Confidential Information as
expressly permitted under this Agreement. 
 “Contract” means any written or oral legally binding contract,
agreement, instrument, commitment, obligation, understanding, or undertaking of any nature (including leases, licenses, mortgages, notes, guarantees, sublicenses, subcontracts, covenants not to compete, covenants not to sue, confidentiality
agreements, options and warranties). 
 “Control” (including any variations such as “Controlled”
and “Controlling”) means, with respect to any item or Patent, Know-How, or other intellectual property right, the legal authority or right (whether by ownership or license, other than by a license or sublicense granted pursuant to
this Agreement) of a Party or its Affiliates to grant to the other Party the right to use such item, or a license, sublicense or access as provided herein to such item, without violating the terms of any agreement or other arrangement with any Third
Party in existence as of the time such Party or its Affiliates would first be required hereunder to grant the other Party such license, access, or other right. For the avoidance of doubt, the foregoing definition of “Control” shall not
apply to the definition herein of “Change of Control.” 
 “Develop” or “Development”
means drug development activities, including test method development and stability testing, assay development and audit development, toxicology, formulation, quality assurance/quality control development, statistical analysis, clinical studies,
packaging development, regulatory affairs, and the preparation, filing and prosecution of NDAs and MAAs. 

“FDA” means the United States Food and Drug Administration or any successor entity thereto.  

  
 28 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 “First Commercial Sale” means the first sale of a Product by Buyer or an
Affiliate of Buyer to a Third Party in a country following Regulatory Approval of such Product in that country. Sales or transfers of reasonable quantities of a Product for research, proof of concept studies or other clinical trial purposes, or for
compassionate or similar use, shall not be considered a First Commercial Sale. 
 “Generic Equivalent” means
any (i) biosimilar of a Product or (ii) any product with the same active ingredient as a Product. 

“Governmental Authority” means any nation or government, any provincial, state, regional, local or other political
subdivision thereof, any supranational organization of sovereign states, and any entity, department, commission, bureau, agency, authority, board, court, official or officer, domestic or foreign, exercising executive, judicial, regulatory or
administrative functions of or pertaining to government. 
 “Health Care Law” shall mean all applicable Laws
relating to patient care and human health and safety, including any such applicable Law pertaining to: (i) the research, development, testing, production, manufacturing, marketing, transfer, distribution, pricing and sale of drugs and medical
devices, including the United States Food, Drug and Cosmetics Act, as amended, and all related rules, regulations and guidelines, the United States Public Health Service Act and all related rules, regulations and guidelines, and equivalent
applicable Laws of other applicable Governmental Authorities; and (ii) the privacy and security of patient-identifying health care information, including the United States Health Insurance Portability and Accountability Act of 1996 (42 U.S.C.
1320d et seq.) and all related rules, regulations and guidelines thereof and equivalent applicable Laws of other applicable Governmental Authorities. 

“Intellectual Property Rights” means (a) Patents, (b) Know-How, (c) industrial designs (whether or not
registered), (d) all rights in all of the foregoing provided by treaties, conventions and common law, (e) all rights to sue or recover and retain damages and costs and attorneys’ fees for past, present and future infringement or
misappropriation of any of the foregoing, (f) any other proprietary or intellectual property rights now known or hereafter recognized in any jurisdiction, and (g) all rights in and to the master cell bank(s) and stability materials
relating exclusively to the Compound or Products. 
 “Inventory” means all raw materials, finished Products
and intermediates, and works in process thereof related to the Business, wherever located, whether in the possession of Sellers or Third Parties. 

“Know-How” means any and all tangible, proprietary, confidential, research, technical and scientific information
existing as of the effective date of this Agreement that is not in the public domain, including information relating to materials, discoveries, unpatented inventions, improvements, practices, methods, protocols, manufacturing techniques, operating
manuals, databases, formulas, knowledge, trade secrets, technologies, processes, assays, sources, skills, experience, techniques, data and the results of experimentation and testing. 

  
 29 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 “Knowledge” means, with respect to Novartis, the actual knowledge after
reasonable inquiry of employees of Novartis responsible for the relevant matter, and with respect to Buyer, the actual knowledge after reasonable inquiry of the founders of Buyer.  

“Liability” means all debts, liabilities and obligations (including with respect to Taxes), whether accrued or fixed,
absolute or contingent, matured or unmatured, determined, determinable or indeterminable, asserted or unasserted, known or unknown, including those arising under any Applicable Laws or Proceeding and those arising under any Contract. 

“Law” means any federal, state, provincial, local, international or multinational law, statute, standard, ordinance,
code, rule, regulation, resolution or promulgation, or any order, writ, judgment, injunction, decree, stipulation, ruling, determination or award entered by or with any Governmental Authority, or any license, franchise, permit or similar right
granted under any of the foregoing, or any similar provision having the force or effect of law. 
 “Loss of Market
Exclusivity” means, with respect to any Product in any country, the following has occurred: (i) the sale of such Product in such country is not covered by a Valid Claim of any Patent owned or controlled by Buyer, its assignees or their
respective Affiliates, (ii) such Product is not subject to regulatory, data or marketing exclusivity (or similar period of exclusivity granted by any Governmental Authority) under Applicable Law, and (iii) the Net Sales of such Product in
that country in any calendar year are less than [***] as compared with the Net Sales of such Product in that country in the calendar year immediately preceding the marketing or sale of the first Generic Equivalent of such Product. 

“MAA” means an application for the authorization to market any Product in any country or group of countries outside
the United States, as defined in the applicable laws and regulations and filed with the Governmental Authority of a given country or group of countries. 

“Manufacture” means activities related to the manufacture, formulation and packaging of the Compound or any Product,
including related quality control and quality assurance activities. 
 “Material Adverse Effect” means any
change, circumstance or effect that, individually or in the aggregate, would or would reasonably be expected to (i) have a materially adverse effect on the Purchased Assets taken as a whole, including the value thereof, or on Buyer’s
ability to receive and develop the Purchased Assets free and clear of any Liens (other than Permitted Liens) pursuant hereto or (ii) prevent or materially delay consummation of the transactions contemplated hereby. 

“NDA” means a New Drug Application in the United States for authorization to market any Product, as defined in the
applicable laws and regulations and filed with the FDA. 

  
 30 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 “Patents” means national and multinational statutory invention registrations,
patents and patent applications (including provisional applications), as well as all renewals, reissues, divisions, substitutions, continuations, continuations-in-part, extensions and reexaminations and all foreign counterparts thereof, registered
or applied for in the United States and all other nations throughout the world. 
 “Permits” means all permits,
licenses, franchises, approvals, authorizations, registrations, certificates, variances and similar rights obtained, or required to be obtained, from Governmental Authorities. 

“Person” means an individual, corporation, partnership, limited liability company, association, trust or other entity or
organization, including a government or political subdivision or an agency or instrumentality thereof. 
 “Proceeding”
means any action, suit, litigation, mediation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding and any informal proceeding), prosecution, contest, hearing, inquiry, inquest, audit,
examination or investigation commenced, brought, conducted or heard by or before, or otherwise involving, any Governmental Authority or any arbitrator or arbitration panel. 

“Product” means any pharmaceutical product containing the Compound (alone or with other active ingredients), in all forms,
presentations, formulations and dosage forms. For clarification, Product will include any Combination Product. 
 “Purchased
IP” means all Patents and Know-How Controlled by any of the Sellers that are exclusively related to the Compound or any Product, including, without limitation, the Patents set forth on Schedule 1.1(a). 

“Regulatory Filings and Approvals” means, with respect to any pharmaceutical product in any jurisdiction, any and all
regulatory applications, filings, approvals, and associated correspondence required to develop, manufacture, market, sell, and import such product in, or into, any jurisdiction, and all approvals from any regulatory authority necessary for the sale
of such product in a given jurisdiction in accordance with all Applicable Laws. 
 “Sales Related Payments Term” means the
period of ten (10) years following the First Commercial Sale of a Product. 
 “Tax” means any federal, state, local or
foreign income, gross receipts, license, payroll, employment, excise, severance, stamp, occupation, premium, windfall profits, environmental, customs duties, capital stock, franchise, profits, withholding, social security, unemployment, disability,
real property, personal property, sales, use, transfer, registration, value added, alternative or add-on minimum, estimated, or other tax, including any interest, penalty or addition thereto, imposed by any Governmental Authority (a “Taxing
Authority”) responsible for the imposition of any such tax (domestic or foreign). 

  
 31 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 “Third Party” means any Person other than Buyer, Novartis or their respective
Affiliates. 
 “Transaction Documents” means this Agreement, the Subscription Agreement, the Morphosys Sublicense, the Bill
of Sale, the Patent Assignment and any other agreements, certificates and instruments executed and delivered in connection with the transactions contemplated by this Agreement. 

“Valid Claim” means a claim of an issued and unexpired patent, or a pending claim of a patent application that is being
prosecuted, that has not been held unpatentable, invalid or unenforceable by a court or other Governmental Authority with no further right of appeal. 

Section 6.2 Survival of Representations and Warranties and Covenants. 

The representations and warranties of the Parties contained in this Agreement shall survive the Closing until the date that is eighteen
(18) months after the Closing Date, provided, that the representations and warranties set forth in Sections 2.1, 2.2, 2.3 and Sections 3.1 and 3.2 shall survive indefinitely. The covenants and agreements of
the Parties contained in this Agreement shall survive the Closing in accordance with their terms. 
 Section 6.3 Notices. 

All notices, requests, demands and other communications which are required or may be given under this Agreement shall be in writing and shall
be deemed to have been duly given when received if personally delivered; upon receipt if transmitted by email; the day after it is sent, if sent for next day delivery to a U.S. address by recognized overnight delivery service (e.g., Federal
Express); and upon receipt, if sent by certified or registered mail, return receipt requested, as follows: 
 If to Buyer: 

Mereo BioPharma 3 Limited 
 15
Stratton Street 
 London 
 W1J
8LQ 
 United Kingdom 

Attention : [***] 
 With a copy
(which shall not constitute notice) to: 
 Proskauer Rose LLP 

Eleven Times Square 
 New York NY
10036 
 Attention: [***] 

  
 32 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 If to Seller: 

Novartis Pharma AG 
 Lichtstrasse
35 
 CH-4002, Basel, Switzerland 

Attention: Head – Business Development & Licensing 

With a copy (which shall not constitute notice) to: 

Novartis Pharma AG 
 Lichtstrasse
35 
 CH-4002, Basel, Switzerland 

Attention: General Counsel 
 or to such other
place and with such other copies as either party may designate as to itself by written notice to the others. 
 Section 6.4
Governing Law; Jurisdiction. 
 This Agreement will be governed by and construed in accordance with the laws of the State of New York,
without regard to the conflict of law principles thereof. Each of the Parties irrevocably agrees that any Proceeding arising out of or relating to this Agreement brought by any other party or its successors or assigns shall be brought and determined
in federal court (or, if such court does not have subject matter jurisdiction, state court) sitting in the City and County of New York, and each of the Parties hereby irrevocably submits to the exclusive jurisdiction of the aforesaid courts for
itself and with respect to its property, generally and unconditionally, with regard to any such Proceeding arising out of or relating to this Agreement and the transactions contemplated hereby. Each of the Parties agrees not to commence any Action
relating thereto except in the courts described above in the City and County of New York, other than Actions in any court of competent jurisdiction to enforce any judgment, decree or award rendered by any such court. Each of the Parties further
agrees that notice as provided herein shall constitute sufficient service of process and the Parties further waive any argument that such service is insufficient. Each of the Parties hereby irrevocably and unconditionally waives, and agrees not to
assert, by way of motion or as a defense, counterclaim or otherwise, in any action or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby, (a) any claim that it is not personally subject to the
jurisdiction of the courts described herein for any reason, (b) that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment
prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) or (c) that (i) the Action in any such court is brought in an inconvenient forum, (ii) the venue of such Action is improper or
(iii) this Agreement, or the subject matter hereof, may not be enforced in or by such courts. The Parties acknowledge and agree that the transactions contemplated by this Agreement are not transactions pursuant to which Buyer shall have any
obligations under the Transfer of Undertakings (Protection of Employment) Regulations 2006. 

  
 33 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 Section 6.5 Waiver of Jury Trial. 

EACH OF THE PARTIES IRREVOCABLY AND UNCONDITIONALLY WAIVES THE RIGHT TO TRIAL BY JURY IN ANY ACTION OR PROCEEDING RELATING TO THIS AGREEMENT,
THE TRANSACTION DOCUMENTS OR ANY OTHER AGREEMENTS CONTEMPLATED HEREBY OR THE CONTEMPLATED TRANSACTIONS AND FOR ANY COUNTERCLAIM THEREIN. 

Section 6.6 Payments; Expenses. 

For the avoidance of doubt, no payments shall become due and payable and neither Party will be obligated to reimburse the other Party for any
costs incurred by the other Party under or in connection with this Agreement unless and until the Closing has occurred. Except as otherwise specified herein, all costs and expenses, including fees and disbursements of counsel, financial advisors and
accountants, incurred in connection with this Agreement and the transactions contemplated hereby will be paid by the Party incurring such costs and expenses, whether or not the Closing will have occurred. 

Section 6.7 Counterparts. 

This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall
constitute one and the same instrument. 
 Section 6.8 Entire Agreement. 

This Agreement, including the Schedules and Exhibits hereto and the documents referred to herein, embodies the entire agreement and
understanding of the Parties hereto in respect of the subject matter contained herein. This Agreement supersedes all prior agreements and understandings (including any confidentiality agreements) between the Parties with respect to such subject
matter. 
 Section 6.9 Amendment and Modification. 

This Agreement may be amended or modified only by written agreement of the Parties hereto. 

Section 6.10 Binding Effect; Benefits. 

This Agreement shall inure to the benefit of and be binding upon the Parties hereto and their respective successors and assigns; nothing in
this Agreement, express or implied, is intended to confer on any Person other than the Parties hereto and their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement. 

  
 34 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 Section 6.11 Assignability. 

This Agreement shall not be assignable by any Party hereto without the prior written consent of the other Party except that (i) either
Party may assign its rights under this Agreement to any of such Party’s Affiliates without the prior written consent of the other Party and (ii) Buyer may assign its rights under this Agreement to any Person acquiring all of the Products
or Purchased Assets. 
 Section 6.12 Interpretation Provisions. 

(a) The words “hereof,” “herein” and “hereunder” and words of similar import when used in this Agreement refer to
this Agreement as a whole and not to any particular provision of this Agreement, and Article, Section, Schedule and Exhibit references are to this Agreement unless otherwise specified. The meaning of defined terms shall be equally applicable to the
singular and plural forms of the defined terms. The term “or” is inclusive and not exclusive, unless its use is preceded by the word “either” or other words of similar import. The terms “include” and
“including” are not limiting and mean “including without limitation.” Use of a particular gender is for convenience only and is not intended to be a part of or to affect or restrict the meaning or interpretation of this
Agreement. 
 (b) References to agreements and other documents shall be deemed to include all subsequent amendments and other modifications
thereto. 
 (c) References to statutes shall include all regulations promulgated thereunder and references to statutes or regulations shall
be construed as including all statutory and regulatory provisions consolidating, amending or replacing the statute or regulation. 
 (d) The
captions and headings of this Agreement are for convenience of reference only and shall not affect the construction of this Agreement. 

(e) The language used in this Agreement shall be deemed to be the language chosen by the Parties to express their mutual intent, and no rule
of strict construction shall be applied against any party. 
 (f) The Schedules and Exhibits to this Agreement are a material part hereof
and shall be treated as if fully incorporated into the body of this Agreement. 
 Section 6.13 Severability. 

Whenever possible, each provision or portion of any provision of this Agreement shall be interpreted in such manner as to be effective and
valid under Applicable Law, but if any provision or portion of any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any Applicable Law or rule in any jurisdiction, such invalidity, illegality or
unenforceability shall not affect the validity, legality or enforceability of any other provision or portion of any provision in such jurisdiction. 

  
 35 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 Section 6.14 Specific Performance. 

The Parties agree that irreparable damage would occur in the event any provision hereof were not performed in accordance with the terms hereof
and that the Parties will be entitled to specific performance of the terms hereof, in addition to any other remedy at law or in equity without the necessity of demonstrating the inadequacy of monetary damages and without the posting of a bond. 

Section 6.15 Disclaimer. 

IT IS UNDERSTOOD, ACKNOWLEDGED AND AGREED THAT, EXCEPT AS SET FORTH HEREIN NOVARTIS MAKES NO EXPRESS OR IMPLIED WARRANTIES OR REPRESENTATIONS
OF ANY KIND OR CHARACTER WITH RESPECT TO THE PURCHASED ASSETS OR ANY OTHER MATTER OR THING REGARDING THE PURCHASED ASSETS. BUYER ACKNOWLEDGES AND AGREES THAT UPON CLOSING SELLERS SHALL SELL AND CONVEY TO BUYER AND BUYER SHALL ACCEPT THE PURCHASED
ASSETS “AS IS, WHERE IS, WITH ALL FAULTS”, EXCEPT TO THE EXTENT EXPRESSLY PROVIDED OTHERWISE IN THIS AGREEMENT. BUYER HAS NOT RELIED AND WILL NOT RELY ON, AND NOVARTIS IS NOT LIABLE FOR OR BOUND BY, ANY EXPRESS OR IMPLIED WARRANTIES,
GUARANTIES, REPRESENTATIONS OR INFORMATION PERTAINING TO THE PURCHASED ASSETS MADE OR FURNISHED BY SELLER, ITS AFFILIATES OR ANY AGENT REPRESENTING OR PURPORTING TO REPRESENT SELLER, TO WHOMEVER MADE OR GIVEN, DIRECTLY OR INDIRECTLY, ORALLY OR IN
WRITING, UNLESS SPECIFICALLY SET FORTH IN THIS AGREEMENT, THE NOVARTIS DISCLOSURE SCHEDULE, THE TRANSACTION DOCUMENTS OR ANY ANCILLARY AGREEMENT. WITHOUT IN ANY WAY LIMITING THE FOREGOING, NOVARTIS HEREBY DISCLAIMS ANY WARRANTY, EXPRESS OR IMPLIED,
OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE AS TO ANY PORTION OF THE PURCHASED ASSETS. BUYER REPRESENTS TO NOVARTIS THAT BUYER HAS CONDUCTED, OR WILL CONDUCT PRIOR TO CLOSING, SUCH INVESTIGATIONS OF THE PURCHASED ASSETS AS BUYER DEEMS
NECESSARY AND WILL RELY SOLELY UPON SAME AND NOT UPON ANY INFORMATION PROVIDED BY OR ON BEHALF OF NOVARTIS OR ITS AGENTS OR EMPLOYEES WITH RESPECT THERETO, OTHER THAN SUCH REPRESENTATIONS, WARRANTIES AND COVENANTS OF NOVARTIS AS ARE EXPRESSLY SET
FORTH IN THIS AGREEMENT. 

  
 36 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 Section 6.16 Obligations of Party’s Affiliates. 

Each Party shall cause its controlled Affiliates that are entities to perform any obligations of such Party and its Affiliates that are
entities in connection with the Purchased Assets and the consummation of the transactions contemplated by this Agreement. 

[Signature page follows] 

  
 37 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 IN WITNESS WHEREOF, the Parties hereto have duly executed this Agreement as of the date first
above written. 
  

			
	Seller:	 	 
	
	NOVARTIS PHARMA AG
		
	By:	 	 /s/ Matt Owens

	Name:	 	Matt Owens
	Title:	 	Global Head Legal Strategic Partnerships & Digital Medicine
		
	By:	 	 /s/ Efthymis Lioulias

	Name:	 	Efthymis Lioulias
	Title:	 	Senior Legal Counsel
		
	Buyer:	 	
	
	MEREO BIOPHARMA 3 LIMITED
		
	By:	 	 /s/ Denise Scots-Knight

	Name:	 	Denise Scots-Knight
	Title:	 	Chief Executive Officer

 [Signature Page to BPS804 Asset Purchase Agreement] 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 SCHEDULE 1.1(a) 

PURCHASED IP 
 [See attached]

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 [***] 

Note: Highlighted rows indicate patent is abandoned 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 SCHEDULE 1.1(b) 

ASSUMED CONTRACTS 
 [***] 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 SCHEDULE 1.1(c) 

REGULATORY FILINGS AND APPROVALS 
 [***] 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 SCHEDULE 1.1(e) 

PURCHASED INVENTORY 
  

			
	PROJECT:	  	BPS804

 [***] 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 SCHEDULE 1.7(f) 

NOVARTIS DISCLOSURE SCHEDULE 
 [***] 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 SCHEDULE 1.7(g) 

CONSENTS 
 [***] 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 EXHIBIT A 

MORPHOSYS SUBLICENSE 

[Intentionally Omitted -please refer to the fully executed version of the Morphosys 

Sublicense, which has been filed as Exhibit 10.20 to the F-1.] 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 EXHIBIT B 

SUBSCRIPTION AGREEMENT 
 [See
attached] 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 Subscription Agreement 

relating to ordinary shares to be 
 allotted by Mereo BioPharma
Group Limited 
  

			
	Dated	  	July 2015

  

	(1)	Institutional Investors 

	(2)	Mereo Founders 

	(3)	Company 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

			
	DATE	  	July 2015

 PARTIES 
  

	(1)	THE PERSONS whose names and addresses are set out in Schedule 1 (the “Institutional Investors”); 

  

	(2)	THE PERSONS named in rows 1 to 9 (inclusive) of Schedule 2 (the “Mereo Founders”) and 

  

	(3)	Mereo BioPharma Group Limited a company registered in England and Wales (company number 9481161) whose registered office is at Green Park House, 15 Stratton Street, London, W1J 8LQ (“the Company”).

 INTRODUCTION 
  

	(A)	The Mereo Newcos, each a wholly owned subsidiary of the Company, intend to enter into agreements to be dated on or around the date of this Agreement to acquire a portfolio of assets from Novartis Pharma AG in accordance
with the terms of the Novartis Asset Sale Agreements. 

  

	(B)	Each of the Investors are to subscribe for their respective Ordinary Shares in cash, save for Novartis which will receive its Ordinary Shares as consideration for the assignment to the Company of the benefit of certain
loan notes issued to Novartis by the Mereo Newcos in exchange for the sale of the Novartis Assets pursuant to the Novartis Asset Sale Agreements. 

  

	(C)	Immediately following Completion, the share capital of the Company shall be held as set out in column 2 of Schedule 2 of this Agreement. 

OPERATIVE PROVISIONS 
  

	1.	DEFINITIONS AND INTERPRETATION 

  

	1.1	In this Agreement the words and expressions set out below shall have the following meanings: 

  

			
	Agreement	  	this agreement, including the Schedules to this agreement
		
	Authorisation	  	means
		
		  	 (a)    an approval, authorisation, consent, declaration, exemption, permit,
licence, notarisation or waiver, however it is described, and including any condition attached to it; and

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

			
		  	 (b)    in relation to anything that could be prohibited or restricted by law
if a Government Agency acts in any way within a specified period, the expiry of that period without that action being taken

		
	Business Day	  	a day, except a Saturday or Sunday, on which banks in the City of London are generally open for business
		
	Business Plan	  	the initial business plan which is attached to this Agreement as Annex A and as may be updated from time to time
		
	Call Notice	  	As defined in clause 2.11
		
	Call Option	  	as defined at clause 2.11
		
	Call Option Price	  	means in respect of each Founder, the price specified in column 3 of Schedule 6, being the nominal value of such shares
		
	Call Option Shares	  	means such number of the Ordinary Shares held by each Founder as is specified at column 2 of Schedule 6
		
	Company’s Solicitors	  	Proskauer Rose (UK) LLP of 110 Bishopsgate, London, EC2N 4AY
		
	Completion	  	completion by the parties of their respective obligations in accordance with clause 5 upon satisfaction of the Conditions
		
	Commitment	  	in respect of each Investor, the amount set out against its name in column 2 of Part A of Schedule 1
		
	Conditions	  	as defined in clause 4
		
	Confidential Information	  	all information which relates to:
		
		  	 (a)    the Group;

		
		  	 (b)    any aspect of the business of the Group operated by any of the
subsidiaries of the Company;

		
		  	 (c)    the provisions and subject matter of this Agreement;
and

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

			
		  	 (d)    the negotiations relating to this Agreement

		
	Controlling Stake	  	more than 50 per cent in number of the issued shares
		
	Dilutive Event	  	any action taken by the Company having the effect that, immediately following such Dilutive Event and but for the operation of clause 7.1 of this Agreement, the shares held by Novartis in the Company would represent less than 19.5%
of the total economic and voting rights in the Company, including but not limited to: any issue of shares in the equity share capital of the Company or the exercise of any right to subscribe for or convert any security into, such shares, whether for
cash or by way of dividend, distribution or capitalisation of profits or reserves (including share premium account and any capital redemption reserve); or any amalgamation or merger of the Company into or with another entity
		
	Drawdown Notice	  	as defined in clause 2.8
		
	Employment Agreements	  	the agreed form employment agreements between the Company and each of Denise Pollard-Knight, Charles Sermon, Richard Bungay and Alastair MacKinnon
		
	Exit	  	any of the following:
		
		  	 (a)    the obtaining of a Listing;

		
		  	 (b)    the completion of a Sale; or

		
		  	 (c)    completion of a liquidation, winding up or dissolution of the
Company

		
	Fully Diluted	  	the aggregate, from time to time, of all shares issued in the equity share capital of the Company, and all such shares capable of being issued by the Company pursuant to all outstanding rights to subscribe for, or convert any
security into, any shares in the equity share capital of the Company as if those outstanding rights had been exercised in full, but excluding the Options

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

			
	Full Title Guarantee	  	means with the benefit of the implied covenants set out in Part 1 of the Law of Property (Miscellaneous Provisions) Act 1994 when a disposition is expressed to be made with full title guarantee
		
	Further Subscription	  	a subscription for Ordinary Shares pursuant to clause 2.7
		
	Government Agency	  	a government or governmental, semigovernmental, administrative, fiscal or judicial body, department, commission, authority, tribunal, agency or entity whether foreign, federal, state, territorial or local
		
	Group	  	the Company and its subsidiary undertakings from time to time and “Group Company” shall be interpreted accordingly
		
	Initial Price	  	£1.84 per Ordinary Share
		
	Invesco	  	Invesco Asset Management Limited acting as agent for and on behalf of the Invesco Fund
		
	Invesco Fund	  	the Invesco Perpetual High Income Fund and with all shares held in the name of its nominee
		
	Invesco Permitted Transferee	  	means:
		
		  	Where the relevant Shareholder is an Investment Manager or a nominee of an Investment Manager:
		
		  	 (a)    any participant or partner in or member of any Investment Fund in
respect of which the shares to be transferred are held (but only in connection with the dissolution of such Investment Fund or any distribution of assets of the Investment Fund pursuant to the operation of the Investment Fund in the ordinary
course); or

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

			
		  	 (b)    any Investment Fund whose business is managed by the Investment Manager
who is or whose nominee is the transferor; or

		
		  	 (c)    any other Investment Manager who manages the business of the Investment
Fund in respect of which the shares are held; or

		
		  	 (d)    any nominee or custodian of (a) to (c); or

		
		  	 (e)    any mandate controlled by or managed by or advised by an Investment
Manager.

		
		  	Where the relevant Shareholder is an Investment Fund or nominee of an Investment Fund to:
		
		  	 (a)    any partner in or member of the Investment Fund which is or whose
nominee is the transferor (but only in connection with the dissolution of such Investment Fund or any distribution of assets of the Investment Fund pursuant to the operation of the Investment Fund in the ordinary course); or

		
		  	 (b)    any other Investment Fund whose business is managed by the same
Investment Manager as manages the Investment Fund which is or whose nominee is the transferor or another Investment Manager in the Invesco group of companies; or

		
		  	 (c)    the Investment Manager who manages the business of the Investment Fund
which is or whose nominee is the transferor; or

		
		  	 (d)    any nominee or custodian of (a) to (c);

		
		  	 (e)    any mandate controlled by or managed by or advised by an Investment
Manager

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

			
	Investment Fund	  	any person (including a company), fund, partnership, investment syndicate or other entity holding shares (including any beneficial interest in shares) in the Company for investment purposes and not being an Employee (as defined in
the New Articles) or Permitted Transferee (as defined in the New Articles) of an Employee
		
	Investment Manager	  	means an organisation whose principal business is to make or advise upon investments
		
	Investors	  	each of (1) the Institutional Investors and (2) the Mereo Founders
		
	Investor Counsel Fees	  	means an aggregate amount of £100,000 to be deducted by Invesco, Woodford and WEIF from their respective subscription fees in accordance with clause 14.2
		
	Listing	  	means the admission of all or any of the shares of the Company or securities representing those shares (including without limitation depositary interests, American depositary receipts, American depositary shares and/or other
instruments) on NASDAQ or on the Official List of the United Kingdom Listing Authority or on the AIM Market operated by the London Stock Exchange Plc or any other recognised investment exchange (as defined in section 285 of the Financial Services
and Markets Act 2000)
		
	Long Stop Date	  	10 Business Days following the date of this Agreement
		
	Mereo Newcos	  	Mereo BioPharma 1 Limited (company number 0946998), Mereo BioPharma 2 Limited (company number 09647035) and Mereo BioPharma 3 Limited (company number 09647034) whose registered offices are at Green Park House, 15 Stratton Street,
London, W1J 8LQ

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

			
	New Articles	  	the articles of association to be adopted by the Company at Completion (in the agreed form) and as may be amended from time to time
		
	Novartis	  	Novartis Pharma AG, Lichtstrasse 35, CH-4002, Basel, Switzerland
		
	Novartis Assets	  	the intellectual property and other assets held by Novartis immediately prior to Completion which are being acquired by the Mereo Newcos pursuant to the terms of the Novartis Asset Sale Agreements
		
	Novartis Asset Sale Agreements	  	the three asset sale agreements and licence agreement to be entered into between Novartis and each of the Mereo Newcos on or around the date of this Agreement in relation to the sale and licence of the Novartis Assets
		
	Ordinary Shares	  	ordinary shares of £0.001 each in the capital of the Company
		
	Options	  	options to acquire Ordinary Shares pursuant to an employee share option scheme
		
	Payment Instructions Agreement	  	the payment instructions agreement between, amongst others, certain investors and the Company’s Solicitors to be entered into on or about the date hereof, in the agreed form
		
	Project Berkeley Data Room	  	the online data room providing information on the Group and the Novartis Assets and made available to the Institutional Investors
		
	Pro Rata Portion	  	means in respect of Invesco, the lower of (i) the proportion which the aggregate number of Ordinary Shares held by the Invesco Fund and any Invesco Permitted Transferee bears to the total aggregate number of Ordinary Shares held by
the Invesco Fund, any Invesco Permitted Transferee, Woodford and WEIF; or (ii) unless Invesco has nominated an alternative fund managed by Invesco to take up all or part of its Pro Rata Portion pursuant to clause 2.17, such number of Ordinary Shares
as would result in the Invesco Fund holding, when aggregated with the Ordinary Shares already held by the Invesco Fund, not more than 19.5% of the then issued voting share capital in the Company; and in
respect

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

			
		  	of Woodford, the proportion which the aggregate number of Ordinary Shares held by Woodford bears to the total aggregate number of Ordinary Shares held by the Invesco Fund, any Invesco Permitted Transferee, Woodford and WEIF; and in
respect of WEIF, the proportion which the aggregate number of Ordinary Shares held by WEIF bears to the total aggregate number of Ordinary Shares held by the Invesco Fund, any Invesco Permitted Transferee, Woodford and WEIF, in each case on the date
of the Call Option Notice.
		
	Qualifying IPO	  	means an initial public offering of shares in the capital of the Company which results in gross proceeds to the Company of not less than £100,000,000 (excluding, for the avoidance of doubt, the Remaining Commitments) at a
price per share representing an uplift to the post-Completion valuation of the Company of not less than 20%
		
	Remaining Commitments	  	in respect of each Investor, the amount specified in column 5 of Part A of Schedule 1 subject to clause 2.9
		
	Sale	  	 (a)    the disposal by the Company of all or substantially all of its
undertaking and assets (where disposal may include, without limitation, the grant by the Company of an exclusive licence of intellectual property not entered into in the ordinary course of business); or

		
		  	 (b)    the sale of (or the grant of a right to acquire or to dispose of) any
of the shares in the capital of the Company (in one transaction or as a series of transactions) which will result in the purchaser of those shares (or grantee of that right) and persons acting in concert with him together acquiring a Controlling
Stake in the Company, except where following completion of the sale the shareholders and the proportion of shares held by each of them are the same as the shareholders and their shareholdings in the Company immediately prior to the
sale

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

			
	Target Group	  	the Company and each of the Mereo Newcos, and “Group Company” shall mean each of them
		
	Transaction Agreements	  	this Agreement and the New Articles
		
	Warranties	  	the warranties given pursuant to clause 6
		
	WEIF	  	CF Woodford Equity Income Fund, acting by its agent Woodford Investment Management LLP, whose details are set out at Schedule 1
		
	Woodford	  	Woodford Patient Capital Trust plc, acting by its agent Woodford Investment Management LLP, whose details are set out at Schedule 1

  

	1.2	Words and expressions which are defined in the Companies Act 2006 shall have the meanings attributed to them in that Act when used in this Agreement unless otherwise defined. 

 

	2.	CAPITAL COMMITMENTS AND SUBSCRIPTIONS FOR ORDINARY SHARES 

 Commitments 

 

	2.1	Each Investor may be required to contribute cash to the Company from time to time in accordance with this clause 2, up to an aggregate amount equal to that Investor’s Commitment. No Investor shall be entitled to
interest on its Commitment. 

 Loan note exchange 
  

	2.2	Novartis shall transfer to the Company on Completion the number of loan notes issued by the Mereo Newcos set opposite its name in column 2 of Part B of Schedule 1 of this Agreement (being all of the loan notes held by
Novartis) in consideration of the issue by the Company to Novartis of the Ordinary Shares to be issued to Novartis pursuant to clause 2.3(b) and clause 7, below. 

Subscription and issue of shares 
  

	2.3	On Completion: 

  

	 	(a)	the Institutional Investors (as set out in Schedule 1) other than Novartis shall subscribe in cash for and shall be issued the number of Ordinary Shares set opposite their name in column 3 of Part A of Schedule 1 for
the price specified in column 4 of Part A of Schedule 1; and 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	 	(b)	the Company shall issue to Novartis of the number of Ordinary Shares set opposite its name in column 3 of Part B of Schedule 1. 

  

	2.4	Following Completion, the share capital of the Company shall be as set out in Schedule 2. 

  

	2.5	The parties hereby agree that full payment of the subscription monies for the respective Institutional Investors’ Ordinary Shares set out in clause 2.3(a) upon Completion shall be satisfied out of the monies that
are or are to be, held by the Company’s Solicitors to the order of the Institutional Investors, pursuant to the Payment Instructions Agreement. 

  

	2.6	Upon entry into this Agreement the Company shall hold a board meeting at which the applications for Ordinary Shares set out in Schedule 1 to this Agreement shall be approved with such Ordinary Shares to be allotted and
issued to the Institutional Investors by the Company subject only to Completion, with the relevant names to be entered into the Company’s register of members upon Completion. 

 

	2.7	Simultaneously with and upon entry into this Agreement, each of the parties who are a party to the Payment Instructions Agreement shall execute and deliver the Payment Instructions Agreement. 

Drawdown of Remaining Commitment 
  

	2.8	Immediately prior to a Listing, or, if earlier, on 31 March 2016 and at any time after that date but before 1 June 2016, the board of directors of the Company may cause the Company to issue a notice
(“Drawdown Notice”) to each Investor, requiring that such Investor subscribe for additional Ordinary Shares at the Initial Price per Ordinary Share, up to an amount equal to such Investor’s Remaining Commitment (subject to
clause 2.9 below). Each such Investor shall contribute the required amount in immediately available cash funds within five (5) Business Days after receipt of such notice. Woodford may transfer all or part of its obligation under this clause to
WEIF and vice versa. 

  

	2.9	The amount that the Invesco Fund may be required to subscribe for additional Ordinary Shares pursuant to clause 2.8 shall not exceed the lower of (i) its Remaining Commitment; and (ii) such amount as would
result in the Invesco Fund holding, immediately following completion of the Further Subscriptions of each Investor, not more than 19.5% of the then issued voting share capital in the Company. 

 

	2.10	The Invesco Fund’s participation in any Further Subscriptions is conditional upon (i) the Company’s continuing compliance with this Agreement and the New Articles; and (ii) such participation not
resulting in a contravention of any applicable laws, regulations or other legal requirements of whatever nature. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 Call Option 
  

	2.11	At any time on or after 31 March 2016, but prior to a Listing Woodford, WEIF and Invesco shall be entitled (“Call Option”) to issue to all (but not some only) of the Founders a notice
(“Call Notice”) requiring such Founder to transfer to the Invesco Fund and Woodford his or her Call Option Shares in consideration of payment to him or her of the Call Option Price. 

 

	2.12	The Call Option is exercised on the date on which the Call Notice is issued, and the sale and purchase of the Call Option Shares shall take place on the date which is ten (10) Business Days after the exercise of
the Call Option, on which date: 

  

	 	(a)	each Founder shall deliver 

  

	 	(i)	to Woodford a duly executed stock transfer form in favour of Woodford in respect of its Pro Rata Portion of the Call Option Shares; 

  

	 	(ii)	to WEIF a duly executed stock transfer form in favour of WEIF in respect of its Pro Rata Portion of the Call Option Shares; 

  

	 	(iii)	to Invesco (or its nominee) a duly executed stock transfer form in favour of the Invesco Fund in respect of its Pro Rata Portion of the Call Option Shares; and 

 

	 	(iv)	to the Company share certificates evidencing his or her ownership of the Call Option Shares set out opposite his or her name at Schedule 6, for cancellation; and 

 

	 	(b)	each of Woodford and Invesco shall pay to each of the Founders in cash or immediately available funds its Pro Rata Portion the Call Option Price. 

 

	2.13	A Call Notice may not be issued to any Founder pursuant to clause 2.11 unless the Institutional Investor issuing such Call Notice also issues a Call Notice to each of the other Founders at the same time and requires
each Founder to transfer an equal percentage portion of their Call Option Shares. 

  

	2.14	The Call Option Shares shall be sold by each Founder with Full Title Guarantee and free from all Encumbrances and together with all rights attaching to them on the date of such transfer. 

 

	2.15	If Invesco, Woodford and WEIF do not issue a Call Option Notice within 30 Business Days of becoming entitled to do so, the Call Option shall automatically lapse and cease to be exercisable. 

 

	2.16	Woodford shall be entitled to specify in the Call Option Notice that some or all of its Pro Rata Portion of a Founder’s Call Option Shares be transferred to WEIF, and vice versa. In such case clause 2.12(a)(i) and
clause 2.12(b) shall be deemed to be amended accordingly. 

  

	2.17	Invesco shall be entitled to specify in the Call Option Notice that some or all of the Invesco Fund’s Pro Rata Portion of a Founder’s Call Option Shares be transferred to an alternative fund managed by Invesco
that is not the Invesco Fund. In such case clause 2.12(a)(ii) and clause 2.12(b) shall be deemed to be amended accordingly. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 Non-Qualifying IPO 
  

	2.18	In the event of any Listing which is not a Qualifying IPO, the parties shall discuss and agree in good faith an adjustment to the number of Ordinary Shares held by the Founders. 

 

	3.	OPTIONS 

  

	3.1	The parties acknowledge and agree that an option pool representing no more than fifteen per cent. (15%) of the diluted share capital of the Company following the issues of shares contemplated by this Agreement
shall be available following Completion for the purposes of incentivising current and future employees of the Company and its group of companies (the “Option Pool”). The Option Pool represents the only shares that may comprise an
Employee Issue under the New Articles. 

  

	3.2	Following Completion, the Company intends to issue the Options as set out in column 5 of Schedule 2 of this Agreement. 

  

	4.	CONDITIONS PRECEDENT 

  

	4.1	The obligations of the Company and the Institutional Investors to be performed at Completion under this Agreement are conditional upon: 

 

	 	(a)	each of the conditions to the Novartis Asset Sale Agreements, other than the condition set out at clause 1.9(b)(viii) of each of the Novartis Asset Sale Agreements, having been duly satisfied or waived in accordance
with the terms of such agreement; 

  

	 	(b)	the Company having received subscription agreements from investors which taken together total aggregate subscriptions to be received on behalf of the Company on Completion of not less than £20,000,000 less the
Investor Counsel Fees (the “Conditions”). 

  

	5.	COMPLETION 

  

	5.1	Subject to the provisions of this Agreement, Completion shall occur at the time and place specified in the Novartis Asset Sale Agreements and simultaneously with completion under the Novartis Asset Sale Agreements.

  

	5.2	On Completion the Company shall: 

  

	 	(a)	adopt the New Articles of the Company; 

  

	 	(b)	enter into the Employment Agreements as agreed between the Company and the relevant employees; 

  

	 	(c)	deliver to each of the Institutional Investors certificates for the Ordinary Shares as set out in clause 2.1; and 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	 	(d)	enter each of the Institutional Investors into the Company’s register of members in respect of the Ordinary Shares set opposite its name in column 3 of Part A of Schedule 1. 

 

	5.3	It is acknowledged and agreed that, immediately following Completion: 

  

	 	(a)	the board of directors of the Company shall be comprised of Denise Pollard- Knight (chief executive officer), Peter Fellner (chairman), Frank Armstrong, Anders Ekblom, Peter Bains and Kunal Kashyap; 

 

	 	(b)	in addition to any right to appoint a director under the New Articles, each of Invesco, Novartis and Woodford shall be entitled to nominate one person to act as an observer of board meetings in accordance with the New
Articles; 

  

	 	(c)	Charles Sermon shall be the company secretary; and 

  

	 	(d)	each of Woodford and Invesco will be entitled to nominate one person to act as a director of the Company, in accordance with and subject to the New Articles. 

 

	6.	WARRANTIES 

  

	6.1	Each Investor warrants to each other party as of the date of this Agreement that: 

  

	 	(a)	if it is a company, it is a company limited by shares duly incorporated and validly existing under the laws of the place of its incorporation; 

 

	 	(b)	it has full legal capacity and power to: 

  

	 	(i)	own its property and to carry on its business; and 

  

	 	(ii)	enter into the Transaction Agreements and to perform its obligations under the Transaction Agreements; 

  

	 	(c)	if it is a company, it has taken all corporate action that is necessary to authorise its entry into the Transaction Agreements and the performance of its obligations under the Transaction Agreements; 

 

	 	(d)	this Agreement constitutes, and will, when executed, constitute legal, valid and binding obligations, enforceable against it in accordance with its terms; 

 

	 	(e)	it holds each Authorisation that is necessary to: 

  

	 	(i)	enable it properly to execute the Transaction Agreements and to perform its obligations under the Transaction Agreements; 

  

	 	(ii)	ensure that the Transaction Agreements are legal, valid, binding and admissible in evidence; and 

  

	 	(iii)	enable it to carry on its business, and it is complying in all material respects with any conditions to which any of these Authorisations is subject; 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	 	(f)	neither its execution of the Transaction Agreements, nor the performance of its obligations under the Transaction Agreements, contravenes: 

 

	 	(i)	any law to which it or any of its property is subject or any order of any Government Agency that is binding on it or any of its property; 

 

	 	(ii)	any Authorisation; 

  

	 	(iii)	any undertaking or instrument binding on it or any of its property; or 

  

	 	(iv)	its constitutional documents or equivalent; and 

  

	 	(g)	the Investors represent that they each fall within one of the following categories of person: 

  

	 	(i)	an investment professional as defined in article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), namely persons authorised under the Financial
Services and Markets Act 2000 (“FSMA”); persons whose ordinary activities involve them investing in unlisted companies; governments; local authorities or international organisations; or a director, officer or employee acting for
such persons in relation to engaging in investment activity; or 

  

	 	(ii)	a person falling within any categories of persons described in paragraphs (2)(a) to (d) of article 49(2) (“high net worth companies, unincorporated associations etc”) of the Order, namely bodies
corporate with called up share capital or net assets of not less than £5 million (except where the body corporate has more than 20 members in which case the share capital or net assets should be not less than £500,000);
unincorporated associations or partnerships with net assets of not less than £5 million; trustees of high value trusts; or a director, officer or employee acting for such persons in relation to engaging in investment activity.

  

	6.2	The Company and each of the Mereo Founders warrants to the Institutional Investors that, as at the date of this Agreement: 

  

	 	(a)	the information on the Group Companies contained in Schedule 4 to this Agreement is true, complete and accurate in all respects; 

  

	 	(b)	the Company owns, and will immediately following Completion own, the full legal and beneficial title in the entire issued share capital of the Mereo Newcos free from all claims, liens, encumbrances, equities and third
party rights; 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	 	(c)	the Company has no interest in the share capital of any body corporate other than the Mereo Newcos; 

  

	 	(d)	each Group Company is private company limited by shares and is and has since its incorporation been, resident in the United Kingdom for United Kingdom tax purposes; 

 

	 	(e)	no Group Company has ever traded or has, or has acquired or disposed of any, any assets or liabilities (whether actual or contingent, present, future or otherwise), borrowed, made any loan or entered into any contract,
or agreed to do any of the foregoing, other than: 

  

	 	(i)	any obligations it has arising under the Novartis Asset Sale Agreements; 

  

	 	(ii)	loan notes issued by each Mereo Newco to Novartis pursuant to the Novartis Asset Sale Agreements, which are transferred to the Company on Completion; 

 

	 	(iii)	any liabilities arising under any employment or consultancy agreements or appointment letters entered into between the Company and any of the Mereo Founders or Richard Bungay, copies of which have been disclosed to the
Institutional Investors; and 

  

	 	(iv)	those disclosed in Schedule 3 to this Agreement or in the Project Berkeley Data Room; 

  

	 	(f)	it has disclosed to the Institutional Investors in Schedule 2 to this Agreement details of the Ordinary Shares issued to the Mereo Founders prior to the date of this Agreement, and each of the issued shares in each
Group Company have been issued in proper legal form and are fully paid or credited as fully paid and immediately prior to Completion each of the issued shares in the Company will, save as disclosed in Schedule 2 , be legally and beneficially owned
by the Mereo Founders and Peter Harper free from all claims, liens encumbrances, equities and third party rights; 

  

	 	(g)	Ernst & Young LLP has provided the Company with a valuation in respect of the Ordinary Shares issued to the Mereo Founders prior to the date of this Agreement; 

 

	 	(h)	save as expressly contemplated by this Agreement and under the Novartis Asset Sale Agreements, there is no debenture or loan capital or any agreement to create or issue any debenture or loan or share capital of any
Group Company or any option to subscribe for or acquire or any agreement to put under option any debenture or loan or share capital of any Group Company and no person has the right (whether pursuant to conversion or otherwise) to call for the issue
of any debenture or share or loan capital of any Group Company under any agreement or other arrangement presently in force; 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	 	(i)	the Company has no indebtedness in the nature of borrowing or loan facilities including without limitation factoring or invoice discounting arrangements; 

 

	 	(j)	save in respect of the loan notes issued by each of the Mereo Newcos which are to be transferred to the Company pursuant to clause 2.2 of this Agreement, no other Group Company has any indebtedness in the nature of
borrowing or loan facilities including without limitation factoring or invoice discounting arrangements; 

  

	 	(k)	no Group Company has or has ever had any or been a subsidiary or an associated company of another company, other than a Group Company or a member of a consortium for tax purposes and nor has it ever been the legal or
beneficial owner of any share or loan capital of any company other than a Group Company; 

  

	 	(l)	the register of members of each Group Company is correct and properly written up to date and there has been no notice of any proceedings to correct or rectify any such register; 

 

	 	(m)	a true and complete copy of the articles of association of each Group Company is included in the Project Berkeley Data Room; 

  

	 	(n)	no Group Company has any full or part time employees or workers; 

  

	 	(o)	save as disclosed at Schedule 3 to this Agreement, no person is entitled to receive from the Company an introduction or finders brokerage or commission or similar fee in respect of the subscriptions or other
transactions contemplated by this Agreement; 

  

	 	(p)	each Group Company has materially complied with all its obligations under the Companies Act 2006 and with all other applicable laws, regulations and other legal requirements; 

 

	 	(q)	no Group Company is a party, or has ever been a party and, so far as Company and each of the Mereo Founders is aware, no facts or circumstances exist, whereby any Group Company could become a party to any dispute or
proceedings of whatever nature; 

  

	 	(r)	no order has been made or resolution passed or petition presented for the winding up or other dissolution of the Company, no receiver or manager or administrator has been or can be appointed over any of its assets and
the Company is not insolvent or unable to pay its debts. None of the Mereo Founders is aware of any facts which are likely to lead to any of the events or circumstances referred to in this paragraph; and 

 

	 	(s)	no Group Company has declared or paid any dividends or effected any distribution (for tax purposes or otherwise) of or in respect of its assets or share capital. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	6.3	Each of the Mereo Founders warrants to the Institutional Investors that as at the date of this Agreement: 

  

	 	(a)	he is not subject to any restrictions by reason of any existing or former employment or any other capacity or agreement which could prevent his participation in the Company or the development of the activities of the
Group Companies in the manner hereby contemplated; 

  

	 	(b)	neither he nor any of his connected persons or associates or any of them has any interest, direct or indirect, in any agreement or arrangement to which any Group Company is party or in any business which has a close
trading relationship with any Group Company or which competes in any way with or could reasonably be expected to become competitive in any way with the business of the Target Group; 

 

	 	(c)	he is not party to any agreement or understanding or arrangement with any other person in connection with his investment in the Company or his liabilities hereunder or his employment or engagement by the Company or any
other present or proposed member of the Group which has not been disclosed to the Institutional Investors; and 

  

	 	(d)	he is not aware of any matter which constitutes a breach of the warranties given by Novartis under the Novartis Asset Sale Agreements. 

 

	6.4	That save for any transfer made under articles 50, 51 or 52 of the New Articles, or an Exit/IPO if earlier, the Mereo Founders undertake to the Institutional Investors not to transfer or otherwise dispose of any of
their shares or any interest in such shares during the two year period immediately following Completion without the prior written consent of shareholders holding a majority of the voting rights in the Company. 

 

	6.5	Each of the Institutional Investors and the Company acknowledges that each of them has executed this Agreement and agreed to perform its obligations under this Agreement in reliance on the warranties that are made in
this clause 6. 

  

	6.6	The Company will not and will procure that none of the relevant Group Companies will waive or amend any material condition to or term of any Novartis Asset Sale Agreement without the prior consent of Invesco and
Woodford. 

  

	7.	FURTHER NOVARTIS SHARE ISSUE 

  

	7.1	On the occurrence of any Dilutive Event after the date of this Agreement, the Company shall issue (“Further Issue”) to Novartis, credited as fully paid such number of Ordinary Shares as is necessary to
ensure that, having regard to the operation of articles 66.3 and 66.4 of the New Articles, immediately following such Further Issue, the shares held by Novartis in the Company represent no more than 19.5 % of the total economic and voting
rights in the Company, subject to clause 7.3 below. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	7.2	Each Investor, other than Novartis, acknowledges the Company’s obligations pursuant to clause 7.1 above and: 

  

	 	(a)	shall insofar as it is lawfully able by the exercise of its rights and powers as a shareholder of the Company, use all reasonable endeavours to procure that the Company shall take all actions reasonably necessary to
comply with its obligations pursuant to clause 7.1 above; 

  

	 	(b)	shall cause any director or officer of the Company who is, from time to time, appointed and/or maintained in office by such Investor, to use his powers as a director or officer of the Company by voting in favour of any
resolution of the directors of the Company, to ensure that the Company shall comply with its obligations pursuant to clause 7.1 above, subject at all times to such director’s or officer’s statutory and fiduciary duties to the Company; and

  

	 	(c)	hereby waives any and all rights of pre-emption or other restriction in relation to any issue of shares to Novartis made pursuant to clause 7.1 above, whether arising by virtue of the Articles (as they may be amended
from time to time), any agreement, law or otherwise. 

  

	7.3	The maximum aggregate number of Ordinary Shares that may be issued by the Company to Novartis on Completion and pursuant to clause 7.1 above shall in no event exceed 14,000,000 Ordinary Shares, provided only that the
maximum aggregate number of Ordinary Shares (14,000,000) prescribed by this clause 7.3 shall be adjusted (“Adjustment”) in the event of any subdivision, consolidation or reclassification of the Ordinary Shares, so that, after
such Adjustment, the aggregate number of Ordinary Shares that may be issued pursuant to a Further Issue (or a series of Further Issues) carry as nearly as possible the same proportion of economic and voting rights in the Company as if the event
giving rise to such Adjustment had not taken place. 

  

	8.	INFORMATION RIGHTS 

  

	8.1	Each Investor who is entitled to appoint a Director under the New Articles, regardless of whether its exercises such right, shall be entitled to receive: 

 

	 	(a)	at the same time as they are delivered to the Company’s board of directors, copies of all board packs or documents and meeting agendas to be discussed or presented at any meeting of the Company’s board of
directors and copies of any other documents circulated to directors; and 

  

	 	(b)	copies of minutes of meetings of the Company’s board of directors as soon as practicable following the relevant meeting. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	8.2	The Company covenants and undertakes to each Investor that it shall provide to each such Investor copies of all financial and other information relating to the business and affairs of the Target Group as such Investor
may require, including: 

  

	 	(a)	as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, management accounts of the Target Group including
the Group’s profit and loss account and cash flow statement and performance against budget in respect of each financial quarter; 

  

	 	(b)	the annual report and audited consolidated accounts of the Target Group in respect of each financial year; 

  

	 	(c)	all documents sent to, and all resolutions passed by, any holders of shares or other securities in the Company, or to any of the Company’s financial lenders; 

 

	 	(d)	the final draft of any proposed public announcement; 

  

	 	(e)	as soon as reasonably practicable following it being requested supply such information as is reasonably necessary to enable each Investor to prepare its tax or other returns and such other information as such Investor
may reasonably request for the purpose of enabling it to comply with any reporting or compliance requirements imposed on such Investor by any statue rule, regulation or otherwise by any governmental agency or authority; and 

 

	 	(f)	any information, to the extent not included in (a) to (d) above, to which a director appointed to the board of the Company would ordinarily be entitled to in the course of carrying out his duties as a director
of the Company. 

  

	8.3	The Company will permit each Investor and its authorised representatives at such Investor’s expense to visit and inspect the properties of the Company, including its corporate books and records, and to discuss the
Company’s business and finances with officers of the Company, in each case for any purpose reasonably related to such Investor’s interest in the Company, during normal business hours following reasonable notice and as often as may be
reasonably requested; provided that any such access provided shall not unduly interfere with the operations of the conduct of the business of the Company. 

  

	9.	BUSINESS PLAN AND BUDGET 

  

	9.1	The Company and each of the Mereo Founders undertakes to each Institutional Investor to carry on, develop and expand the business of the Target Group in accordance with the Business Plan. 

 

	9.2	The Company shall provide to each Investor, not later than 30 days prior to the start of each financial year: 

  

	 	(a)	a detailed budget and cash flow forecast for the Group in respect of that financial year; and 

  

	 	(b)	an updated business plan for the Group, including updated medium and long term assumptions and projections. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	10.	ASSIGNMENT OF THIS AGREEMENT 

  

	10.1	No party shall: 

  

	 	(a)	assign any of its rights under this Agreement; 

  

	 	(b)	transfer any of its obligations under this Agreement; 

  

	 	(c)	sub-contract or delegate any of its obligations under this Agreement; or 

  

	 	(d)	charge or deal in any other manner with this Agreement or any of its rights or obligations, 

provided that: 
  

	 	(e)	Woodford may assign any of its rights under this Agreement to any person to whom it is entitled to transfer shares in the Company pursuant to article 48.1(b) of the Articles in connection with a transfer of shares in
the Company to that person; and 

  

	 	(f)	the Invesco Fund may assign any of its rights under this Agreement to any person to whom they are entitled to transfer shares in the Company pursuant to article 48.1(b) of the Articles in connection with a transfer of
shares in the Company to that person and Invesco may exercise any of their respective rights under this Agreement for the benefit of any such person. 

  

	10.2	Any purported assignment, transfer, sub-contracting, delegation, charging or dealing in contravention of this clause shall be ineffective. 

 

	11.	ANNOUNCEMENTS 

  

	11.1	Save as expressly provided for in the Novartis Asset Sale Agreements, the parties shall not make any public announcement or issue a press release or respond to any enquiry from the press or other media concerning or
relating to the Novartis Asset Sale Agreements or this Agreement or their subject matter or any ancillary matter without the prior written approval of each of the Institutional Investors and Denise Pollard-Knight. 

 

	11.2	Notwithstanding any other provision in this Agreement, each party may, without the prior written approval of the other parties, make or permit to be made an announcement concerning or relating to this Agreement or its
subject matter or any ancillary matter if and to the extent required by: 

  

	 	(a)	law or regulation; 

  

	 	(b)	any securities exchange on which such party’s securities are listed or traded; or 

  

	 	(c)	any regulatory or governmental or other authority with relevant powers to which a party is subject. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	12.	CONFIDENTIALITY 

  

	12.1	Each of the Institutional Investors and the Mereo Founders and, in respect of Confidential Information of the type referred to in paragraphs (c) and (d) of the definition of Confidential Information, the
Company undertakes that it shall both for a period of three (3) years after the term of this Agreement preserve the confidentiality of the Confidential Information, and except to the extent otherwise expressly permitted by this Agreement, not
directly or indirectly reveal, report, publish, disclose or transfer or use for its own or any other purposes such Confidential Information. 

  

	12.2	Notwithstanding any other provision in this Agreement, any party may disclose Confidential Information if and to the extent: 

  

	 	(a)	required by law; 

  

	 	(b)	required by any securities exchange on which such party’s securities are listed or traded; 

  

	 	(c)	required by any regulatory or governmental or other authority with relevant powers to which such party is subject; 

  

	 	(d)	required to vest the full benefit of this Agreement in that party or to enforce any of the rights of that party in this Agreement; 

  

	 	(e)	required by its professional advisers, officers or employees to provide their services (provided that the relevant disclosee undertakes, or is under a similar duty, to keep such Confidential Information (or other
information which is to be treated as confidential) confidential); 

  

	 	(f)	that information is in or has come into the public domain through no fault of that party; or 

  

	 	(g)	each of the other parties have given prior written consent to the disclosure. 

  

	13.	TERMINATION 

  

	13.1	Subject to clause 13.2, this Agreement shall terminate and be of no further force or effect upon: 

  

	 	(a)	the Long Stop Date having occurred without Completion having occurred; 

  

	 	(b)	an Exit; or 

  

	 	(c)	the written agreement of all of the Investors. 

  

	13.2	On termination of this Agreement, clauses 11 (Announcements) and 12 (Confidentiality) shall survive and continue in full force and effect for a period of three (3) years following such date but all
other rights and obligations of the parties shall cease immediately. Termination shall not affect the parties’ accrued rights and obligations as at such termination. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	14.	COSTS AND EXPENSES 

  

	14.1	Subject to clause 13.2, each party shall bear its own costs and expenses in connection with this Agreement. 

  

	14.2	The Company shall on Completion make a contribution to the fees and expenses of each Institutional Investor up to a maximum of [***]. For the avoidance of doubt, prior to the transfer of funds to the Company’s
Solicitors pursuant to clause 2.5, Woodford and WEIF shall deduct an aggregate sum of [***] from their combined subscription monies; and Invesco shall deduct the sum of [***] from its subscription monies. 

 

	15.	CUMULATIVE REMEDIES 

 The rights, powers, privileges and remedies conferred upon any of
the Investors in this Agreement are cumulative and are not exclusive of any other rights, powers, privileges or remedies provided by law. 
  

	16.	WAIVER 

  

	16.1	A waiver of any right, power, privilege or remedy provided by this Agreement must be in writing and may be given subject to any conditions thought fit by the grantor. For the avoidance of doubt, any omission to
exercise, or delay in exercising, any right, power, privilege or remedy provided by this Agreement shall not constitute a waiver of that or any other right, power, privilege or remedy. 

 

	16.2	A waiver of any right, power, privilege or remedy provided by this Agreement shall not constitute a waiver of any other breach or default by the other party and shall not constitute a continuing waiver of the right,
power, privilege or remedy waived or a waiver of any other right, power, privilege or remedy. 

  

	16.3	Any single or partial exercise of any right, power, privilege or remedy arising under this Agreement shall not preclude or impair any other or further exercise of that or any other right, power, privilege or remedy.

  

	17.	ENTIRE AGREEMENT 

  

	17.1	This Agreement and the documents referred to or incorporated in it constitute the entire agreement between the parties relating to the subject matter of this Agreement and supersedes and extinguishes any prior drafts,
agreements, undertakings, representations, warranties and arrangements of any nature, whether or not in writing, between the parties in relation to the subject matter of this Agreement. 

 

	17.2	Each of the parties acknowledges and agrees that it has not entered into this Agreement in reliance on any statement or representation of any person (whether a party to this Agreement or not) other than as expressly
incorporated in this Agreement. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	17.3	Nothing contained in this Agreement or in any other document referred to or incorporated in it shall be read or construed as excluding any liability or remedy for fraud. 

No responsibility for decision to invest 
  

	17.4	Each of the Institutional Investors agrees that: 

  

	 	(a)	they have not relied on or been induced to acquire any Ordinary Shares or enter into this Agreement by any representation, warranty or undertaking given by the Company, the Mereo Founders or any of their connected
persons; and 

  

	 	(b)	neither the Company, the Mereo Founders nor any of their connected persons will have any liability to any of them (in equity, contract or tort (including negligence), under the Misrepresentation Act 1967 or in any other
way) for a representation, warranty or undertaking, 

 to the extent not incorporated into any of the Transaction Agreements.

  

	18.	AMENDMENTS 

 No amendment, change or addition to this Agreement shall be effective or
binding on any party unless in writing and executed by all the parties. 
  

	19.	NO PARTNERSHIP 

 Nothing in this Agreement is intended to or shall be construed as
establishing or implying any partnership of any kind between the parties. 
  

	20.	FURTHER ASSURANCE 

  

	20.1	Each of the parties shall, at its own cost, use all reasonable endeavours from time to time on or following Completion, on being required to do so by the Company (acting reasonably), to execute any additional documents
in a form satisfactory to the Company and to do or procure that any other acts or things are done to give full effect to this Agreement and secure to the Investors and the Company the full benefit of the rights, powers, privileges and remedies
conferred upon the Investors and the Company in this Agreement. 

  

	20.2	Each of the parties other than the Company (and the Company in relation to votes it controls at board or general meetings of other Group Companies) shall at all times exercise the votes that it controls at general
meetings and/or board meetings to give effect to this Agreement. 

  

	21.	RIGHTS OF THIRD PARTIES 

  

	21.1	This Agreement does not confer any rights on any person or party (other than the parties to this Agreement) pursuant to the Contracts (Rights of Third Parties) Act 1999. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	22.	SEVERAL LIABILITY 

 The Investors shall be severally liable for all representations,
warranties, undertakings, covenants, agreements and obligations made, given or entered into by them in this Agreement. 
  

	23.	COUNTERPARTS 

 This Agreement may be executed in any number of counterparts, each of
which shall constitute an original, and all the counterparts shall together constitute one and the same agreement. 
  

	24.	SERVICE OF PROCESS 

 Novartis shall at all times maintain an agent for service of process
and any other documents in proceedings in England or any other proceedings in connection with this Agreement. Such agent shall be Novartis Pharmaceuticals UK Limited, currently of 200 Frimley Business Park Frimley/Camberley, Surrey GU16 7SR, United
Kingdom and any claim form, judgment or other notice of legal process shall be sufficiently served on Novartis if delivered to the agent at its address for the time being. Novartis irrevocably undertakes not to revoke the authority of this agent and
if, for any reason, the Company requests Novartis to do so it shall promptly appoint another agent with an address in England and advise the Company. If, following such a request, Novartis fails to appoint another agent; the Company shall be
entitled to appoint one on behalf of Novartis at Novartis’ expense. 
  

	25.	NOTICES 

  

	25.1	Any communication to be given in connection with this Agreement shall be in writing (which shall include text transmitted by e-mail) in English and shall either be delivered by hand or sent by first class post or
e-mail: 

  

	 	(a)	to any company or partnership which is a party, at the address set out next to its name in Schedule 2 to this Agreement (or such other address as it may notify to the other parties to this Agreement for such purpose);
and 

  

	 	(b)	to any individual who is a party, at the address of that individual shown in Schedule 2 to this Agreement (or such other address as it may notify to the other parties to this Agreement for such purpose),

 or in each such case such other address as the recipient may notify to the other parties for such purpose in accordance with
clause 25.2. 
  

	25.2	A communication sent according to clause 25.1 shall be deemed to have been received: 

  

	 	(a)	if delivered by hand, at the time of delivery; 

  

	 	(b)	if sent by pre-paid first class post, on the second day after posting; or 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	 	(c)	if sent by e-mail, at the time of transmission by the sender. 

 If, under the preceding
provisions of this clause 25.2, a communication would otherwise be deemed to have been received outside normal business hours in the place of receipt, being 9:30 a.m. to 5:30p.m. on a Business Day, it shall be deemed to have been received at
9:30a.m. on the next Business Day. 
  

	25.3	A party may notify the other parties to this Agreement of a change to its name, relevant person, address or e-mail address for the purposes of clause 25.1 provided that such notification shall only be effective on:

  

	 	(a)	the date specified in the notification as the date on which the change is to take place; or 

  

	 	(b)	if no date is specified or the date specified is less than five clear Business Days after the date on which notice is deemed to have been served, the date falling five clear Business Days after notice of any such change
is deemed to have been given. 

  

	25.4	The provisions of clauses 25.1 to 25.4 shall not apply in relation to the service of any claim form, application notice, order, judgment or other document relating to or in connection with any proceeding, suit or action
arising out of or in connection with this Agreement. 

  

	26.	SEVERANCE 

  

	26.1	If any provision of this Agreement is held to be invalid or unenforceable by any judicial or other competent authority, all other provisions of this Agreement will remain in full force and effect and will not in any way
be impaired. 

  

	26.2	If any provision of this Agreement is held to be invalid or unenforceable but would be valid or enforceable if some part of the provision were deleted, the provision In question will apply with the minimum modifications
necessary to make it valid and enforceable. 

  

	27.	CAPACITY OF INVESTORS 

  

	27.1	Each of the parties acknowledges and agrees that: 

  

	(a)	Invesco is acting at all times as agent for and on behalf of the Invesco Fund; 

  

	(b)	Invesco shall have no liability to acquire the Shares allocated to the Invesco Fund under this Agreement; and 

  

	(c)	Invesco shall have no liability as principal in respect of the Invesco Fund’s obligations under this Agreement, including, but not limited to, the obligation to purchase the Shares from the Company.

  

	27.2	Woodford Investment Management LLP has entered into this agreement as agent of WPCT and WEIF and as such assumes no responsibility or liability whatsoever. Any consents or actions to be made or taken or any rights to be
exercised by WPCT and WEIF hereunder shall be exercised by Woodford Investment Management LLP. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	27.3	WPCT shall hold its shares through its nominee and will require the share certificate to be in the name of: Nortrust Nominees Limited a/c WIZ01. The WPCT share certificate shall be sent to: Northern Trust, 50 Bank
Street, London E14 5NT for the attention of Jordan Hutchinson, UK Residual Settlements. 

  

	27.4	WEIF shall hold its shares through its nominee and will require the share certificate to be in the name of: Nortrust Nominees Limited a/c WIX01. The WEIF share certificate shall be sent to: Northern Trust, 50 Bank
Street, London E14 5NT for the attention of Jordan Hutchinson, UK Residual Settlements. 

  

	28.	INTERPRETATION 

  

	28.1	The clause and paragraph headings and the table of contents used in this Agreement are inserted for ease of reference only and shall not affect its interpretation. 

 

	28.2	References in this Agreement and the Schedules to the parties, the Introduction, Schedules and clauses are references respectively to the parties, the Introduction and Schedules to and clauses of this Agreement.

  

	28.3	References to persons include bodies corporate, unincorporated associations and partnerships, in each case whether or not having a separate legal personality. 

 

	28.4	References to “writing” or “written” include any other non-transitory form of visible reproduction of words. 

  

	28.5	References to times of the day are to that time in London and references to a day are to a period of 24 hours running from midnight. 

 

	28.6	Except where the context specifically requires otherwise, words importing one gender shall be treated as importing any gender, words importing individuals shall be treated as importing corporations and vice versa, words
importing the singular shall be treated as importing the plural and vice versa, and words importing the whole shall be treated as including a reference to any part of it. 

 

	28.7	References to any English legal term or legal concept shall in respect of any jurisdiction other than England be deemed to include that legal term or legal concept which most approximates in that jurisdiction to such
English legal term or legal concept. 

  

	29.	GOVERNING LAW AND JURISDICTION 

  

	29.1	This Agreement and any dispute or claim arising out of or in connection with it or its subject matter, whether of a contractual or non-contractual nature, shall be governed by and construed in accordance with the law of
England and Wales. The parties irrevocably submit to the exclusive jurisdiction of the Courts of England for the purpose of settling any dispute arising out of or in connection with this Agreement. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	30.	DEED 

 This Agreement is executed as a deed by the parties and is delivered and takes effect on the date
at the beginning of this Agreement. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 SCHEDULE 1 

PART A: CASH SUBSCRIPTIONS FOR ORDINARY SHARES ON COMPLETION 
  

																	
	 (1)

Name
	  	(2)
Commitment
£	 	  	(3)
Number of Ordinary
Shares Issued on
Completion	 	  	(4)
Price paid for Ordinary
Shares Issued on
Completion
£	 	  	(5)
Remaining
Commitment
£	 
	 Invesco Perpetual High Income Fund
	  	 	27,600,000	 	  	 	3,848,913	 	  	 	7,082,000	 	  	 	20,518,000	 
	 Woodford Patient Capital Trust plc (Nortrust Nominees Limited a/c WIZ01)
	  	 	20,000,000	 	  	 	3,218,126	 	  	 	5,921,351	 	  	 	14,078,649	 
	 CF Woodford Equity Income Fund (Nortrust Nominees Limited a/c WIX01)
	  	 	28,938,345	 	  	 	3,802,527	 	  	 	6,996,649	 	  	 	21,941,695	 

 PART B: NOVARTIS SUBSCRIPTIONS FOR ORDINARY SHARES 

 

									
	 (1)

Name
	  	(2)
Loan Notes	 	  	(3)
Number of Ordinary Shares Issued on
Completion	 
	 Novartis Lichtstrasse 35, CH-4002, Basel, Switzerland
	  	 	25,812,941	 	  	 	3,849,000	 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 SCHEDULE 2 

POST-COMPLETION SHARE CAPITAL OF THE COMPANY1 

 

																			
	  
	  	 (1)

Name and Address and
 Contact
Details
	  	(2)
Number of
Ordinary Shares	 	  	(3)
Price paid for
Ordinary Shares
£ / shares	 	  	(4)
Proportion of
voting capital	 	 	(5)
Number of
options over
Ordinary Shares	 
	1.	  	[***]	  	 	1,050,000	 	  	 	1050	 	  	 	5.3	% 	 	 	580,597	 
	2.	  	[***]	  	 	708,000	 	  	 	708	 	  	 	3.6	% 	 	 	290,298	 
	3.	  	[***]	  	 	575,000	 	  	 	575	 	  	 	2.9	% 	 	 	290,298	 
	4.	  	[***]	  	 	337,000	 	  	 	337	 	  	 	1.7	% 	 	 	290,298	 
	5.	  	[***]	  	 	23,000	 	  	 	23	 	  	 	0.1	% 	 	 	58,060	 
	6.	  	[***]	  	 	337,000	 	  	 	337	 	  	 	1.7	% 	 	 	81,284	 
	7.	  	[***]	  	 	95,000	 	  	 	95	 	  	 	0.5	% 	 	 	81,284	 
	8.	  	[***]	  	 	1,735,000	 	  	 	1735	 	  	 	8.8	% 	 	 	81,284	 
	9.	  	[***]	  	 	125,000	 	  	 	125	 	  	 	0.6	% 	 	 	267,075	 
	10.	  	[***]	  	 	15,000	 	  	 	15	 	  	 	0.1	% 	 			
	11.	  	[***]	  				  				  				 	 	290,298	 
	12.	  	[***]	  				  				  				 	 	580,597	 
	13.	  	Other employees/directors	  				  				  				 	 	566,663	 
	14.	  	Novartis Pharma AG Lichtstrasse 35, CH-4002 Basel Switzerland	  	 	3,849,000	 	  	 

	Issued in
consideration
for
retirement of
loan notes in
Mereo
Newcos	 
 
 
 
 
 
 	  	 	19.5	% 	 			
	15.	  	 Invesco Perpetual High Income Fund Invesco Asset Management Limited (as agent for and on behalf of its discretionary managed client) at
Perpetual Park, Perpetual Park Drive, Henley-on-Thames, Oxfordshire RG9 1HH
  
 Email:
[***]
  
 With copy to:

 
 Address: Jones Day,

21 Tudor Street,
 London EC4Y 0DJ

 
 Email: [***]
	  	 	3,848,913	 	  	£	7,082,000	 	  	 	19.5	% 	 			

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

																			
	16.	  	CF Woodford Equity Income Fund (Nortrust Nominees Limited a/c W1X01, Northern Trust, 50 Bank Street, London E14 5NT)	  	 	3,802,527	 	  	£	6,996,649	 	  	 	19.3	% 	 			
	17.	  	Woodford Patient Capital Trust plc (Nortrust Nominees Limited a/c WIZ01, Northern Trust, 50 Bank Street, London E14 5NT)	  	 	3,218,126	 	  	£	5,921,351	 	  	 	16.3	% 	 			
	18.	  	WG Partners One Carey Lane, London EC2V 8AE	  	 	21,730	 	  				  	 	0.1	% 	 			
		  		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	 	  
	  
	 
		  	TOTAL	  	 	19,740,296	 	  	£	20,005,000	 	  	 	100.0	% 	 	 	3,458,036	 
		  		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	 	  
	  
	 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 SCHEDULE 3 

LIABILITIES 
 Please note that the
following liabilities of the Company exist: 
  

	1.1	fees of £[***] are payable and will become payable in respect of an [***] engagement letter dated 1 April 2015 appointing [***] as advisers to carry out work on share valuations agreed fees comprising a fund
raising cost of £[***] will become payable on Completion in respect of a [***] engagement letter with the Company dated 30 June 2015 relating to the provision of financial advisory services in connection with a private placement for the
Company, with additional fees of up to [***]% of the total of the Commitment set out in column 2 of Part A of Schedule 1 (payable on the draw down of such Commitment); fees of £[***] are payable in respect of advice received from [***] in
respect of a review of employment contracts; 

  

	1.2	fees, costs and expenses costs incurred by [***] by or on behalf of the Company in connection with the preparation and negotiation of the Novartis Asset Sale Agreement of £[***] and the Transaction Agreements for
the fund raising of £[***], and the transactions contemplated therein, are payable and will be payable by the Company; fees, costs and expenses costs incurred by the legal counsel of the Institutional Investors of £[***] for the fund
raising will be payable by the Company; 

  

	1.3	certain pre-Completion expenses incurred on behalf of the Company by [***] including travel and subsistence and accommodation costs of £[***] and consultants fees for diligence activities of £[***] will
become repayable; 

  

	1.4	consultancy payments of £[***] will become payable to [***], a director of the Company, relating to assistance with diligence activities and contractual advice prior to Completion; 

 

	1.5	a post transaction commitment of clinical trial start-up expenses of $[***] funded at risk by [***] prior to Completion will become repayable; 

 

	1.6	a post transaction commitment payment of $[***] will become due to Novartis representing the Company’s [***]% share of a one-off payment to a third party to cancel certain future milestone and royalty obligations;

  

	1.7	the Company has engaged [***] to provide design services for its website with an estimated cost of £[***]; 

  

	1.8	the Company has engaged [***] pursuant to an engagement letter dated 23 June 2015 in respect of reviewing, negotiating and completing a new agreement for lease with an estimated cost of £[***] which shall be
a post transaction commitment; and 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	1.9	the Company has engaged [***] pursuant to an engagement letter dated 12 March 2015 with an estimated total cost of £[***], although [***] fees in respect of the work carried out pursuant to the engagement
letter have been paid to date by [***]. 

 Total fund raising costs comprise up to £[***] and comprise [***] % of the Commitments. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 SCHEDULE 4 

INFORMATION ON THE GROUP 

THE COMPANY 
  

					
	1.	  	Date of incorporation:	  	10.03.2015
			
	2.	  	Jurisdiction of incorporation:	  	United Kingdom
			
	3.	  	Registered number:	  	09481161
			
	4.	  	Directors:	  	 Frank Armstrong
  

Peter Bains
  

Anders Ekblom
  

Kunal Kashyap
  

Denise Pollard-Knight

			
	5.	  	Secretary:	  	Charles Sermon
			
	6.	  	Registered office:	  	 Green Park House, 15 Stratton Street
  

London W1J 8LQ

			
	7.	  	Accounting reference date:	  	31/12
			
	8.	  	Charges outstanding:	  	None

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 SCHEDULE 5 

THE MEREO NEWCOS 
 A. Mereo BioPharma 1
Limited 
  

					
	1.	  	Date of incorporation:	  	18.06.2015
			
	2.	  	Jurisdiction of incorporation:	  	United Kingdom
			
	3.	  	Registered number:	  	09646998
			
	4.	  	Issued Share Capital:	  	1 ordinary share of £1 fully paid or credited as fully paid
			
	5.	  	Shareholder:	  	The Company
			
	6.	  	Directors:	  	 Denise Pollard-Knight
  

Alastair Mackinnon
  

Charles Sermon
  

Richard Bungay

			
	7.	  	Registered office:	  	 Green Park House, 15 Stratton Street
  

London W1J 8LQ

			
	8.	  	Accounting reference date:	  	31/12
			
	9.	  	Charges outstanding:	  	None

 B. Mereo BioPharma 2 Limited 
  

					
	1.	  	Date of incorporation:	  	18.06.2015
			
	2.	  	Jurisdiction of incorporation:	  	United Kingdom
			
	3.	  	Registered number:	  	09647035
			
	4.	  	Issued Share Capital:	  	1 ordinary share of £1 fully paid or credited as fully paid
			
	5.	  	Shareholder:	  	The Company

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

					
	6.	  	Directors:	  	 Denise Pollard-Knight
  

Alastair Mackinnon
  

Charles Sermon
  

Richard Bungay

			
	7.	  	Registered office:	  	 Green Park House, 15 Stratton Street
  

London W1J 8LQ

			
	8.	  	Accounting reference date:	  	31/12
			
	9.	  	Charges outstanding:	  	None

 C. Mereo BioPharma 3 Limited 
  

					
	1.	  	Date of incorporation:	  	18.06.2015
			
	2.	  	Jurisdiction of incorporation:	  	United Kingdom
			
	3.	  	Registered number:	  	09647034
			
	4.	  	Issued Share Capital:	  	1 ordinary share of £1 fully paid or credited as fully paid
			
	5.	  	Shareholder:	  	The Company
			
	6.	  	Directors:	  	 Denise Pollard-Knight
  

Alastair Mackinnon
  

Charles Sermon
  

Richard Bungay

			
	7.	  	Registered office:	  	 Green Park House, 15 Stratton Street
  

London W1J 8LQ

			
	8.	  	Accounting reference date:	  	31/12
			
	9.	  	Charges outstanding:	  	None

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 SCHEDULE 6 

Call option Shares 
  

					
	 Founder
	 	 Call Option Shares
	 	 Call option Price £

	 [***]
	 	617,404	 	617.00
	 [***]
	 	550,488	 	550.00
	 [***]
	 	447,077	 	447.00
	 [***]
	 	262,026	 	262.00
	 [***]
	 	17,883	 	18.00
	 [***]
	 	262,026	 	262.00
	 [***]
	 	73,865	 	74.00
	 [***]
	 	51,282	 	51.00
	 [***]
	 	711,795	 	712.00
	 [***]
	 	6,154	 	6.00

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 Annex A 

Company Presentation 

[attached separately] 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

			
	EXECUTED as a Deed (but not delivered	  	)
	until dated) by	  	)
	WOODFORD INVESTMENT	  	)
	MANAGEMENT LLP as agent for and on	  	)
	behalf of WOODFORD PATIENT	  	)
	CAPITAL TRUST PLC, acting by:	  	
		  	AUTHORISED SIGNATORY
		
	Witness signature:	  	
		
	Witness name:	  	
		
	Witness address:	  	
		
	Witness occupation:	  	
		
	EXECUTED as a Deed (but not delivered	  	)
	until dated) by	  	)
	WOODFORD INVESTMENT	  	)
	MANAGEMENT LLP as agent for and on	  	)
	behalf of CF WOODFORD Equity Income	  	)
	Fund, a sub fund of CF Woodford	  	
	Investment Fund acting by:	  	
		  	AUTHORISED SIGNATORY
		
	Witness signature:	  	
		
	Witness name:	  	
		
	Witness address:	  	
		
	Witness occupation:	  	

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

			
	EXECUTED as a Deed (but not delivered	  	)
	until dated) by	  	)
	INVESCO ASSET MANAGEMENT	  	)
	LIMITED acting as agent for and on behalf of its	  	)
	Discretionary managed client the	  	)
	INVESCO PERPETUAL HIGH INCOME	  	)
	FUND, acting by:	  	)
		  	Director
		
		  	Witness

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

			
	NOVARTIS PHARMA AG

			
		
	By:	 	  

	Name:	 	  

	Title:	 	  

			
		
	By:	 	  

	Name:	 	  

	Title:	 	  

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

							
	EXECUTED as a Deed (but not delivered	 	)	 		 	
	until dated) by	 	)	 		 	
	MEREO BIOPHARMA GROUP	 	)	 		 	
	LIMITED, acting by:	 	)	 		 	
		 	 )
 Director

		
		 	Director

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

							
	EXECUTED as a Deed (but not delivered	 	)	 		 	
	until dated) by	 	)	 		 	
	DENISE POLLARD-KNIGHT	 	)	 		 	
		
		 	  

		 	 Denise Pollard-Knight

		
	in the presence of:	 	  

		 	Witness
			
		 	Witness name:	 	  

			
		 	Witness name:	 	  

			
		 	Witness occupation:	 	  

				
	EXECUTED as a Deed (but not delivered	 	)	 		 	
	until dated) by CHARLES SERMON	 	)	 		 	
		 	)	 	  

		 		 	Charles Sermon	 	
		
	in the presence of:	 	  

		 	Witness	 	
			
		 	Witness name:	 	  

			
		 	Witness name:	 	  

			
		 	Witness occupation:	 	  

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

							
	EXECUTED as a Deed (but not delivered	 	)	 	
	until dated) by ALASTAIR MACKINNON	 	)	 
		 	)	 	  

		 		 	Alastair MacKinnon
		
	in the presence of:	 	  

		 	Witness	 	
			
		 	Witness name:	 	  

			
		 	Witness name:	 	  

			
		 	Witness occupation:	 	  

				
	EXECUTED as a Deed (but not delivered	 	)	 		 	
	until dated) by JOHN RICHARD	 	)	 		 	
		 	)	 	  

		 		 	John Richard	 	
		
	in the presence of:	 	  

		 	Witness	 	
			
		 	Witness name:	 	  

			
		 	Witness name:	 	  

			
		 	Witness occupation:	 	  

  

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

							
	EXECUTED as a Deed (but not delivered	 	)	 	
	until dated) by ENRIQUE MILLAN	 	)	 
		 	)	 	  

		 		 	Enrique Millan
		
	in the presence of:	 	  

		 	Witness	 	
			
		 	Witness name:	 	  

			
		 	Witness name:	 	  

			
		 	Witness occupation:	 	  

				
	EXECUTED as a Deed (but not delivered	 	)	 		 	
	until dated) by FRANK ARMSTRONG	 	)	 		 	
		 	)	 	  

		 		 	Frank Armstrong	 	
		
	in the presence of:	 	  

		 	Witness	 	
			
		 	Witness name:	 	  

			
		 	Witness name:	 	  

			
		 	Witness occupation:	 	  

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

							
	EXECUTED as a Deed (but not delivered	 	)	 		 	
	until dated) on behalf of NXT	 	)	 		 	
	SCIENCE AB by	 	)	 		 	
		 	)	 	  

		 		 	on behalf of NXT Science AB
		
	in the presence of:	 	  

		 	Witness
			
		 	Witness name:	 	  

			
		 	Witness name:	 	  

			
		 	Witness occupation:	 	  

				
	EXECUTED as a Deed (but not delivered	 	)	 		 	
	until dated) by KUNAL KASHYAP	 	)	 		 	
		 	)	 	  

		 		 	Kunal Kashyap	 	
		
	in the presence of:	 	  

		 	Witness
			
		 	Witness name:	 	  

			
		 	Witness name:	 	  

			
		 	Witness occupation:	 	  

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

							
	EXECUTED as a Deed (but not delivered	 	)	 		 	
	until dated) by PETER BAINS	 	)	 		 	
		 	)	 	  

		 		 	Peter Bains	 	
		
	 in the presence of:
	 	  

		 	Witness	 	
			
		 	Witness name:	 	  

			
		 	Witness name:	 	  

			
		 	Witness occupation:	 	  

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 EXHIBIT C 

BILL OF SALE 
 [See attached]

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 BPS804 BILL OF SALE AND ASSIGNMENT 

This BPS804 BILL OF SALE AND ASSIGNMENT (this “Bill of Sale and Assignment”), dated July 29, 2015, by and between Mereo
BioPharma 3 Limited, a private limited company incorporated in England and Wales (“Buyer”), and Novartis Pharma AG, a company organized under the laws of Switzerland (“Seller”). Capitalized terms used but not
defined herein will have the meanings given to them in the BPS804 Asset Purchase Agreement, dated July 28, 2015 (the “Agreement”), by and between Buyer and Seller. 

Section 1. Buyer and Seller are parties to the Agreement, providing for, among other things, the transfer of the Purchased Assets
by Seller to Buyer. Notwithstanding the foregoing, the Purchased Assets transferred, assigned, conveyed and delivered under this Bill of Sale and Assignment shall not include the Excluded Assets. 

Section 2. In consideration of the mutual obligations, releases and promises set forth in the Agreement, Seller by this Bill of
Sale and Assignment does hereby convey, grant, bargain, transfer, assign, release and deliver to Buyer, and its successors and assigns, all the right, title and interest of Seller in and to the Purchased Assets free and clear of all Liens except
Permitted Liens, as those terms are defined in the Agreement. Buyer assumes no liabilities or obligations of Seller involving the Purchased Assets which are related to the period prior to the date hereof, and any such liabilities or obligations
shall remain the sole responsibility of Seller. 
 Section 3. Seller hereby appoints Buyer, and its successors and assigns, as
Seller’s true and lawful attorney, with full power or substitution, in Seller’s name but on behalf and for the benefit of Buyer, and its successors and assigns, to demand and receive any and all of the Purchased Assets, to give receipts
and releases for and in respect of the same and any part thereof, and from time to time to institute and prosecute in Seller’s name or otherwise, for the benefit of Buyer, and its successors and assigns, any and all proceedings at law, in
equity or otherwise, which Buyer, and its successors or assigns, may deem proper for the collection or reduction to possession of any of the Purchased Assets or for the collection and enforcement of any claim or right of any kind hereby conveyed,
transferred and assigned, or intended so to be, and to do all acts relating to the Purchased Assets which Buyer, and its successors or assigns, will deem desirable. This power of attorney is coupled with an interest and is irrevocable. 

Section 4. Seller hereby covenants that, from time to time after the delivery of this Bill of Sale and Assignment, at Buyer’s
request and without further consideration, Seller will do, execute, acknowledge and deliver, or will cause to be done, executed, acknowledged and delivered, all such further acts, deeds, conveyances, transfers, assignments, powers of attorney and
assurances as reasonably may be requested by Buyer to more effectively convey, transfer to and vest in Buyer, and to put Buyer in possession of, any of the Purchased Assets. 

Section 5. For the avoidance of doubt, this Bill of Sale and Assignment does hereby transfer, convey and assign to Buyer all worldwide
right, title and interest in and to the Purchased IP, as defined in the Agreement, together with the goodwill symbolized thereby, including all rights to sue and recover for past infringement. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 Section 6. Nothing in this Bill of Sale and Assignment, express or implied, is
intended or shall be construed to expand or defeat, impair or limit in any way the rights, obligations, claims or remedies of the parties as set forth in the Agreement. In the event of any conflict or inconsistency between the terms of the Agreement
and the terms hereof, the terms of the Asset Agreement shall govern. 
 Section 7. This Bill of Sale and Assignment is executed
by, and will be binding upon, Seller and Buyer and their respective successors and assigns, effective immediately on the date hereof. 

Section 8. This Bill of Sale and Assignment shall be governed by and construed in accordance with the Laws of the State of New
York (excluding any principles of conflicts of laws that would cause the application of the laws of any other jurisdiction). 

Section 9. This Bill of Sale and Assignment may be executed by facsimile or .PDF signature. This Bill of Sale and Assignment may
be executed in any number of counterparts, all of which taken together shall constitute one and the same agreement and any of the parties hereto may execute this Bill of Sale and Assignment by signing any such counterpart. Any individual signing
this Bill of Sale and Assignment represents and warrants that he or she has full authority to do so. 
 [Remainder of page intentionally
left blank] 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 IN WITNESS WHEREOF, this Bill of Sale and Assignment has been duly executed and delivered by the
parties hereto as of the date and year first above written. 
  

			
	NOVARTIS PHARMA AG

 
			
		
	By:	 	  

	Name:	 	
	Title:	 	
		
	By:	 	  

	Name:	 	
	Title:	 	

 
			
	
	MEREO BIOPHARMA 3 LIMITED

 
			
		
	By:	 	  

	Name:	 	
	Title:	 	

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 EXHIBIT E 

PATENT ASSIGNMENT 
 [See
attached] 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 BPS804 PATENT ASSIGNMENT 

This BPS804 Patent Assignment (“Assignment”) is executed and delivered as of July 29, 2015 by and between Novartis Pharma AG, a Swiss
corporation with its principal place of business at Novartis Campus, CH-4056 Basel, Switzerland (“Assignor”) and Mereo BioPharma 3 Limited, a limited liability company with its registered office at Green Park House, 15 Stratton
Street, London, W1J8LQ, United Kingdom (“Assignee”). 
 WHEREAS: 

Assignor owns the entire right, title, and interest in and to each patent and patent application listed on Schedule 1 hereto, and the inventions
described in and underlying such patents and patent applications (collectively, the “Patents”); 
 Assignor and Assignee are parties to an
agreement entitled BPS804 Asset Purchase Agreement dated July 28, 2015 (“Agreement”), pursuant to which Assignor has agreed, inter alia, to transfer certain assets; and 

Pursuant to the Agreement and subject to the terms of this Assignment, the Assignor wishes to assign to the Assignee all right, title, interest in and to its
rights in the Patents. 
 NOW IT IS HEREBY AGREED AS FOLLOWS: 
  

	1.	CONSIDERATION 

 The good and valuable consideration given by or on behalf of the Assignee is the amount provided
under the Agreement, the receipt and adequacy of which are hereby acknowledged by Assignor. 
  

	2.	ASSIGNMENT 

 The Assignor hereby assigns, sells, conveys, transfers, and delivers to the Assignee, and the
Assignee hereby purchases, accepts and acquires, all of the entire right, title and interest in and to the Patents, together with all rights, privileges, and advantages thereto, including, without limitation, the right to take, defend, or appeal
proceedings and recover (and retain) damages, and obtain all other remedies in respect to past infringements thereof, and the right to file patent applications under the laws of the United States and any other country that claim priority from any
patent application therein, wherever such right may be legally exercised, including the right to claim the benefits of the International Convention for such applications. 

Assignor hereby authorizes and requests the United States Commissioner of Patents, and the Patent Office officials in foreign countries as are duly authorized
by the respective foreign patent laws to issue patents, to issue any and all patents directed to the Patents to the Assignee as the owner thereof. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 For the avoidance of doubt, the term “Patents” shall include all continuations,
continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s)
claiming priority to any patent listed in Schedule 1, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals; all patents, utility models,
or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law
permitting remedies for infringement prior to issuance of the patent; all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such
registrations, confirmations and importation certificates; and all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and
supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said Assignee to the
full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and
entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made. 
  

	3.	FURTHER ASSURANCES 

 Assignor hereby agrees to execute all documents, assist in all proceedings and take any
reasonable further steps that are reasonably necessary (at the sole cost and expense of Assignee) to effectuate the transfer of the Patents to Assignee, or the perfection, registration, or recordation of the rights of Assignee thereto, as may be
reasonably appropriate. If Assignor does not, within thirty (30) days of presentment, return the requested executed documents, then Assignee is hereby granted a limited power of attorney to execute all such documents on behalf of Assignor in
accordance with 37 C.F.R. § 3.73. This power of attorney is coupled with an interest and is irrevocable. 
  

	4.	MISCELLANEOUS PROVISIONS 

 Should any provision of this Assignment be deemed invalid or unenforceable by reason
of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or
unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this
Assignment in any other jurisdiction. 
 This Assignment shall be governed by the laws of the State of New York, without regard to the conflict of law
principles thereof. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 This Assignment may be executed in two counterparts, and each such counterpart hereof shall be deemed to be an
original instrument, but both such counterparts together shall constitute but one agreement. Delivery of an executed counterpart of a signature page of this Assignment by facsimile or other electronic transmission shall be effective as delivery of a
manually executed original counterpart of this Assignment. 
 [Signature Page Follows] 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 IN WITNESS WHEREOF, Assignor and Assignee have caused this Patent Assignment to be duly signed
on their behalf. 
  

			
	Assignor:
	
	NOVARTIS PHARMA AG

 
			
		
	By:	 	  

	Name:	 	  

	Title:	 	  

		
	By:	 	  

	Name:	 	  

	Title:	 	  

 
			
		
	Assignee:	 	
	
	MEREO BIOPHARMA 3 LIMITED

 
			
		
	By:	 	  

	Name:	 	  

	Title:	 	  

  
 [Signature Page to BPS804
Patent Assignment] 
 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 Schedule 1 

[See attached] 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 [***] 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 EXHIBIT F 

LOAN NOTE 
 [See attached]

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 Dated     July 2015 

 
  

EXCHANGE LOAN NOTE INSTRUMENT 

MEREO BIOPHARMA 3 LIMITED 

constituting 
 up to
£11,615,824 unsecured fixed rate exchange loan notes 
  
  

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 CONTENTS 
  

							
	Clause	  	Page	 
			
	1.	  	Interpretation	  	 	1	 
	2.	  	Amount of Notes	  	 	2	 
	3.	  	Status of Notes	  	 	3	 
	4.	  	Issue and Form of Notes	  	 	3	 
	5.	  	Conditions of Issue	  	 	3	 
	6.	  	Undertaking by Company	  	 	3	 
	7.	  	Register of Notes	  	 	3	 
	8.	  	Freedom from Equities	  	 	4	 
	9.	  	Meetings of Noteholders	  	 	4	 
	10.	  	Further Notes	  	 	4	 
	11.	  	Governing Law and Jurisdiction	  	 	4	 
		
	Schedule	  			
			
	1.	  	Form of Note	  	 	5	 
	2.	  	Provisions for Meetings of Noteholders	  	 	14	 
		
	 Signatories
	  	 	18	 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 THIS INSTRUMENT is made by way of deed on July 2015 by Mereo BioPharma 2 Limited, a private limited
company incorporated in England and Wales with registered number 09647034, whose registered office is at Green Park House, 15 Stratton Street, London, W1J 8LQ (the “Company”). 

WHEREAS the Company has, pursuant to its articles of association and by a resolution of its board of directors passed on or about the date of this
Instrument, created and authorised the issue of up to £11,615,824 unsecured fixed rate exchange loan notes to be constituted as provided below. 

NOW THIS INSTRUMENT WITNESSES AND IT IS DECLARED as follows: 
  

	1.	INTERPRETATION 

  

	1.1	In this Instrument: 

 Business Day means a day (other than a Saturday or a Sunday) on
which banks are generally open in London for normal business; 
 Conditions means the conditions of the Notes set out in Schedule 1,
as from time to time modified in accordance with this Instrument; 
 Directors means the board of directors for the time being of the
Company or a duly authorised committee of the board; 
 Exit means: 

(a) a Listing; or 
 (b) a Sale;

 Extraordinary Resolution means a resolution passed at a meeting of the Noteholders duly convened and held in accordance with the
provisions of this Instrument by a majority consisting of not less than three-quarters of the votes cast on the resolution; 
 Final
Repayment Date means, in respect of a Note, the twentieth anniversary (plus one day) of the date of issue of that Note; 
 Group
means in relation to the Company, the Company’s subsidiary undertakings and parent undertakings and all the other subsidiary undertakings of each of its parent undertakings; 

Interest Period means each period of three months ending on 31 March, 30 June, 30 September and 31 December in each
year; 
 Interest Rate means a per annum rate of 2% above the official bank rate published by the Bank of England from time to time;

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 Listing means: 
  

	 	(a)	the admission of any of the Parent’s equity shares to trading on the London Stock Exchange’s market for listed securities becoming effective in accordance with paragraph 2.1 of the London Stock Exchange’s
Admission and Disclosure Standards; or 

  

	 	(b)	the grant of permission for the dealing in any of the Parent’s equity shares on any other public securities market (including the Alternative Investment Market of the London Stock Exchange or any successor market)
becoming effective, 

 whether effected by way of an offer for sale, a new issue of shares, an introduction, a placing or
otherwise; 
 Noteholder means a person whose name is entered in the Register as the holder of a Note; 

Notes means the unsecured fixed rate exchange loan notes constituted by this Instrument or the nominal amounts represented by them and
for the time being outstanding, as the case requires; 
 Parent means Mereo BioPharma Group Limited, a private limited company
incorporated in England and Wales with registered number 09481161 and whose registered office is at Green Park House, 15 Stratton Street, London, W1J 8LQ; 

Register means the register of holders of the Notes kept by or on behalf of the Company; 

Sale means the sale of any part of the share capital of the Parent to any person resulting in that person together with any person
acting in concert (as defined in the City Code on Takeovers and Mergers) which would result in such person or persons holding more than 50 per cent of the issued share capital of the Parent; 

subsidiary undertaking and parent undertaking have the meanings given in section 1162 of the Companies Act 2006; 

references to this Instrument are to this Instrument and the Schedules and include any instrument supplemental to this Instrument; and

 words denoting the singular number only include the plural number and vice versa; words denoting one gender include the other genders; and
words denoting a person include a corporation and an unincorporated association of persons. 
  

	1.2	Any reference, express or implied, to an enactment includes references to: 

  

	 	(a)	that enactment as re-enacted, amended, extended or applied by or under any other enactment (before or after the date of this Instrument); 

 

	 	(b)	any enactment which that enactment re-enacts (with or without modification); and 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	 	(c)	any subordinate legislation made (before or after the date of this Instrument) under that enactment, as re-enacted, amended, extended or applied as described in paragraph 1.2(a) above, or under any enactment referred to
in paragraph 1.2(b) above, 

 and enactment includes any legislation in any jurisdiction. 

 

	1.3	Subclauses 1.1 and 1.2 above apply unless the contrary intention appears. 

  

	1.4	The headings in this Instrument do not affect its interpretation. 

  

	2.	AMOUNT OF NOTES 

 The aggregate nominal amount of the Notes constituted by this
Instrument is limited to £11,615,824. The Notes will be issued fully paid in integral multiples of £1. 
  

	3.	STATUS OF NOTES 

  

	3.1	The Notes shall be known as unsecured fixed rate exchange loan notes. The Notes shall be issued in registered form and shall be transferable in accordance with the provisions of this Instrument.

  

	3.2	The Notes when issued shall be direct and unsecured obligations of the Company and will rank pari passu for all purposes, including the payment of capital and of interest, without any discrimination or preference
between them, with all other unsecured and unsubordinated obligations of the Company, except to the extent provided by law. 

  

	4.	ISSUE AND FORM OF NOTES 

  

	4.1	Each Note shall be in or substantially in the form set out in Schedule 1, shall have a denoting serial number and the Conditions endorsed on it. Each Note shall be executed by or on behalf of the Company.

  

	4.2	Every person who becomes a Noteholder shall be entitled without charge to receive a Note stating the total nominal amount of the Note held by him but in the case of a Note held jointly by several persons the joint
holders will be entitled to only one Note in respect of their joint holding and delivery of the Note to one of such persons shall be sufficient delivery to all of them. 

 

	5.	CONDITIONS OF ISSUE 

 The Conditions and other provisions contained in the Schedules
shall be deemed to be incorporated in this Instrument and the Notes shall be held subject to and with the benefit of the Conditions and of those provisions, all of which shall be binding on the Company and the Noteholders and all persons claiming
through or under them respectively. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	6.	UNDERTAKING BY COMPANY 

 The Company undertakes, for the benefit of each Noteholder, to
perform and observe the obligations on its part contained in this Instrument, to the intent that this Instrument shall enure for the benefit of all Noteholders each of whom may enforce the provisions of this Instrument against the Company so far as
his holding of Notes is concerned. 
  

	7.	REGISTER OF NOTES 

  

	7.1	The Company shall cause a register to be maintained at its registered office (or such other place as the Company may, from time to time have appointed for the purpose). The Register shall show the amount of the Notes
for the time being outstanding, the dates of issue and all subsequent transfers or changes of ownership of the Notes, the names and addresses of the Noteholders and the nominal amounts of the Notes held by the Noteholders respectively. In the event
of a change in the location of the Register, the Company shall, where practicable, give not less than 21 days’ notice to the Noteholders before such change takes effect. 

 

	7.2	The Company shall not be bound to register more than four persons as the joint holders of any Note. 

  

	7.3	Any change of name or address on the part of any Noteholder shall forthwith be notified by the Noteholder to the Company and the Company shall alter the Register accordingly. 

 

	7.4	The Register shall be open to inspection at all reasonable times during normal office hours. 

  

	8.	FREEDOM FROM EQUITIES 

  

	8.1	Notwithstanding any notice the Company may have of the right, title, interest or claim of any other person, to the fullest extent permitted by law, the Company: 

 

	 	(a)	may treat the registered holder of any Note as the absolute owner of it; 

  

	 	(b)	shall not enter notice of any trust on the Register or otherwise be bound to take notice or see to the execution of any trust to which any Note may be subject; and 

 

	 	(c)	may accept the receipt from the registered holder for the time being of any Note for the interest from time to time accruing due or for any other monies payable in respect of it as a good discharge to the Company.

  

	8.2	The Company will recognise every Noteholder as entitled to his Notes free from any equity, set-off or counterclaim on the part of the Company against the original or any intermediate holder of the Notes.

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	9.	MEETINGS OF NOTEHOLDERS 

 Meetings of Noteholders may be convened and held in accordance
with the provisions of Schedule 2. 
  

	10.	FURTHER NOTES 

 The Company may from time to time, by resolution of the Directors, cancel
any unissued Notes or create and issue further unsecured loan notes either ranking pari passu in all respects (or in all respects except for the first payment of interest) so as to form a single series with the Notes or carrying such rights as to
interest, redemption and otherwise as the Directors may think fit. Any further unsecured loan notes which are to form a single series with the Notes shall be constituted by an instrument expressed to be supplemental to this Instrument. Where the
Notes already in issue are listed on a recognised stock exchange, application will be made to list any further notes on such recognised stock exchange. 
  

	11.	GOVERNING LAW AND JURISDICTION 

  

	11.1	This Instrument and the Notes and any non-contractual obligations arising out of or in connection with it shall be governed by English law. 

 

	11.2	The English courts have exclusive jurisdiction to settle any dispute arising out of or in connection with this Instrument and/or the Notes (including a dispute relating to any noncontractual obligations arising out of
or in connection with this Instrument and/or the Notes) and the Company and the Noteholders submit to the exclusive jurisdiction of the English courts. 

  

	11.3	The Company and the Noteholders waive any objection to the English courts on grounds that they are an inconvenient or inappropriate forum to settle any such dispute. 

IN WITNESS of which this Instrument has been executed as a deed and delivered on the date which appears first on page 1. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 SCHEDULE 1 

FORM OF NOTE 
 Nominal
Amount   
  

£                      
       
 MEREO BIOPHARMA 3 LIMITED 

(incorporated in England and Wales with registered number 09647034) 

(the Company) 

UNSECURED FIXED RATE EXCHANGE LOAN NOTES 

THIS IS TO CERTIFY that the person(s) named below is/are the registered holder(s) of the nominal amount specified above of the unsecured fixed rate
exchange loan notes of the Company, which Notes are constituted by an Instrument made by the Company on [    ] 2015 as amended and/or restated from time to time (the Instrument) and are issued subject to and with the benefit of
the provisions of the Instrument including the Conditions endorsed on this Note. 
 NAME(S) OF HOLDER(S): 

[name of holder] of [address of holder] 

Dated: 🌑 
  

							
	EXECUTED as a deed by MEREO BIOPHARMA 3	 	)	 		 	
	LIMITED	 	)	 		 	
	acting by	 	)	 	  
	 	
		 	)	 	Director	 	
				
		 		 	  
	 	
		 		 	Director	 	

 Notes: 
 The Notes
are repayable and bear interest in accordance with the Conditions endorsed on this Note. 
  

	1.	The Conditions contain restrictions on the transferability of this Note. 

  

	2.	This Note must be surrendered before any transfer, whether of the whole or any part, can be registered. The Note must be lodged together with the instrument of transfer (which must be signed by the transferor or by a
person authorised to sign on behalf of the transferor) at the Company’s registered office from time to time. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	3.	The Notes and any non-contractual obligations arising out of or in connection with the Notes shall be governed by English law. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 NOTICE OF REPAYMENT 

 

	To:	[            ] 

  

	1.	We being the registered holder(s) of this Note give notice that I/we require repayment of all/£[        ] of the nominal amount of this Note in accordance with Condition 4.
(note 1 below) 

  

	2.	We authorise and request you to: 

  

	 	(a)	[make the electronic transfer to: [insert account details]/[make the cheque payable to the person whose name is set out below or, if none is set out, to us]; and 

 

	 	(b)	send by prepaid registered post to the person whose name and address is set out below or, if none is set out, to the registered address of the sole or first-named Noteholder (if applicable) the cheque and a Note for the
balance (if any) of the nominal amount of this Note which is not repaid. 

  

							
		 	Name	 	  
	  	
				
		 	Address	 	  
	  	
				
		 		 	  
	  	
		 		 	(note 2 below)	  	

 Dated [                ] 

 

							
		 	Signature(s) of Noteholder(s)	 	  
	  	
				
		 	(note 3 below) 	 	  
	  	
				
		 		 	  
	  	

 Notes: 
  

	1.	Delete and/or complete as appropriate. If repayment is required of part only, the repayment specified must be an integral multiple of £1. If no indication is given of the nominal amount of the Note to be repaid,
all of the Note will be repaid. 

  

	2.	Insert in BLOCK CAPITALS the name of the person to whom you wish the cheque to be made payable and/or the address of the person to whom you wish the cheque and any balance Note to be sent (if, in either case, it is
different from that of the sole or first-named holder). If this space is left blank, the cheque will be made payable to the sole holder or all of the joint holders and it and any balance Note will be sent to the registered address of the sole or
firstnamed holder. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	3.	In the case of joint holders ALL must sign. A body corporate should execute under its common seal or with the signature of two directors, a director and the company secretary or a director and a witness, or under the
hand of some officer or agent duly authorised on behalf of the holder, in which event the Note must be accompanied by the authority under which this Notice is completed. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 CONDITIONS 

Terms defined in the Instrument have the same meaning in these Conditions. 
  

	1.	Form and status 

  

	1.1	This Note is one of a series of Notes and is issued subject to and with the benefit of the provisions of the Instrument. A copy of the Instrument may be inspected during normal office hours at the registered office of
the Company. The Instrument does not contain any restrictions on borrowing, or on the charging or disposal of assets, by the Company or any of its subsidiaries. 

  

	2.	Repayment 

  

	2.1	The Company may on giving not less than seven days’ notice to the Noteholders, repay at par all or part of the Notes. 

  

	2.2	To the extent not previously repaid, purchased by the Company or cancelled, the Notes will be repaid by the Company at par on the earlier of: 

 

	 	(a)	an Exit; and 

  

	 	(b)	the Final Repayment Date. 

  

	2.3	On any repayment of principal to a Noteholder under this Condition or Condition 4 the Company shall pay to him interest accrued but unpaid on the amount repaid up to (but excluding) the date of repayment, in accordance
with Condition 3. 

  

	3.	Interest 

  

	3.1	Until such time as the Notes are repaid, purchased or cancelled by the Company in accordance with the provisions of the Instrument or these Conditions, interest on the outstanding principal amount of the Notes shall
accrue daily and shall compound on the last day of each Interest Period at a rate equal to the Interest Rate. Any interest which falls for calculation will be calculated on the basis of a 365 or 366 day year (as the case may be). 

 

	3.2	Interest which has accrued on the Notes shall be rolled up and shall be payable upon the redemption of the Notes to the persons registered as Noteholders. Any such rolled up interest shall rank in priority to, and shall
be repaid prior to, the Notes. 

  

	3.3	All payments of interest in respect of the Notes will be made subject to deduction of any income tax required to be withheld or deducted. On or as soon as practicable following each date on which any interest is paid to
a Noteholder the Company shall deliver to the Noteholder a certificate as to the gross amount of the relevant interest payment and the amount of tax deducted. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	3.4	Interest on any Notes becoming liable to repayment shall cease to accrue as from the due date for repayment of the Notes unless, against due delivery of those Notes for repayment, payment of the principal and interest
payable is not made by the Company on the due date (in which case interest will continue to accrue until, but excluding, the date of actual payment). 

  

	4.	Acceleration 

  

	4.1	A Noteholder may require the Company to repay at par all or part of the Notes held by him, together with all accrued interest thereon, if any of the following events occurs: 

 

	 	(a)	the Company fails to pay within 30 days of the due date any principal or interest payable in respect of the Notes held by that Noteholder (except for any amounts withheld under Condition 3.3); 

 

	 	(b)	an order is made by a competent court or an effective resolution is passed for winding-up of the Company (other than a voluntary winding-up for the purposes of an amalgamation, reconstruction or merger on terms
previously approved by an Extraordinary Resolution); 

  

	 	(c)	the commencement of any insolvency proceedings in relation to the Company; or 

  

	 	(d)	an encumbrancer takes possession of, or an administrator or administrative receiver or a manager or receiver is appointed for or over the whole (or substantially the whole) of the undertaking or property of the Company,
unless the same is removed, stayed, paid out or discharged within 30 days. 

  

	4.2	The Company shall notify the Noteholders of the happening of any of the events specified in Condition 4.1 as soon as reasonably practicable after becoming aware of the same. 

 

	4.3	In order to require repayment under this Condition a Noteholder must complete and sign the Notice of Repayment printed on the Note to be repaid (or complete such other form of Notice of Repayment as the Director may
from time to time prescribe) and lodge it at the registered office of the Company (or at such other place as the Company may direct by notice to the Noteholders) while the relevant event specified in Condition 4.1 is continuing and, upon that notice
being given to the Company, all of the Notes held by that Noteholder (and all accrued interest accrued thereon) will become immediately repayable. A Notice of Repayment given in accordance with this Condition shall be irrevocable. 

 

	5.	Surrender of Notes on repayment and prescription 

  

	5.1	Whenever any Notes are due to be repaid under any of these Conditions (in whole or in part) the Noteholder shall, not less than five days before the due date for such repayment, deliver those Notes or an indemnity (if
the Note has been defaced, worn out, lost or destroyed) to the registered office for the time being of the Company (or to such other place as the Company may direct by notice to the Noteholders). 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	5.2	If part only of the principal amount of any Note so delivered is repaid, the Company shall cancel such Note and without charge issue to the Noteholder a new Note for the balance of the principal amount due to him.

  

	5.3	If any Noteholder fails or refuses to deliver up any Note which is liable to be repaid in whole or in part under these Conditions at the time and place fixed for repayment, or fails or refuses to accept payment of the
monies due on repayment, those monies may be set aside by the Company and paid into a separate bank account and held by the Company for that Noteholder on the following terms: 

 

	 	(a)	the Company shall not be responsible for the safe custody of such monies or for any interest accruing on them; 

  

	 	(b)	the Company may deduct from such interest (if any) as those monies may earn while on deposit, any expenses incurred by the Company in that connection; 

 

	 	(c)	any such amount so paid or deposited, together with such interest (if any) accruing on it in accordance with Condition 3, will immediately be paid to the Noteholder or his successors upon delivery of the relevant Note
at any time during the period of ten years from the making of the deposit; and 

  

	 	(d)	any such amount so paid or deposited, together with such interest (if any) accruing on it in accordance with Condition 3, which remains unclaimed after a period of ten years from the making of the deposit shall revert
to the Company, notwithstanding that in the intervening period the obligation to pay the same may have been provided for in the books, accounts and other records of the Company. 

 

	6.	Payments 

  

	6.1	If any payment of principal or interest in respect of the Notes would otherwise fall to be made on a day which is not a Business Day, payment shall be postponed to the next day which is a Business Day and no further
interest or other payment will be made as a consequence of any such postponement. 

  

	6.2	Payment of any principal or interest in respect of any Note will be made to the person shown in the Register as the holder of that Note at the close of business on the fifth Business Day before the relevant payment date
(the “Record Date”), notwithstanding any intermediate transfer or transmission of the Note. 

  

	6.3	Payment of any principal or interest in respect of any Note shall be made by electronic transfer to the account specified for such purpose by the Noteholder (or Noteholders in the case of joint holders) in writing to
the Company, failing which notification any such payment shall be made by cheque sent by registered post to the registered address of the Noteholder or, in the case of joint Noteholders, to the registered address of that one of them who is first
named on the Register on the Record Date (or to such person and to such address as the Noteholder or joint Noteholders may in writing to the Company direct prior to the Record Date). Every such cheque shall be made payable to the person to whom it
is sent (or to such person as the Noteholder or joint Noteholders may direct in writing to the Company prior to the Record Date) and receipt of the cheque shall be a good discharge to the Company. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	6.4	Every such cheque shall be sent by registered post not later than the Business Day preceding the due date for payment. Payments will be subject in all cases to any applicable fiscal and other laws and regulations but
shall otherwise be made without set-off or counterclaim. 

  

	7.	Purchase 

 The Company may at any time purchase any Notes by tender (available to all
Noteholders alike) or by private treaty at any price. 
  

	8.	Cancellation 

 Notes purchased or repaid by the Company will be cancelled and shall not
be available for reissue. 
  

	9.	Modification 

  

	9.1	The provisions of the Instrument (including the Conditions) and the rights of the Noteholders may from time to time be amended, modified, abrogated or compromised or any arrangement agreed in any respect with the
sanction of an Extraordinary Resolution and the written consent of the Company. 

  

	9.2	Any such amendment, modification, abrogation, compromise or arrangement effected pursuant to Condition 9.1 shall be binding on all Noteholders. 

 

	10.	Transfer 

  

	10.1	The directors of the Company shall recognise any transfer which is evidenced in writing and made in accordance with these Conditions. The transferor shall remain the legal owner of the Notes to be transferred until the
name of the transferee is entered in the Register in respect of those Notes. 

  

	10.2	Every instrument of transfer must be lodged for registration at the registered office of the Company accompanied by the relevant Note(s) and such other evidence as the Company may require to prove the title of the
transferor or his right to transfer the Notes or the authority of the person signing the instrument. 

  

	10.3	No transfer of a Note shall be registered: 

  

	 	(a)	if a notice requiring repayment of that Note (in whole or in part) has been given; or 

  

	 	(b)	when the Register is closed. 

  

	10.4	If part only of the principal amount of any Note so lodged is transferred, the Company shall without charge issue to the Noteholder a new Note for the balance of the principal amount due to him. All instruments of
transfer which are registered may be retained by the Company. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	11.	Transmission 

  

	11.1	Any person becoming entitled to a Note in consequence of the death or bankruptcy of any Noteholder or otherwise by operation of law may upon producing evidence that he sustains the character in respect of which he
proposes to act under this Condition or of his title to the Note as the Directors shall reasonably require be registered himself as the Noteholder or, subject to Condition 10, may transfer the Note. 

 

	11.2	The executors or administrators of a deceased holder of a Note (not being one of several joint holders) shall be the only persons recognised by the Company as having any title to or interest in such Note.

  

	11.3	In the case of the death of any of the joint holders of a Note the survivors or survivor will be the only persons or person recognised by the Company as having any title to or interest in such Note. 

 

	12.	Substitution and exchange 

  

	12.1	The Company may at any time and from time to time, with the consent of the Noteholders by Extraordinary Resolution, be replaced and substituted by any member of the Company’s Group as principal debtor or principal
debtors (on one or more occasion) (in such capacity, the “Substituted Debtor”) in respect of all or any of the Notes provided that: 

  

	 	(a)	either the Company obtains an opinion from independent tax counsel (obtained shortly before such substitution takes place and based on full disclosure of relevant facts) to the effect that there is no significant risk
that the substitution will be treated as a disposal of the Notes for the purpose of United Kingdom taxation of chargeable gains or HM Revenue and Customs confirms in writing that the substitution will not be treated as a disposal of the Notes for
the purpose of United Kingdom taxation of chargeable gains; 

  

	 	(b)	such documents (if any) are executed by the Substituted Debtor as may be necessary to give full effect to the substitution (the “Documents”), including those pursuant to which the Substituted Debtor
shall undertake in favour of each relevant Noteholder to be bound by the terms and conditions of the relevant Notes as fully as if the Substituted Debtor had been named in the Instrument and the Notes as the principal debtor in respect of those
Notes; and 

  

	 	(c)	the relevant Notes are guaranteed by the Company. 

  

	12.2	Upon execution of the Documents, the relevant Notes shall have effect as if the Substituted Debtor were named in the Notes as principal debtor in place of the Company and the Company shall be released from all its
obligations in respect of the Notes. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	12.3	Not less than 20 Business Days after execution of the Documents, the Company shall give notice of any substitution to the Noteholders. 

 

	12.4	The Company may, with the consent of the Noteholders by Extraordinary Resolution, at any time require all or any of the Noteholders to exchange the Notes for loan notes issued by the Substituted Debtor on the same terms
and conditions as those applicable to the Notes provided that the Company’s right to require an exchange pursuant to this Condition shall be exercisable only if: 

 

	 	(a)	the Company has either obtained the consent of the relevant Noteholders or it has obtained the opinion of independent tax counsel that such exchange will not crystallise a charge to any of the Noteholders to United
Kingdom capital gains tax or corporation tax on chargeable gains and has obtained all relevant clearances from the relevant United Kingdom taxation authority or such exchange will fall within the provisions of section 135 of the Taxation of
Chargeable Gains Act 1992 and prior clearance has been received from HM Revenue and Customs under section 138 of the Taxation of Chargeable Gains Act 1992 in respect of such exchange; 

 

	 	(b)	the loan notes issued in exchange will be issued on the same terms as the Loan Notes, save that the terms of the new loan notes will not include any further right of the issuer to require exchange or any similar right
of exchange or conversion into other shares or securities; and 

  

	 	(c)	the loan notes issued in exchange are guaranteed by the Company. 

  

	12.5	The Company shall not be entitled to exercise its power of substitution or exchange under this Condition in respect of any holding of Notes if to do so would result in the holders of such Notes receiving payments of
interest under withholding or deduction in respect of tax (or an increase in the rate of any such withholding or deduction) provided that this Condition shall not prevent the Company exercising its power of substitution or its power of exchange if
the Substituted Debtor is a company resident in the United Kingdom for the purposes of United Kingdom taxation notwithstanding that the substitution or exchange may result in the holders of the Notes receiving payments of interest under withholding
or deduction in respect of tax (or an increase in the rate of any such withholding or deduction). 

  

	12.6	For the avoidance of doubt, in the event that the Company or any Substituted Debtor complies fully with the provisions of this Condition, neither the Company nor the Substituted Debtor shall be liable for any tax or
increase in tax of a Noteholder or to make any payment in respect of any withholding or deduction in respect of tax (or an increase in the rate of any such withholding or deduction) which arises in connection with a substitution or exchange.

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	13.	Dealings with Notes 

 Each Noteholder: 

 

	 	(a)	agrees that the Company may, at any time redeem at any price (in whole or in part), exchange, substitute, convert, deferred, cancel, capitalise by way of an issue of shares of any class in the capital of the Company or
otherwise deal with in any manner, provided that each holder of Notes shall be treated equally (pro rata to their holding of Notes) and provided that the economic position of each holder of Notes as against each other holder of Notes (in respect of
their holding of Notes only) shall not be affected; and 

  

	 	(b)	undertakes to exercise all powers and rights lawfully available to it to procure the amendment of this Instrument to the extent necessary to give effect to the provisions of this Condition 13. 

 

	14.	Lost or destroyed Notes 

 If a Note is defaced, lost or destroyed it may be renewed on
payment by the Noteholder of the expenses of renewal and on such terms (if any) as to evidence and indemnity as the Directors may require but so that, in the case of defacement, the defaced Note shall be surrendered before a new Note is issued. An
entry as to the issue of a new Note and indemnity (if any) shall be made in the Register. 
  

	15.	Notices 

  

	15.1	Any notice to be given under this Instrument must (unless expressly provided otherwise) be in writing and be delivered or sent by prepaid registered post or fax to the Noteholder to be served at its address or fax
number appearing in this Instrument, or at such other address and/or fax number as it may have notified to the Company in accordance with this Condition 15.1. 

  

	15.2	In the case of joint Noteholders, a notice or document served on the Noteholder whose name stands first in the Register shall be sufficient notice to all the joint Noteholders. 

 

	15.3	Any notice shall be deemed to have been given or made: 

  

	 	(a)	if delivered, at the time of delivery; or 

  

	 	(b)	if sent by prepaid registered post, on the second Business Day (or if posted from outside the United Kingdom, on the fifth Business Day) after it was posted. 

 

	15.4	In proving service of a notice or document it shall be sufficient to prove that delivery was made or that the envelope containing the communication was properly addressed and posted by prepaid first class registered
post or by prepaid registered airmail or that the fax message was properly addressed and transmitted, as the case may be. 

  

	16.	Governing Law 

  

	16.1	The Notes and any non-contractual obligations arising out of or in connection with the Notes shall be governed by English law. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	16.2	The English courts have exclusive jurisdiction to settle any dispute arising out of or in connection with the Notes (including a dispute relating to any non-contractual obligations arising out of or in connection with
the Notes) and the Company and the Noteholders submit to the exclusive jurisdiction of the English courts. 

  

	16.3	The Company and the Noteholders waive any objection to the English courts on grounds that they are an inconvenient or inappropriate forum to settle any such dispute. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 SCHEDULE 2 

PROVISIONS FOR MEETINGS OF NOTEHOLDERS 
  

	1.	Calling of meetings 

  

	1.1	The Company may at any time convene a meeting of the Noteholders. The Company shall also convene a meeting of the Noteholders if so required in writing signed by Noteholders representing not less than one-tenth in
nominal amount of the Notes for the time being outstanding (excluding any in respect of which a notice requiring repayment has been given). 

  

	1.2	Every such meeting and every adjourned meeting shall be held at the registered office of the Company for the time being or such other place as the Company may specify. 

 

	2.	Notice of meetings 

  

	2.1	At least 14 or, in the case of a meeting convened for the purpose of considering an Extraordinary Resolution, at least 21 clear days’ notice of any meeting of Noteholders shall be given to the Noteholders.

  

	2.2	Any such notice shall specify the place, day and time of the meeting and the general nature of the business to be transacted at the meeting but, except in the case of a resolution to be proposed as an Extraordinary
Resolution, it shall not be necessary to specify the terms of any resolution to be proposed. Any such notice shall include a statement to the effect that proxies may be appointed in accordance with the provisions of this Schedule. 

 

	2.3	The accidental omission to give notice to, or the non-receipt of notice by, any of the Noteholders shall not invalidate the proceedings at any meeting. 

 

	3.	Chairman 

 A person (who need not be a Noteholder) nominated in writing by the Company
shall be entitled to take the chair at a meeting of the Noteholders but if no such nomination is made or if at any meeting the person nominated is not present within 15 minutes after the time appointed for the holding of the meeting, the Noteholders
present shall choose one of their number to be chairman. 
  

	4.	Quorum 

 At a meeting of the Noteholders two or more persons present in person or by
proxy holding or representing a majority in nominal amount of the Notes for the time being outstanding shall form a quorum for the transaction of business. No business (other than the choosing of a chairman) shall be transacted at any meeting unless
the requisite quorum is present at the commencement of business. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	5.	Absence of quorum 

 If within 15 minutes from the time appointed for a meeting of the
Noteholders a quorum is not present, the meeting shall, if convened upon the requisition of Noteholders, be dissolved. In any other case it shall stand adjourned to such day and time (being not less than 14 nor more than 42 clear days after the time
of the original meeting) and to such place as the chairman may decide. At such adjourned meeting, one or more Noteholders present in person or by proxy shall form a quorum. 
  

	6.	Notice of adjourned meeting 

 At least 14 clear days’ notice of any meeting
adjourned through want of a quorum shall be given in the same manner as for an original meeting and such notice shall state the quorum required at such adjourned meeting. It shall not otherwise be necessary to give any notice of an adjourned
meeting. 
  

	7.	Adjournment of meeting 

 The chairman may with the consent of (and shall if directed by)
any meeting adjourn the same from time to time (being not less than 14 nor more than 42 clear days after the time of the original meeting) and from place to place but no business shall be transacted at any adjourned meeting except business which
might lawfully have been transacted at the original meeting. 
  

	8.	Voting on a poll 

  

	8.1	Every question submitted to a meeting of Noteholders shall be decided by a poll. A poll shall be taken at the meeting without adjournment and the result of such poll shall be deemed to be the resolution of the meeting
as at the date of the taking of the poll. 

  

	9.	Persons entitled to attend and vote 

  

	9.1	Any persons duly authorised by the Company (including, without limitation, their respective legal and financial advisers) shall be entitled to attend and speak at any meeting of the Noteholders. No person shall
otherwise be entitled to attend or vote at any meeting of the Noteholders unless he is registered as a Noteholder or is a representative of a corporation which is a Noteholder or a proxy of a person who is a Noteholder. 

 

	9.2	At any meeting of Noteholders every person who is so present shall have one vote in respect of every £1 nominal of Notes of which he is the holder or in respect of which he is a representative or proxy.

  

	9.3	Without prejudice to the obligations of any proxies any person entitled to more than one vote need not use all his votes or cast all the votes to which he is entitled in the same way. 

 

	9.4	In the case of joint Noteholders the vote of the senior who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders and for this purpose seniority shall
be determined by the order in which the names stand in the Register. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	10.	Proxies 

  

	10.1	A Noteholder may appoint a proxy (who need not be a Noteholder) by instrument in writing in any usual or common form or in any other form which the Directors may approve or accept. The instrument appointing a proxy
shall be signed by the appointor or his agent authorised in writing or, if the appointor is a corporation, shall either be executed under its common seal or be signed by an agent or officer authorised for that purpose. The Company may, but shall not
be bound to, require evidence of the authority of any such agent or officer. 

  

	10.2	An instrument appointing a proxy shall, unless the contrary is stated in it, be valid for any adjournment of a meeting as well as for the meeting to which it relates. No instrument appointing a proxy shall be valid
after the expiration of 12 months from its date of execution. 

  

	10.3	A vote given in accordance with the terms of an instrument of proxy shall be valid notwithstanding the previous death or insanity of the principal or revocation of the proxy or of the authority under which the proxy was
executed or (until registered) the transfer of the Note in respect of which the vote is given provided that no intimation in writing of such death or insanity, revocation or transfer was received by the Company at its registered office before the
commencement of the meeting or adjourned meeting, or of the taking of the poll, at which the proxy is used. 

  

	11.	Deposit of proxies 

 An instrument appointing a proxy and the power of attorney or other
authority (if any) under which it is signed, or a notarially certified copy of such power or authority, shall be deposited at such place as the Company may, in the notice convening the meeting, direct or, if no such place is appointed, at the
registered office of the Company not less than 48 hours before the time appointed for holding the meeting or taking the poll at which the person named in the instrument proposes to vote and in default the instrument shall not be treated as valid.

  

	12.	Corporate representatives 

 Any corporation which is a Noteholder may by resolution of
its directors or other governing body authorise any person to act as its representative at any meeting of Noteholders and such representative shall be entitled to exercise the same powers on behalf of the corporation which he represents as that
corporation could exercise if it were an individual Noteholder present in person at the meeting. 
  

	13.	Powers of meeting 

 A meeting of the Noteholders shall in addition to all other powers
(but without prejudice to any powers conferred on other persons in the Instrument) have the following powers exercisable only by Extraordinary Resolution namely: 
  

	 	(a)	to sanction any proposal by the Company for any amendment, modification, abrogation, variation or compromise of, or arrangement in respect of, the rights of the Noteholders against the Company whether such rights shall
arise under the Conditions, the Instrument or otherwise; 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

	 	(b)	to sanction the exchange or substitution for the Notes of, or the conversion of the Notes into, other obligations or securities of the Company, or any other person or entity; 

 

	 	(c)	to assent to any amendment, modification, abrogation or variation of the Conditions or other provisions of this Instrument which is proposed by the Company; 

 

	 	(d)	to authorise any person to execute and do all such documents, deeds, acts and things as may be necessary to carry out and give effect to any Extraordinary Resolution; 

 

	 	(e)	to give any authority or sanction which under the provisions of this Instrument is required to be given by Extraordinary Resolution; and 

 

	 	(f)	to appoint any persons (whether Noteholders or not) as a committee or committees to represent the interests of the Noteholders and to confer upon such committee or committees any powers or discretions which the
Noteholders could themselves exercise by Extraordinary Resolution. 

  

	14.	Effect of Extraordinary Resolution 

 An Extraordinary Resolution passed at a meeting of
the Noteholders duly convened and held in accordance with this Instrument shall be binding upon all the Noteholders, whether present or not at such meeting, and each of the Noteholders shall be bound to give effect to it accordingly. The passing of
any such resolution shall be conclusive evidence that the circumstances of any such resolution justify its passing. 
  

	15.	Minutes 

 Minutes of all resolutions and proceedings at every meeting of Noteholders
shall be made and duly entered in books to be from time to time provided for that purpose by the Company. Any such minutes, if they purport to be signed by the chairman of the meeting at which such resolutions were passed or proceedings transacted
or by the chairman of the next succeeding meeting of the Noteholders, shall be conclusive evidence of the matters contained in them. Until the contrary is proved, every meeting in respect of which minutes of the proceedings have been made and signed
in accordance with this Condition shall be deemed to have been duly held and convened and all resolutions passed or proceedings transacted at such meeting to have been duly passed and transacted. 

 

	16.	Resolutions in writing 

 A resolution in writing proposed by the Company and signed by
the holders of not less than three-quarters in nominal amount of the Notes for the time being in issue shall have effect in the same manner as an Extraordinary Resolution duly passed at a meeting of Noteholders duly convened and held. Such a
resolution may be contained in one document or in several documents in like form, each signed by one or more of the Noteholders. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 SIGNATORIES 
  

							
	EXECUTED as a deed by MEREO BIOPHARMA 3	  	)	  		  	
	LIMITED	  	)	  		  	
		  	)	  	  
	  	
		  	)	  	Director	  	
				
	in the presence of:	  		  		  	
		  	)	  		  	
		  	)	  		  	
		  	)	  	  
	  	
		  	)	  	signature of Witness	  	
		  	)	  		  	
		  	)	  		  	
		  	)	  	  
	  	
		  	)	  		  	
		  	)	  	name of Witness	  	
		  	)	  		  	
		  	)	  	  
	  	
		  	)	  		  	
		  	)	  	  
	  	
		  	)	  		  	
		  	)	  	  
	  	
		  	)	  		  	
		  	)	  	  
	  	
		  	)	  		  	
		  	)	  	Address	  	
		  	)	  		  	
		  	)	  	  
	  	
		  	)	  		  	
		  	)	  	Occupation	  	

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 EXHIBIT G 

COMPOUND 
  

			
	 PROJECT:
	  	BPS804
		
	 TRADEMARK:
	  	[***]
		
	 NON-PROPRIETARY:
	  	[***]
		
	 MECHANISM OF ACTION:
	  	[***]
		
	 [***]
	  	[***]
		
	 [***]
	  	[***]

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 EXHIBIT H 

FORM OF NOVARTIS INVOICE 
 [See
attached] 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 SAMPLE INVOICE 

 

					
	Sender’s Logo	  	INVOICE	 	
		  	INVOICE DATE:	 	
	 Novartis Pharma AG
 Lichtstrasse 35
	  	                201    	 	
	 CH-4056
 Basel, Switzerland
	  		 	
	Phone and Fax Nr.	  	INVOICE No.: XXXX	 	
			
	Bill To:	  	                        For:	 	
	Mereo BioPharma 3 Limited	  	                        BPS804 (Royalties X Quarter 201    )	 	
	 Green Park House
 15 Stratton Street

London W1J 8LQ
	  	
		
	 DESCRIPTION [Please specify the event for which the
invoice is due]
	 	 AMOUNT (USD)

		
	Product X (royalties XXXX – YYYY 201_ calculated based on Mereo provided sales & royalty report	 	US$ 000’000.00
		
	Novartis Contract Code	  	
	
	Please remit by wire transfer within 60 days to:
	 Receiving Bank -
            
	  	
	 Swift Code -
            
	  	
	 ABA Number -
            
	  	
	 Credit Account -
            
	  		 	
	 Beneficiary -
            
	  		 	
	 TOTAL
	  		 	000’000,00

 If you have any questions concerning this invoice, contact 

             

or e-mail to              

VAT -Reg. No. Xxxxxxxxxx (if applicable) 
  

 
  

Version: 29 July 2015
                                         
                       Page 31 of 138 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.EX-10.21

 Exhibit 10.21 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 
 SUBLICENSE AGREEMENT 

This SUBLICENSE AGREEMENT (this “Agreement”), effective as of July 29, 2015 (the “Effective
Date”), is by and between MEREO BIOPHARMA 3 LIMITED, a private limited company incorporated in England and Wales (“Buyer”) and a wholly owned subsidiary of MEREO BIOPHARMA GROUP LIMITED, a company incorporated in England
and Wales (“Mereo”), and NOVARTIS PHARMA AG, a Swiss company (“Novartis”). 
 RECITALS: 

WHEREAS, Novartis and Buyer have entered into that certain Asset Purchase Agreement, dated as of July 28, 2015 (as it may be further
amended, the “Purchase Agreement”) pursuant to which Novartis transferred and assigned to Buyer certain assets and rights of Novartis and its Affiliates, and licensed to Buyer certain other assets and rights of Novartis and its
Affiliates, related to the Compound or Product (as defined therein); 
 WHEREAS, Novartis and Morphosys (as defined below), have entered
into that certain 2nd Amended and Restated Collaboration and License Agreement dated as of November 6, 2012, and any ensuing commercial license thereunder (the “Morphosys
Agreement”), to collaborate in the utilization of the Morphosys HuCAL antibody library and other Morphosys technologies on behalf of Novartis in order to facilitate the research, discovery and development of novel therapeutic, prophylactic,
and diagnostic antibody products by Novartis; 
 WHEREAS, pursuant to the Purchase Agreement, Novartis has transferred and assigned or
licensed to Buyer all assets owned by Novartis and its Affiliates arising under the Morphosys Agreement to the extent related to the development, manufacturing, or commercialization of Therapeutic Antibody Products (as defined below); and 

WHEREAS, Morphosys has granted to Novartis a commercial therapeutic license, together with additional licenses, to develop, manufacture and
commercialize Therapeutic Antibody Products (as defined below), and upon the terms and conditions set forth in this Agreement, Novartis desires to grant to Buyer, and Buyer desires to obtain from Novartis, a sublicense of the foregoing rights; 

NOW, THEREFORE, in consideration of the respective representations, warranties, covenants and agreements contained herein, and for other
valuable consideration, the receipt and adequacy of which are hereby acknowledged, Novartis and Buyer, intending to be legally bound, agree as follows: 

ARTICLE I 
 DEFINITIONS

 The terms in this Agreement with initial letters capitalized, whether used in the singular or the plural, shall have the meaning set
forth below or, if not listed below, the meaning as defined as it first appears in this Agreement. 

 1.1    “Affiliate” shall mean with respect to any
Person, any other Person directly or indirectly controlling, controlled by, or under common control with such other Person. 

1.2    “Agreement” shall have the meaning set forth in the Preamble, and shall include, for the
avoidance of doubt, all Exhibits and Schedules attached hereto. 
 1.3    “Applicable Law” shall
mean all federal, provincial, state, local and foreign law (including of the United States), whether statutory, common or otherwise, constitution, treaty, convention, ordinance, code, rule, regulation, order, injunction, judgment, decree, ruling or
other similar requirement. 
 1.4    “Bona Fide Collaborator” shall mean, with respect to a
particular Party, a Third Party conducting activities for, on behalf of, in collaboration with or pursuant to an agreement with such Party or its Affiliates related to such Party’s or its Affiliates’ research, development, and
commercialization purposes. 
 1.5    “Business Day” shall mean a day on which banking
institutions in London, United Kingdom, New York, New York, and Basel, Switzerland are open for business. 

1.6    “Buyer” shall have the meaning set forth in the Preamble. 

1.7    “Calendar Quarter” shall mean each calendar quarter ending on March 31st, June 30th,
September 30th and December 31st. 
 1.8    “Calendar Year” shall mean each calendar year
starting on January 1st and ending on December 31st. 

1.9    “Collaboration” shall have the meaning set forth in the Morphosys Agreement. 

1.10    “Collaboration Invention” shall mean any discovery, Invention, Know-How or trade secret made (including conceived) by or on behalf of either Novartis or Morphosys in the course of performing activities [***] to the development of Therapeutic Antibody Products in the
Field of Use or the Collaboration, whether before or after the Effective Date. 
 1.11    “Collaboration
Patent Rights” shall mean the rights and interests in and to issued patents and pending patent applications in any country, including, but not limited to, all provisional applications, substitutions, continuations, continuations-in-part, divisions, and renewals, all letters patent granted thereon, and all reissues, reexaminations, extensions and supplementary patent certificates thereof,
whether owned solely or jointly by a Party, [***]. 
 1.12    “Collaboration Term” shall
mean the period from the Effective Date through December 1, 2017. The Collaboration Term may be extended for a further two-year increment by Buyer providing notice to Novartis before May 1, 2017, for
a total Collaboration Term until December 1, 2019. 

  
 2 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 1.13    “Commercialization” means activities directed
to obtaining pricing and reimbursement approvals, marketing, promoting, distributing, importing, exporting, using, offering for sale, or selling a pharmaceutical product or therapy anywhere in the world. When used as a verb,
“Commercialize” means to engage in Commercialization. 
 1.14    “Commercially
Reasonable Efforts” shall mean, with respect to [***], including to [***], as applicable, [***] with the [***] of [***] in pursuing the [***] or [***] of a [***] or [***] at a
[***] of [***] or [***], taking into account [***] of the [***] or [***], including [***] and [***] or [***] and [***] or [***] and [***] and [***] including
[***] and [***] of the [***] of the [***] or [***] in [***] of [***] and [***], and all other [***] including [***] or [***]. 

1.15    “Confidential Information” shall have the meaning assigned in
Section 7.1. 
 1.16    “Control” (including any variations such as
“Controlled” and “Controlling”) means, with respect to any item or Patent, Know-How, or other intellectual property right, the legal authority or right (whether by ownership
or license, other than by a license or sublicense granted pursuant to this Agreement) of a Party or its Affiliates to grant to the other Party the right to use such item, or a license, sublicense or access as provided herein to such item, without
violating the terms of any agreement or other arrangement with any Third Party in existence as of the time such Party or its Affiliates would first be required hereunder to grant the other Party such license, access, or other right. 

1.17     “Cover”, “Covered” or “Covering” shall mean, with
respect to a Patent, that, in the absence of a license granted to a Person under a Valid Claim included in such Patent, the Manufacture, use, distribution or sale of a Therapeutic Antibody Product or other product or therapy, as applicable, by such
Person would infringe such Valid Claim. 
 1.18    “Development” shall mean any and all
preclinical and clinical drug development activities [***] to the discovery and development of pharmaceutical products or therapies and submission of information to a Regulatory Authority, including test method development and stability
testing, toxicology, animal efficacy studies, formulation, quality assurance/quality control development, statistical analysis, clinical studies, clinical trials and testing, regulatory affairs, product approval and registration, chemical or
biological development and development manufacturing, process development, upscaling, validation, packaging development and manufacturing and development documentation efforts in support of development activities anywhere in the world. When used as
a verb, “Develop” means to engage in Development. 
 1.19    “Effective Date”
shall have the meaning set forth in the Preamble. 
 1.20    “EMA” shall mean the
European Medicines Agency or any successor agency thereto. 
 1.21    “Encumbrance” shall mean
any claim, charge, equitable interest, hypothecation, lien, mortgage, pledge, option, license, assignment, power of sale, retention of title, right of pre-emption, right of first refusal or security interest
of any kind, other than the overriding obligations to the U.S. government as set forth in Public Law 96-517 (35 U.S.C. §§ 200-204), as amended, or any
similar obligations under Applicable Law of any other country or jurisdiction. 

  
 3 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 1.22    “FDA” shall mean the United States Food and
Drug Administration or any successor agency thereto. 
 1.23    “Field of Use” shall mean the
[***] and/or [***] of [***] in [***] or [***], excepting only [***], and except the [***] of any [***] as part of [***]. 

1.24    “First Commercial Sale” shall mean the first sale of a Therapeutic Antibody Product by
Buyer, its Affiliates or sublicensees to a Third Party in a country following Regulatory Approval of such Therapeutic Antibody Product in that country. Sales or transfers of [***] of a Therapeutic Antibody Product for research, proof-of-concept studies or other clinical trial purposes, or for compassionate or similar use, shall not be considered a First Commercial Sale. 

1.25    “HuCAL Antibody” shall mean, individually and collectively: (i) an antibody or
antibody fragment (including but not limited to antibody fragments such as Fv, Fab, F(ab’)2, single chain antibody, antibody conjugate bound to a toxin or bound to a label, or any other antibody moiety) that, in each case, is based on
[***] and/or includes [***] that have been [***] the [***]) (or any [***]) [***]; and (ii) any antibody or antibody fragment (including but not limited to antibody fragments such as Fv, Fab,
F(ab9)2, single chain antibody, antibody conjugate bound to a toxin or bound to a label, or any other antibody moiety) that, in each case, has been derived (either physically or by reverse engineering, in one or more steps) from an antibody or
antibody fragment referred to in sub-section (i) hereof. 

1.26    “Indication” shall mean a specific disease or condition. 

1.27    “Infectious Diseases” shall mean any disease resulting from the presence of a pathogenic
microbial agent, including but not limited to viruses, bacteria, fungi, protozoa, multicellular parasites and prions. 

1.28    “Inventions” shall mean any Know-How or other
subject matter invented in the performance of activities under the Morphosys Agreement by or on behalf of Morphosys or Novartis or under this Agreement by or on behalf of any Party or both Parties jointly. 

1.29    “Know-How” shall mean any data, information,
inventions, proprietary information, trade secrets or technology (whether or not proprietary or protectable under patent, copyright or similar Applicable Law and whether stored or transmitted in oral, documentary, electronic or other form). Know-How shall include ideas, concepts, formulas, methods, procedures, designs, compositions, plans, documents, discoveries, developments, techniques, protocols, specifications, works of authorship, biological
materials, and any information relating to research and development plans, experiments, results, compounds, therapeutic leads, candidates and products, clinical and preclinical data, clinical trial results, and manufacturing information, plans and
standard operating procedures, including any scientific, regulatory, pre-clinical or clinical information or data regarding specific Indications and any marketing, financial, commercial, personnel and other
business information and plans. 

  
 4 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 1.30     “Major Market Country” shall mean,
individually and collectively, [***]. 
 1.31    “Manufacturing” shall mean any and all
activities and operations involved in or relating to the manufacturing, quality control testing (including in-process, release and stability testing), releasing or packaging of a pharmaceutical product or
therapy, for pre-clinical, clinical or commercial purposes. When used as a verb, “Manufacture” means to engage in Manufacturing. 

1.32    “Morphosys” shall mean Morphosys AG, a German stock corporation having its
principal place of business at Lena-Christ-Strasse 48, 82152 Martinsried/Planegg, Germany. 

1.33    “Morphosys Agreement” shall have the meaning set forth in the Recitals. 

1.34    “Morphosys Collaboration Technologies” shall mean, individually and collectively,
(i) the technologies described in Exhibit A, and (ii) any Morphosys Improvement Technologies that are technological advances (whether or not patentable) of the technologies described in the foregoing (i). 

1.35    “Morphosys Improvement Technologies” shall mean, individually and collectively,
technological advances (whether patentable or not) of Morphosys Collaboration Technologies, which advances occur prior to or during the Collaboration Term; provided, however, that Morphosys Improvement Technologies shall not include advances
related to specific HuCAL Antibodies or anything not relating to the general operation and use of Morphosys Technologies or Morphosys Improvement Technologies. 

1.36    “Morphosys IP” shall mean, individually and collectively, Morphosys Know-How and Morphosys Patent Rights. 
 1.37    “Morphosys Know-How” shall mean, individually and collectively, all know how prior to or during the Collaboration Term, including but not limited to inventions, discoveries, compositions, technology, data, techniques,
specifications, designs and other information (whether or not patentable) of any type whatsoever: (a) that are not generally known; (b) that relate to the Morphosys Technologies or Morphosys Improvement Technologies and/or the use thereof;
and (c) in which Morphosys has an ownership or other licensable interest with the right to grant licenses thereunder, without violating the terms of any agreement or other arrangement with any third party. 

1.38    “Morphosys Patent Rights” shall mean, individually and collectively, all United States
patent applications, United States patents, non-United States patent applications and non-United States patents: (i) that are listed in Exhibit B; or
(ii) that claim at least a portion of the Morphosys Improvement Technologies, any divisional or continuation application of “(i)” or “(ii)”, and any reissue or reexamination, extension and supplementary patent certificates
thereof of any of “(i)” or “(ii)” or of any patent claiming priority thereto. Exhibit B shall be updated from time to time to include, for example, the patent application serial numbers that contain at least one
(1) claim covering at least a portion of the Morphosys Improvement Technologies. 

  
 5 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 1.39    “Morphosys Technologies” shall mean,
individually and collectively, Morphosys Collaboration Technologies, Morphosys HuCAL Library (as defined in the Morphosys Agreement), and Morphosys HuCAL Library Ancillary Technologies (as defined in the Morphosys Agreement). 

1.40    “Net Sales” shall mean with respect to a Therapeutic Antibody Product, the gross amount
invoiced by Buyer and any Affiliate or sublicensee or marketing partner to third party customers for such Therapeutic Antibody Product, less: 

(a)    Normal and customary trade and quantity discounts and non-affiliated
brokers’ or agents’ commissions actually allowed and taken and not already reflected in the amount invoiced; 

(b)    Amounts repaid or credited by reason of defects, rejections, returns, recalls, allowances, or
government-imposed retroactive price reductions; 
 (c)    Third party cash rebates and chargebacks related to
sales of finished Therapeutic Antibody Products, to the extent allowed; 
 (d)    Government-imposed retroactive
price reductions that are actually allowed or granted; 
 (e)    Tariffs, duties, excise, sales, value-added, and
other consumption taxes and customs duties to the extent included in the invoice price and paid by or on behalf of Buyer; 

(f)    Cash discounts for timely payment; 

(g)    Delayed ship order credits; 

(h)    Discounts pursuant to indigent patient programs and patient discount programs of any nature; 

(i)    A fixed charge of [***] to cover warehousing and distribution expenses; 

(j)    Any otherwise specifically identifiable costs or charges included in the gross invoiced sales price of such
Therapeutic Antibody Product falling within categories equivalent to those listed above; and 

  
 6 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 (k)    Uncollectible amounts on previously sold products, but not such
amounts that, but for the failure to collect such amounts within [***] years from the date of the respective invoice, would have been collectible; provided that: 

(i)    In the case of any sale or other disposal of a Therapeutic Antibody Product between or among Buyer and its
Affiliates or sublicensees or marketing partners, for resale, Net Sales shall be calculated as above only on the value charged or invoiced on the first arm’s length sale to a third party; 

(ii)    In the case of any sale, which is not invoiced or is delivered before invoice, Net Sales shall be calculated at
the time of shipment; 
 (iii)    In the case of any sale or other disposal, such as barter or counter-trade, of any
Therapeutic Antibody Product, or part thereof, otherwise than in an arm’s length transaction exclusively for money, Net Sales shall be calculated as above on the value of the consideration received or, if higher, on the fair market price of the
Therapeutic Antibody Product in the relevant country of sale or disposal; and 
 (iv)    In the event that a Therapeutic
Antibody Product is sold as part of a combination product, Net Sales of the Therapeutic Antibody Product, for the purpose of determining royalty payments, shall be determined by multiplying Net Sales of the combination product by the fraction
A/(A+B), where A is the weighted (by sales volume) average sales price of the Therapeutic Antibody Product when sold separately in finished form and B is the weighted average sale price of the other product(s) sold separately in finished form. 

In the event that such average sales price cannot be determined for both the Therapeutic Antibody Product and the other product(s) in
combination, Net Sales for purposes of determining payments hereunder shall be mutually agreed by the Parties based on the relative value contributed by each component, and [***]. 

1.41    “Novartis” shall have the meaning set forth in the Preamble. 

1.42    “Party” shall mean Novartis or Buyer; “Parties” shall mean Novartis and
Buyer. 
 1.43    “Patent Rights” shall mean patents and all substitutions, divisions,
continuations, continuations-in-part, reissues, reexaminations and extensions thereof and supplemental protection certificates relating thereto, any confirmation patents
or registration patents or patents of addition based on any such patents, and all counterparts thereof or substantial equivalents in any country, including utility models and industrial designs (collectively, “Patents”) and any
applications or provisional applications for any of the foregoing (“Patent Applications”). 

1.44    “Person” shall mean any corporation, limited or general partnership, limited liability
company, joint venture, trust, unincorporated association, governmental body, authority, bureau or agency, any other entity or body, or an individual. 

  
 7 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 1.45    “Phase III Clinical Trial” shall mean a
controlled pivotal clinical study of a product that is prospectively designed to demonstrate statistically whether such product is effective and safe for use in a particular Indication in a manner sufficient to obtain Regulatory Approval to market
such product. 
 1.46    “Purchased IP” shall have the meaning set forth in the Purchase
Agreement. 
 1.47    “Regulatory Approval” shall mean, with respect to a Therapeutic Antibody
Product in any country or jurisdiction, any approval (including where required, pricing and reimbursement approvals), registration, license or authorization from a Regulatory Authority in a country or other jurisdiction that is necessary to market
and sell such Therapeutic Antibody Product in such country or jurisdiction. 
 1.48    “Regulatory
Authority” shall mean any federal, national, multinational, state, provincial or local regulatory agency, department, bureau or other governmental entity with authority over the marketing, pricing or sale of a pharmaceutical product or
therapy in a country, including the FDA, EMA and any corresponding national or regional regulatory authorities. 

1.49    “Royalty Term” shall have the meaning set forth in Section 5.2(a) 

1.50    “Term” shall have the meaning set forth in Section 11.1. 

1.51    “Therapeutic Antibody Product” shall mean [***] to [***] for [***] a
[***] and any [***] or [***]. 
 1.52    “Third Party” shall mean any
Person other than Buyer, Novartis or their respective Affiliates. 
 1.53    “Third Party In-License” shall mean the Morphosys Agreement along with the commercial license granted to Novartis pursuant to the Morphosys Agreement. 

1.54    “United States” or “US” shall mean the United States of America, its
territories and possessions. 
 1.55    “Valid Claim” shall mean, with respect to any country,
either: (i) a claim of an issued and unexpired patent which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the
time allowed for appeal, and which has not been admitted to be invalid or unenforceable through reissued or disclaimer or otherwise; or (ii) a claim of a pending patent application that has not been abandoned or finally rejected without the
possibility of appeal [***]. 

  
 8 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 ARTICLE II 

SUBLICENSE AND LICENSE GRANTS 

2.1    Sublicense and License Grants to Buyer. 

(a)    Exclusive Commercial Therapeutic Sublicense. Novartis hereby grants to Buyer, and Buyer hereby
accepts from Novartis, an exclusive, worldwide, royalty-bearing sublicense (with the right to grant further sublicenses) under Morphosys Patent Rights and Morphosys Know-How within the Field of Use to make,
have made, develop, have developed, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported, export or have exported, Therapeutic Antibody Products. 

(b)    Preclinical and Clinical Monitoring Sublicense. Novartis hereby grants to Buyer, and Buyer hereby
accepts from Novartis, a non-exclusive, royalty-free sublicense (with the right to grant further sublicenses) to use and have used, but not sell or have sold, HuCAL Antibodies directed against sclerostin for
in vitro diagnostics in a preclinical or clinical setting, to the extent [***] to obtain Regulatory Approval for Therapeutic Antibody Products. 

(c)    Right to Sublicense. Buyer may sublicense its rights under this Section 2.1
to Bona Fide Collaborators as permitted under the Morphosys Agreement. 
 2.2    No Implied Licenses.
Except as specifically set forth in this Agreement, neither Party shall acquire any license or other intellectual property interest, by implication or otherwise, in any intellectual property disclosed to it under this Agreement or under any
Patent Rights Controlled by the other Party or its Affiliates. 

2.3    Know-How and Materials Transfer. The Parties acknowledge and
agree that the provisions of Section 5.3 of the Purchase Agreement shall apply to the rights granted hereunder. 

ARTICLE III 
 THIRD
PARTY COVENANTS-NOT-TO-SUE & ADDITIONAL SUBLICENSES 

3.1    CAT Covenant. Novartis hereby grants to Buyer the benefits of the covenant-not-to-sue (“CAT Covenant”) under a framework agreement between Morphosys and Cambridge Antibody Technology (“CAT Framework
Agreement”), with regard to the “CAT Patent Rights” described in Appendix 3.02 of the CAT Framework Agreement, in order to permit Buyer to practice any licenses granted to it herein by Novartis. Buyer hereby
acknowledges that it has read the redacted copy of the CAT Framework Agreement. Novartis makes no representations that the benefits of the CAT Covenant shall extend to Buyer if Buyer: (i) conducts “Alternative Selection” (as
such term is defined in Appendix 3.02 of the CAT Framework Agreement); (ii) [***]; or (iii) enters into a “Challenge of a CAT Patent Right” (as such term is defined in Section 3.07(c) of
the CAT Framework Agreement). 

  
 9 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 3.2    AME Sublicense. Novartis hereby grants to Buyer a
sublicense to the patent rights listed in Section 1.2 (“AME Patent Rights”) of that certain sublicense agreement entered into by and between Morphosys and Applied Molecular Evolution (“AME
Sublicense Agreement”), to the extent necessary to practice any rights granted by Novartis to Buyer herein; provided, however, that the sublicense to the AME Patent Rights shall be subject to the limitations of the AME Sublicense
Agreement and the “Kauffman Agreement” (as such term is defined in Section 1.10 of the AME Sublicense Agreement). Buyer hereby acknowledges that it has read the redacted copies of the AME Sublicense
Agreement and the Kauffman Agreement. Buyer also acknowledges that [***]. 
 3.3    Dyax
Sublicense. Novartis hereby grants to Buyer a sublicense under the patent rights listed in Section 1.5 (“Dyax Patent Rights”) of that certain patent license agreement entered into by and between
Morphosys and Dyax Corp. (“Dyax License Agreement”), to the extent necessary to practice any license granted by Novartis to Buyer herein; provided, however, that the sublicense to the Dyax Patent Rights shall be subject to
the limitations of the Dyax License Agreement. Buyer hereby acknowledges that it has read the redacted copy of the Dyax License Agreement and agrees to abide by the provisions contained therein. In particular, Buyer acknowledges that [***]
and [***]and [***]. Buyer also acknowledges that [***]. 
 ARTICLE IV 

DILIGENCE 

4.1    Diligence. Buyer shall, itself, through its Affiliates or sublicensees, use Commercially Reasonable
Efforts to Develop and Commercialize a Therapeutic Antibody Product. Subject to the right set forth in Section 11.3, Buyer shall be in violation of its due diligence obligation if (a) Buyer decides to discontinue all
efforts on developing therapeutic antibodies against sclerostin, or (b) Buyer conducts no significant work on Developing therapeutic antibodies against sclerostin for a consecutive [***] period. 

ARTICLE V 
 FINANCIAL
PROVISIONS 
 In full consideration for the rights granted to Buyer hereunder, and solely to the extent Novartis is required to make such
payments to Morphosys, Buyer hereby agrees to make the following payments to Novartis: 

  
 10 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 5.1    Milestone Payments. 

(a)    Subject to the terms and conditions of this Article V, Buyer shall pay, or cause to be paid, to
Novartis the following one-time payments upon the achievement of the milestone events set forth below: 

(i)    [***] if, and the first time, [***] or [***] a [***] or [***] in the [***] in
[***] covering the [***] Therapeutic Antibody Product; 
 (ii)    [***] if, and the first time,
[***] or an [***] an [***] or [***] or [***] in the [***] in [***] or [***] for the [***] Therapeutic Antibody Product [***]; and 

(iii)    [***] if, and the first time, [***] or an [***] or [***] in the [***] in
[***] for the [***] Therapeutic Antibody Product [***]. 
 (b)    For clarity, in the event
that a Therapeutic Antibody Product [***], then [***] Therapeutic Antibody Product [***] of [***]. 

5.2    Royalty Payments. 

(a)    “Royalty Term” shall mean the period beginning on the Effective Date and continuing until:
(i) the earliest of: (x) twelve (12) years after First Commercial Sale in such country; (y) the expiration of the last Valid Claim included in Morphosys Patent Rights in such country, which Valid Claim Covers [***] such
Therapeutic Antibody Product; and (z) the expiration of the last Valid Claim included in the Collaboration Patent Rights in such country, which Valid Claim Covers [***] such Therapeutic Antibody Product; or (ii) ten (10) years after
First Commercial Sale in such country, whichever is later. 
 (b)    Royalty Rate. Buyer shall pay to
Novartis royalties in the amount of [***]% of Net Sales of Therapeutic Antibody Products sold by Buyer and its Affiliates on a country-by-country basis during the
Royalty Term; provided, however, the corresponding royalty rate under this Agreement [***] to the extent any Royalty Term extends beyond the expiration of the last to expire relevant Valid Claim. 

(c)    The following terms shall apply to any royalty payments due under this Agreement: 

(i)    Royalty payments shall be made to Novartis within [***] days following the end of each Calendar Quarter for
which royalties are due. Each royalty payment shall be accompanied by a report summarizing the total Net Sales for each Therapeutic Antibody Product during the relevant Calendar Quarter and the calculation of royalties, if any, due thereon. 

(ii)    All royalties shall be payable in full in US Dollars, regardless of the countries in which sales are made. For the
purpose of computing Net Sales for Therapeutic Antibody Products sold in a currency other than US Dollars, Buyer shall convert the amounts into US Dollars from the currency in which such amounts are received by Buyer using Buyer’s then-current
standard exchange rate methodology applied to its external reporting for the translation of foreign currency sales into US Dollars. 

  
 11 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 (iii)    Any amounts not paid by Buyer to Novartis within the respective
time period shall bear interest at a rate of [***]. Notwithstanding the foregoing, if the obligation to pay a particular payment hereunder is disputed in good faith, and the resolution of such dispute demonstrates that such payment is not due
hereunder, then no interest thereon shall be paid by Buyer. 
 (iv)    All consideration set forth herein shall be
[***] any applicable value added tax (“VAT”), and any VAT payable shall be borne by [***]the [***] and [***] to [***]. If provision is made in Applicable Law or regulation of any country for
withholding of taxes, levies or other charges with respect to [***] to [***] such [***] or [***] for and on [***] of [***] to the [***], and shall promptly [***] with [***] of such
[***]. [***] shall [***] to [***] such [***] or [***] from [***] to [***]. Each Party agrees to assist the other Party in claiming exemption from such deductions or withholdings under double
taxation or similar agreement or treaty from time to time in force and in minimizing the amount required to be so withheld or deducted. 

(v)    For the avoidance of doubt, the obligation for Buyer to pay royalties under this
Section 5.2 is imposed only once with respect to the same unit of Therapeutic Antibody Product, notwithstanding such Therapeutic Antibody Product may be Covered by more than one Valid Claim of the Morphosys Patent Rights.

 5.3    Third Party Obligations. 

(a)    Notwithstanding any other provision of this Agreement, Novartis shall remain responsible for the payment of
royalty, milestone and other payment obligations, if any, due to Morphosys and any other Third Party under the Third Party In-License. All such payments shall be made promptly by Novartis in accordance with
the terms of the Third Party In-License. 
 (b)    In the event that
milestone and royalty payment obligations of Novartis to Morphosys under the Morphosys Agreement terminate or are otherwise excused, all milestone payments and royalty payments set forth in this Article V shall terminate. 

5.4    Payment Terms. All payments hereunder shall be payable within [***] days after receipt by
Buyer, or its nominee designated for that purpose in advance by Buyer in writing to Novartis, of an invoice by Novartis covering such payment. Except as otherwise stated herein, all payments due hereunder shall be made in US Dollars. All payments
shall be non-creditable against any other fees due hereunder. 

  
 12 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 ARTICLE VI 

RECORDS 

6.1    Records Retention. Buyer and its Affiliates shall keep for [***] from the date of each payment
of royalties complete and accurate records of sales of each Therapeutic Antibody Product in sufficient detail to allow the accruing royalties to be determined accurately. Buyer shall maintain all records in accordance with IFRS accounting standards.
Within [***] days following each Calendar Year, Buyer shall provide Novartis with an annual summary report setting out the development stage and estimated timeline for achievement of the next development stage for the Therapeutic Antibody
Product(s). Buyer shall also notify Novartis in writing of the achievement of each event triggering a payment, within [***] days of occurrence. 

6.2    Audits. 

(a)    Novartis shall have the right for a period of [***] after receiving any report or statement with
respect to any payment triggering event or financial calculation hereunder and Novartis shall have the right during the term of the Agreement (no more than [***] per year), and upon [***] notice to Buyer to appoint an independent
auditor (the “Auditor”) [***] acceptable to Buyer to inspect the relevant records of Buyer or its Affiliates to verify such reports, statements, records or books of accounts, as applicable. Before beginning its audit, the
Auditor shall execute an undertaking acceptable to Buyer and Novartis by which the Auditor shall keep confidential all information reviewed during such audit. The Auditor shall have the right to disclose to Novartis solely its conclusions regarding
any payments owed to Novartis. 
 (b)    Buyer shall make its records available for inspection by such Auditor
during regular business hours at such place or places where such records are customarily kept, upon [***] notice from Novartis, solely to verify the accuracy of the reports, payments, records or books of accounts. Such inspection right shall
not be exercised by Novartis more than [***] in any calendar year. Additionally, Novartis may not audit the sales of any Therapeutic Antibody Product in any given period more than once. 

(c)    Novartis shall pay for such inspections, as well as its own attorney fees associated with enforcing its
rights with respect to any payments hereunder, except that in the event there is any upward adjustment in aggregate amounts payable for any year shown by such inspection of more than [***] of the amount paid, Buyer shall pay for such
inspection, including reasonable attorney fees related to enforcement. 

  
 13 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 ARTICLE VII 

CONFIDENTIALITY 

7.1    Each Party may disclose to the other Party proprietary information, materials and technical, business and
strategic information under this Agreement of a confidential or proprietary nature (“Confidential Information”). Confidential Information shall also comprise any information regarding the subject matter of this
Agreement. Notwithstanding the foregoing, it is understood and agreed that the receiving Party’s obligations of confidentiality and non-use herein shall not apply to any information which, as can be
demonstrated by competent proof: 
 (a)    is, at the time of disclosure, or thereafter becomes, a part of the
public domain or publicly known or available through no fault or negligence of the receiving Party or any of its Affiliates; 

(b)    was otherwise in the receiving Party’s lawful possession prior to disclosure by the disclosing Party,
other than under an obligation of confidentiality; 
 (c)    was independently discovered or developed by the
receiving Party or any of its Affiliates, without use of the other Party’s Confidential Information; or 

(d)    is lawfully disclosed to the receiving Party or any of its Affiliates on a
non-confidential basis by a third party who is not in violation of an obligation of confidentiality to the disclosing Party relative to such information. 

7.2    For a period of [***] after the receipt of any such Confidential Information, the receiving Party
shall keep confidential, shall not use, and shall not disclose to third parties, any such Confidential Information of the other Party, except as expressly permitted hereunder. Each Party may disclose Confidential Information to its Affiliates,
provided that any such Affiliate accepts the Confidential Information on the terms herein. Notwithstanding the foregoing, Buyer may disclose Confidential Information to non-Affiliate third
parties conducting activities for, on behalf of, in collaboration with or pursuant to an agreement with Buyer or its Affiliates, related to Buyer’s or its Affiliates’ research, Development, Manufacturing, and Commercialization purposes,
but only to the extent that such Confidential Information is reasonably related to such activities of such party(ies), and then only to the extent such party(ies) previously has agreed in writing to maintain the confidentiality of information
provided to it by Buyer or its Affiliates on terms similar to those herein. In addition, the Parties shall have the right to disclose a redacted version of the Agreement to applicable parties for the limited purpose of due diligence in connection
with any restructuring, financing, merger, acquisition, existing or prospective collaboration of one of the Parties or any similar event, with the prior consent of the other Party, which shall not be unreasonably withheld; provided,
however, that the Parties shall agree in good faith upon such redactions. In addition, a Party may disclose the full terms of the Agreement to its investment bankers, lawyers, accountants and other professional advisors without the
other Party’s prior approval, provided that such disclosure is made under terms of confidentiality. Each Party may disclose the other’s information that comprises Confidential Information to the extent such disclosure
is reasonably necessary in: (i) filing, prosecuting or defending litigation; (ii) filing, prosecuting or defending Patent Rights (but only to the extent that each Party gives its consent to the other Party to make such disclosure, which
consent shall not be unreasonably withheld); or (iii) complying with Applicable Law or governmental regulations (including the rules and regulations of the United States Securities and Exchange Commission or any national securities exchange);
provided, however, that if a Party is required to make any disclosure of the other Party’s Confidential Information, it will give reasonable advance notice to the other Party of such disclosure requirement and will use reasonable
efforts to assist such other Party in efforts to secure confidential treatment of such Confidential Information required to be disclosed. Upon any termination of this Agreement or Morphosys Agreement, and upon request, a Party shall return to a
requesting Party all copies of any of such requesting Party’s Confidential Information that is not the subject of a license granted hereunder. 

  
 14 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 7.3    The Parties shall also be permitted hereunder to disclose the
general nature of this Agreement to the extent reasonably necessary to obtain financing from third parties or potential collaborators, and to make such other disclosures as mutually agreed by the Parties. Except to the extent already disclosed in
any mutually agreed press release or other public communication, no public announcement concerning the existence or the terms of the Agreement or concerning the transactions described herein shall be made, either directly or indirectly, by the
Parties, except as may be legally required by Applicable Law, without first obtaining the approval of the other Party and agreement upon the nature, text, and timing of such announcement, which approval and agreement shall not be unreasonably
withheld. Once any written statement is approved for disclosure by both Parties, either Party may make subsequent public disclosures of the contents of such statement without the further approval of the other Party. 

7.4    Novartis and its Affiliates agree not to publish or publicly present any results, data, or scientific
findings with respect to: (i) the efforts that generated or optimized any Therapeutic Antibody Product, or (ii) the biological activity of a drug product or biological activity identified through the use of a Therapeutic Antibody Product.
In the event of information already within the public domain, consent shall not be required prior to planned submission for publication or public presentation so long as such information is properly attributed in accordance with commonly accepted
practices. 
 7.5    Publicity. Novartis shall not issue any press release or public announcement
relating to this Agreement without the prior written approval of Buyer, [***], except that Novartis may issue such a press release or public announcement if required by Applicable Law, including by the rules or regulations of the United
States Securities and Exchange Commission or similar regulatory agency in a country other than the United States or of any stock exchange or NASDAQ; provided that Buyer has received at least [***] days prior notice of such intended
press release or public announcement and Novartis considers in good faith Buyer’s comments thereon, unless Novartis was and is prevented by Applicable Law from providing such advance notice, and Novartis includes in such press release or public
announcement only such information relating to the Therapeutic Antibody Product(s) or this Agreement as is required by such Applicable Law. 

  
 15 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 ARTICLE VIII 

INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION 

8.1    Ownership of Intellectual Property and Inventions. 

(a)    All Morphosys Patent Rights, Morphosys Know-How and Morphosys
Improvement Technologies are owned by Morphosys. 
 (b)    All Inventions,
Know-How and Patent Rights developed by Buyer after the date of this agreement shall be solely owned by Buyer. 

(c)    Inventorship shall be determined in accordance with applicable US inventorship laws. Novartis hereby assigns
and agrees to assign, and shall [***] cooperate and [***] to cause its Affiliates, employees, agents, consultants and any other individuals who participated in any respect to the conception or reduction to practice of any Inventions on
its behalf to take all necessary actions and execute all necessary documents in order to assign any applicable Collaboration Inventions and Collaboration Patent Rights exclusively related to the Therapeutic Antibody Product to Buyer. 

8.2    Branding. Buyer will have sole responsibility, ownership and decision making power, at its
sole expense, for all aspects of naming and branding the Therapeutic Antibody Product(s) worldwide, including creating, selecting, prosecuting and enforcing trademarks and domain names. 

ARTICLE IX 

REPRESENTATIONS, WARRANTIES AND COVENANTS 

9.1    Mutual Representations and Warranties. Each Party hereby represents and warrants to the other Party
as of the Effective Date as follows: 
 (a)    Corporate Existence and Power. It is a corporation duly
organized, validly existing, and in good standing under the laws of the jurisdiction in which it is incorporated, and has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business
or other activities as they are now being conducted and as contemplated in this Agreement, including the right to grant the licenses granted by it hereunder. 

(b)    Authority and Binding Agreement. (i) It has the corporate power and authority and the legal
right to enter into this Agreement and perform its obligations hereunder; (ii) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations
hereunder; and (iii) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its terms. 

  
 16 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 (c)    Consents. All consents, approvals and authorizations
from all governmental authorities or other Third Parties required to be obtained by such Party in connection with this Agreement have been obtained. 

(d)    No Conflict. It is not a party to any agreement or commitment that would prevent it from granting the
rights granted or intended to be granted to the other Party under this Agreement or performing its obligations under this Agreement. 

9.2    Representations and Warranties by Novartis. Novartis hereby represents and warrants to Buyer as of
the Effective Date as follows: 
 (a)    to the knowledge of Novartis, Schedule 9.2(a) attached hereto
sets forth a complete and accurate list of all Patent Rights included in the Morphosys Patent Rights in existence as of the Effective Date, indicating the owner or co-owners thereof if such Patent is not
solely owned by Novartis; 
 (b)    Novartis has the right to grant to Buyer the sublicenses under the Morphosys
IP that it purports to grant hereunder and has not granted any Third Party rights that would otherwise interfere or be inconsistent with Buyer’s rights hereunder; Novartis has not breached in any material respect and is otherwise in full
compliance with the terms of the Third Party In-License, including the following: 

(i)    Novartis has timely paid all annual license fee payments and other payments due and payable to Morphosys; 

(ii)    Novartis has fully complied with all obligations and restrictions with respect to confidential information under
Article 9 of the Morphosys Agreement; and 
 (iii)    Novartis has fully complied with and is in good standing
with respect to the Exclusive Commercial License (as defined in the Morphosys Agreement) obtained from Morphosys; 

(c)    Novartis has the right to use and disclose and to enable Buyer to use and disclose (in each case under
appropriate conditions of confidentiality) the Morphosys Know-How free from Encumbrances; 

(d)    Novartis has not initiated or been involved in any proceedings, actions or claims in which it alleges that
any Third Party is or was infringing or misappropriating any Morphosys IP, nor have any such proceedings, actions or claims been threatened by Novartis, nor does Novartis know of any valid basis for any such proceeding; 

  
 17 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 (e)    there are no pending, and, to Novartis’s knowledge, there
are no threatened, actions, claims, or proceedings of any nature, civil, criminal, regulatory or otherwise, in law or in equity, against Novartis or any of its Affiliates or licensees or, to the knowledge of Novartis, pending or threatened against
any Third Party, in each case involving the Morphosys IP, or relating to the transactions contemplated by this Agreement; 

(f)    there are no agreements or arrangements to which Novartis or any of its Affiliates is a party that would
limit the rights granted to Buyer under this Agreement or that restrict or would result in a restriction on the Parties’ ability to perform the activities contemplated by this Agreement; 

(g)    except for the sublicenses, benefits, and other rights granted in Article III of this Agreement,
there are no sublicenses, benefits, or other rights arising under or related to CAT Framework Agreement, AME Sublicense Agreement, Kauffman Agreement, or the Dyax License Agreement that would be [***] for Buyer to exercise its rights under
this Agreement, including but not limited to Buyer’s right to Develop, Manufacture, and/or Commercialize Therapeutic Antibody Products; 

(h)    to the knowledge of Novartis, the Morphosys Know-How has not been
used or disclosed by any Person except pursuant to valid and appropriate non-disclosure and/or license agreements which have not been breached; and 

(i)    Novartis has disclosed or made available to Buyer all [***] scientific and technical information
known to it relating to the Therapeutic Antibody Products, including (i) [***] of any Therapeutic Antibody Product and (ii) the results of all clinical trials conducted related to the [***] of any Therapeutic Antibody Product.

 9.3    Covenants by Novartis. 

(a)    No Encumbrances. Novartis covenants and agrees that from the Effective Date until the expiration of
the Term, neither it nor its Affiliates shall enter into any agreement with any Third Party, whether written or oral, with respect to, or otherwise assign, transfer, license, convey its right, title or interest in or to or grant any other
Encumbrance to or under, the Morphosys IP. 
 (b)    Third Party
In-License. During the Term, Novartis shall comply with and maintain in full force the Third Party In-License and shall not amend or modify such Third Party In-License, which amendment or modification may affect the rights granted to Buyer under this Agreement, without the prior written consent of Buyer. Novartis shall promptly provide written notice to Buyer describing
any breach, alleged breach or potential breach of a Third Party In-License of which it becomes aware and provide Buyer with copies of any correspondence related thereto. Buyer shall be entitled to
[***], including through [***], and [***]. In the event of termination of the Morphosys Agreement, Novartis shall promptly use best efforts to enable Buyer to obtain a license from Morphosys that grants substantially the same
rights granted to Buyer under this Agreement. In addition, within a period of [***] after the Effective Date (unless the Parties agree to extend such period), Novartis shall enable Buyer to negotiate with Morphosys a direct license to replace
this Agreement. 

  
 18 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 (c)    Further Assurances. 

(i)    The Parties acknowledge and agree that Novartis intends to grant to and confer upon Buyer all of the rights and
benefits accorded to Novartis under the Morphosys Agreement to the extent [***] to Therapeutic Antibody Products and the Development, Manufacturing, and/or Commercialization thereof, and, in the event that the grant of any such rights or
benefits is not expressly set forth in this Agreement, all such rights and benefits shall be deemed to have been granted to Buyer. 

(ii)    Each Party shall [***] to take such action as is [***] or appropriate in order to complete the
transactions contemplated hereby on the terms and subject to the conditions set forth herein. 
 (iii)    After the
Effective Date, at the request of Buyer from time to time, Novartis shall (i) [***] to obtain and deliver such Third Party consents and (ii) execute and deliver to Buyer such certificates, consents and other instruments of sale,
conveyance, assignment and transfer, and take all such other action, in each case, [***] be requested by Buyer to more effectively sell, convey, assign, transfer to or otherwise confer upon Buyer the rights and benefits purported to be
granted under this Agreement. 
 9.4    DISCLAIMER OF WARRANTIES. EXCEPT AS PROVIDED IN SECTION 9.1
OR SECTION 9.2 OF THIS AGREEMENT OR IN THE PURCHASE AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR OF VALIDITY OR NON-INFRINGEMENT OF ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHTS, OR ANY OTHER EXPRESS OR IMPLIED WARRANTIES. 

ARTICLE X 

INDEMNIFICATION 

10.1    Indemnification by Novartis. Subject to the other provisions of this Article X, Novartis
shall defend Buyer, its Affiliates and its sublicensees and each of their respective officers, directors, agents, representatives and employees (collectively, “Buyer Indemnitees”) from and against all charges, allegations, notices,
civil, criminal or administrative claims, demands, complaints, causes of action, proceedings or investigations of a Third Party (collectively, “Claims”), and indemnify and hold harmless such Buyer Indemnitees from and against any
and all losses, liabilities, obligations, awards, settlements, penalties, fines, sanctions, damages and [***] costs (including awards of court costs and reasonable attorneys’ fees) (collectively, “Losses”) that result
from any such Claims, where and to the extent that such Claims are made or brought against any Buyer Indemnitee by or on behalf of a Third Party, and solely to the extent such Claim is based on or arises out of: 

  
 19 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 (a)    the breach of any obligation, covenant, warranty or
representation made by Novartis under this Agreement or any other agreement entered into in connection with this Agreement; 

(b)    any action or omission of Novartis, its agents, employees, or officers related to its rights and/or
obligations under this Agreement; 
 (c)    any violation of Applicable Law by Novartis, its Affiliates or
sublicensees relating to the Morphosys Agreement, this Agreement or Therapeutic Antibody Products; or 

(d)    gross negligence, recklessness or willful misconduct of Novartis; 

provided, however, except in each case in the foregoing (a)-(d) to the extent that such Claim or Loss is attributable to any matter for
which Buyer is obligated to indemnify a Novartis Indemnitee pursuant to Section 10.2. 

10.2    Indemnification by Buyer. Subject to the other provisions of this Article X, Buyer shall
defend Novartis and its Affiliates and each of their respective officers, directors, agents, representatives and employees (collectively, “Novartis Indemnitees”), from and against all Claims, and indemnify and hold harmless such
Novartis Indemnitees from and against any and all Losses that result from such Claims, where and to the extent that such Claims are made or brought against any Novartis Indemnitee by or on behalf of a Third Party, and solely to the extent such Claim
is based on or arises out of: 
 (a)    the breach of any obligation, covenant, warranty or representation made
by Buyer under this Agreement or any other agreement entered into in connection with this Agreement; 

(b)    any action or omission of Buyer, its agents, employees, or officers related to its rights and/or obligations
under this Agreement; 
 (c)    any violation of Applicable Law by Buyer, its Affiliates or sublicensees in the
course of its activities under this Agreement; 
 (d)    gross negligence, recklessness or willful misconduct of
Buyer; or 
 (e)    use, Development, Manufacture, sale, or other disposition of Therapeutic Antibody Products by
Buyer, its Affiliates, or sublicensees; 

  
 20 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 provided, however, except in each case in the foregoing (a)-(e) to the extent that such
Claim or Loss is attributable to any matter for which Novartis is obligated to indemnify a Buyer Indemnitee pursuant to Section 10.1. 

10.3    Indemnification Procedures. A Person entitled to indemnification pursuant to either
Section 10.1 or Section 10.2 will hereinafter be referred to as an “Indemnitee.” A Party obligated to indemnify an Indemnitee hereunder will hereinafter be referred to as an
“Indemnitor.” In the event a Buyer Indemnitee or Novartis Indemnitee is seeking indemnification under either Section 10.1 or Section 10.2, Buyer or Novartis, as applicable, will
inform the Indemnitor of a Claim as soon as reasonably practicable after it receives notice of the Claim, it being understood and agreed that the failure to give notice of a Claim as provided in this Section 10.3 will not
relieve the Indemnitor of its indemnification obligation under this Agreement except and only to the extent that such Indemnitor is actually and materially prejudiced as a result of such failure to give notice. The Indemnitee will permit the
Indemnitor to assume direction and control of the defense of the Claim, and, at the Indemnitor’s expense, will cooperate as reasonably requested in the defense of the Claim. The Indemnitee will have the right to retain its own counsel at its
own expense. The Indemnitor may not settle such Claim, or otherwise consent to an adverse judgment in such Claim without the Indemnitee’s prior written consent, not to be unreasonably withheld or delayed; provided, that the Indemnitor
shall not require such consent with respect to the settlement of any Claim under which the sole relief provided is for monetary damages that are paid in full by the Indemnitor, which would not materially diminish or limit or otherwise adversely
affect the rights, activities or financial interests of the Indemnitee, and which does not result in any finding or admission of fault by the Indemnitee. If the Indemnitor does not assume direction and control of the defense of the Claim, the
Indemnitee may not settle such Claim, or otherwise consent to an adverse judgment in such Claim without the Indemnitor’s prior written consent, not to be unreasonably withheld or delayed. 

10.4    LIMITATION OF LIABILITY. OTHER THAN WITH RESPECT TO A PARTY’S GROSS NEGLIGENCE OR WILLFUL
MISCONDUCT, OR IN CONNECTION WITH A PARTY’S INDEMNIFICATION OBLIGATIONS HEREUNDER OR A BREACH OF ITS CONFIDENTIALITY OBLIGATIONS, NEITHER PARTY WILL BE LIABLE WITH RESPECT TO ANY SUBJECT MATTER OF THlS AGREEMENT UNDER ANY CONTRACT, NEGLIGENCE,
STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES OR LOST PROFITS; [***]. 

ARTICLE XI 
 TERM AND
TERMINATION 
 11.1    Term. This Agreement shall be effective as of the Effective Date and shall
continue, unless terminated earlier pursuant to this Article XI, until the earlier of: (a) termination of the Morphosys Agreement; or (b) on a
product-by-product, country-by-country basis in accordance with its terms until, with
respect to a Therapeutic Antibody Product in a particular country, the expiration of such Therapeutic Antibody Product’s Royalty Term in such country (the “Term”). Upon expiration (but not earlier termination, unless otherwise
expressly provided in this Article XI) of the Term, on a product-by-product and
country-by-country basis, the licenses granted to Buyer hereunder shall continue in effect and become non-exclusive, fully paid-up, royalty-free, perpetual and irrevocable with respect to such Therapeutic Antibody Product and such country. 

  
 21 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 11.2    Termination by Either Party. 

(a)    Except as otherwise provided in this Agreement, if either Party: (i) defaults in the material
performance of or fails to be materially in compliance with a material agreement, condition or covenant of this Agreement, or (ii) makes any materially false reports which results in a material adverse effect on the other Party, the Party not
in default may terminate this Agreement at its option following a [***] day period after written notice in the case of a payment breach, or a [***] day period after written notice in the case of any other breach, unless such default or
breach is cured within these periods. 
 (b)    Without prejudice to any other provision of this Agreement, if
either Party expressly refuses to perform, in whole or in part, this Agreement or any of its material obligations under this Agreement in connection with electing not to perform the Agreement under any bankruptcy laws or an insolvency petition, such
refusal will be considered a material breach that may not be cured. In such event, the other Party may terminate this Agreement at its option by giving notice to the Party who refused to perform, and such termination in the event of refusal to
perform will be effective as of the date of such termination notice, without application of a cure period. 

11.3    Termination by Buyer. Buyer may, in its sole discretion, exercisable at any time during the Term,
terminate this Agreement in its entirety for any reason or no reason at all, effective upon [***] days’ written notice to Novartis. 

11.4    Effect of Termination. 

(a)    Except as set forth in this Article XI, the rights and obligations of the Parties hereunder shall
terminate as of the date of early termination of this Agreement. 
 (b)    Survival. The expiration or
termination of any right or obligation under this Agreement for any reason will not affect obligations, including the payment of any royalties and milestones, that have accrued as of the effective date of such expiration or termination, as the case
may be. The provisions set forth in this Section 11.4, Sections 9.1 and 9.2, and Articles VI (Records), VII (Confidentiality), X (Indemnification), and XII (Miscellaneous),
as well as any other provision that by its terms or by the context thereof is intended to survive expiration or termination, shall survive such expiration or termination. 

  
 22 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 ARTICLE XII 

MISCELLANEOUS 

12.1    Governing Law and Jurisdiction. This Agreement shall be governed by and construed under the laws of
New York, without giving effect to the conflicts of laws provision thereof. Each Party irrevocably submits to the exclusive jurisdiction of the United States District Court for the Southern District of New York, for the purposes of any suit, action
or other proceeding arising out of this Agreement. Each Party agrees to commence any such action, suit or proceeding in the United States District Court for the Southern District of New York or, if such suit, action or other proceeding may not be
brought in such court for jurisdictional reasons, in the Supreme Court of the State of New York, New York County. Each Party further agrees that service of any process, summons, notice or document by a nationally recognized overnight courier
(receipt requested) to such Party’s respective address set forth in Section 12.2 shall be effective service of process for any action, suit or proceeding in New York with respect to any matters to which it has
submitted to jurisdiction in this Section 12.1. Each Party irrevocably and unconditionally waives any objection to the laying of venue of any action, suit or proceeding arising out of this Agreement in the United States
District Court for the Southern District of New York, and hereby and thereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has
been brought in an inconvenient forum. 
 12.2    Notices. All notices, requests, demands and other
communications which are required or may be given under this Agreement shall be in writing and shall be deemed to have been duly given when received if personally delivered; upon receipt if transmitted by email; the day after it is sent, if sent for
next day delivery to a U.S. address by recognized overnight delivery service (e.g., Federal Express); and upon receipt, if sent by certified or registered mail, return receipt requested, as follows: 

If to Buyer: 
 Mereo
BioPharma 3 Limited 
 15 Stratton Street 

London 
 W1J 8LQ 

United Kingdom 
 Attention:
[***] 

  
 23 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 With a copy (which shall not constitute notice) to: 

Proskauer Rose LLP 
 Eleven Times
Square 
 New York NY 10036 

Attention: [***] 
 Email:
[***] 
 If to Seller: 

Novartis Pharma AG 
 Lichtstrasse
35 
 CH-4002, Basel, Switzerland 

Attention: Head – Business Development & Licensing 

With a copy (which shall not constitute notice) to: 

Novartis Pharma AG 
 Lichtstrasse
35 
 CH-4002, Basel, Switzerland 

Attention: General Counsel 
 or to such other
place and with such other copies as either party may designate as to itself by written notice to the others. 

12.3    Specific Performance. The Parties agree that irreparable damage would occur in the event any
provision hereof were not performed in accordance with the terms hereof and that the Parties will be entitled to specific performance of the terms hereof, in addition to any other remedy at law or in equity without the necessity of demonstrating the
inadequacy of monetary damages and without the posting of a bond. 
 12.4    Severability. Whenever
possible, each provision or portion of any provision of this Agreement shall be interpreted in such manner as to be effective and valid under Applicable Law, but if any provision or portion of any provision of this Agreement is held to be invalid,
illegal or unenforceable in any respect under any Applicable Law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of any other provision or portion of any
provision in such jurisdiction. 
 12.5    Interpretation. 

(a)    The words “hereof,” “herein” and “hereunder” and words of similar import when
used in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement, and Article, Section, Schedule and Exhibit references are to this Agreement unless otherwise specified. The meaning of defined terms
shall be equally applicable to the singular and plural forms of the defined terms. The term “or” is inclusive and not exclusive, unless its use is preceded by the word “either” or other words of similar import. The terms
“include” and “including” are not limiting and mean “including without limitation.” Use of a particular gender is for convenience only and is not intended to be a part of or to affect or restrict the meaning or
interpretation of this Agreement. 

  
 24 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 (b)    References to agreements and other documents shall be deemed to
include all subsequent amendments and other modifications thereto. 
 (c)    References to statutes shall include
all regulations promulgated thereunder and references to statutes or regulations shall be construed as including all statutory and regulatory provisions consolidating, amending or replacing the statute or regulation. 

(d)    The captions and headings of this Agreement are for convenience of reference only and shall not affect the
construction of this Agreement. 
 (e)    The language used in this Agreement shall be deemed to be the language
chosen by the Parties to express their mutual intent, and no rule of strict construction shall be applied against any party. 

(f)    The Schedules and Exhibits to this Agreement are a material part hereof and shall be treated as if fully
incorporated into the body of this Agreement. 
 12.6    Integration; Amendments. This Agreement,
including the Schedules and Exhibits hereto and the documents referred to herein, embodies the entire agreement and understanding of the Parties hereto in respect of the subject matter contained herein. This Agreement supersedes all prior agreements
and understandings (including any confidentiality agreements) between the Parties with respect to such subject matter. This Agreement may be amended or modified only by written agreement of the Parties hereto. 

12.7    Independent Contractors; No Agency. Neither Party shall have any responsibility for the hiring,
firing or compensation of the other Party’s employees or for any employee benefits. No employee or representative of a Party shall have any authority to bind or obligate the other Party to this Agreement for any sum or in any manner whatsoever,
or to create or impose any contractual or other liability on the other Party without said Party’s written approval. For all purposes, and notwithstanding any other provision of this Agreement to the contrary, each Party’s legal
relationship under this Agreement to the other Party shall be that of independent contractor. The Parties agree and acknowledge that neither owes any fiduciary duties to the other. 

12.8    Assignment; Successors. This Agreement shall not be assignable by any Party hereto without the prior
written consent of the other Party except that (i) either Party may assign its rights under this Agreement to any of such Party’s Affiliates without the prior written consent of the other Party and (ii) Buyer may assign its rights
under this Agreement to any Person acquiring all or any portion of the Therapeutic Antibody Product or Purchased IP. This Agreement shall be binding upon, and shall inure to the benefit of, all permitted successors and assigns. 

  
 25 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 12.9    Subcontracting. Buyer may subcontract the performance
of any of its activities hereunder to Third Parties at its discretion, provided that the subcontractor agrees to comply with the confidentiality obligations set forth in Article VII. Each Party shall be responsible for the acts or
omissions of such Party’s subcontractors in exercising rights under the subcontract which would constitute a breach hereunder. 

12.10    Execution in Counterparts; Electronic Signatures. This Agreement may be executed in counterparts,
each of which counterparts, when so executed and delivered, shall be deemed to be an original, and all of which counterparts, taken together, shall constitute one and the same instrument even if both Parties have not executed the same counterpart.
Signatures provided by facsimile transmission or by electronic delivery in PDF format shall be deemed to be original signatures. 

12.11    Waivers. No failure on the part of Buyer or Novartis to exercise and no delay in exercising any
right, power, remedy or privilege under this Agreement, or provided by statute or at law or in equity or otherwise, shall impair, prejudice or constitute a waiver of any such right, power, remedy or privilege or be construed as a waiver of any
breach of this Agreement or as an acquiescence therein, nor shall any single or partial exercise of any such right, power, remedy or privilege preclude any other or further exercise thereof or the exercise of any other right, power, remedy or
privilege. 
 12.12    Expenses. Except as otherwise specified herein, all costs and expenses, including
fees and disbursements of counsel, financial advisors and accountants, incurred in connection with this Agreement and the transactions contemplated hereby will be paid by the Party incurring such costs and expenses, whether or not the Closing will
have occurred. 
 12.13    Anti-Bribery; Anti-Corruption. Each Party and their respective Affiliates shall
comply fully at all times with all Applicable Law and regulations, including but not limited to the US Foreign Corrupt Practices Act and all other applicable anti-bribery, anti-corruption laws, of each jurisdiction in which such Parties conduct
business with each other under this Agreement or otherwise in connection with this Agreement. 

12.14    Export Clause. Each Party acknowledges that Applicable Laws and regulations of the US restrict the
export and re-export of commodities and technical data of US origin. Each Party agrees that it shall not export or re-export restricted commodities or the technical data
of the other Party in any form without the appropriate US and foreign government licenses. 
 [Signature Page Follows] 

  
 26 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
Treatment has been requested with respect to the omitted portions. 

 IN WITNESS WHEREOF, Novartis and Buyer have caused this Sublicense Agreement to be duly executed
by their authorized representatives, as of the date first written above. 
  

			
	NOVARTIS PHARMA AG	  	MEREO BIOPHARMA 3 LIMITED 
		
	 By: /s/ Matt Owens
 Name: Matt
Owens
 Title: Global Head Legal Strategic

Partnerships & Digital Medicine
  

By: /s/ Efthymis Lioulias
 Name: Efthymis
Lioulias
 Title: Senior Legal Counsel
	  	 By: /s/ Denise Scots-Knight
 Name:
Denise Scots-Knight
 Title: Chief Executive Officer

  
 [Signature Page to Sublicense Agreement]

  
 [***] Certain information
in this document has been omitted and filed separately with the 
 Securities and Exchange Commission. Confidential Treatment has been
requested with respect 
 to the omitted portions. 

 Schedule 9.2(a) 

[***] 
  

 

  
 [***] Certain information
in this document has been omitted and filed separately with the 
 Securities and Exchange Commission. Confidential Treatment has been
requested with respect 
 to the omitted portions. 

 EXHIBIT A 

MORPHOSYS COLLABORATION TECHNOLOGIES 

[***] 
  

 

  
 [***] Certain information
in this document has been omitted and filed separately with the 
 Securities and Exchange Commission. Confidential Treatment has been
requested with respect 
 to the omitted portions. 

 EXHIBIT B 

MORPHOSYS PATENT RIGHTS 
 [***]

  
  

  
 [***] Certain information
in this document has been omitted and filed separately with the 
 Securities and Exchange Commission. Confidential Treatment has been
requested with respect 
 to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}]]